Heart Failure

• 

  Subject Areas on Research

  • "Not the 'grim reaper service'": an assessment of provider knowledge, attitudes, and perceptions regarding palliative care referral barriers in heart failure. 
  • "Targeting the Heart" in Heart Failure: Myocardial Recovery in Heart Failure With Reduced Ejection Fraction. 
  • "Time Is Muscle" in Acute Heart Failure: Critical Concept or Fake News? 
  • #WordsMatter Continued: Moving from "Candidacy" To "Benefit Derived". 
  • 10-Year Risk Equations for Incident Heart Failure in the General Population. 
  • 2013 ACCF/ACR/ASE/ASNC/SCCT/SCMR appropriate utilization of cardiovascular imaging in heart failure: a joint report of the American College of Radiology Appropriateness Criteria Committee and the American College of Cardiology Foundation Appropriate Use Criteria Task Force. 
  • 2013 ACCF/ACR/ASE/ASNC/SCCT/SCMR appropriate utilization of cardiovascular imaging in heart failure: an executive summary: a joint report of the ACR Appropriateness Criteria ® Committee and the ACCF Appropriate Use Criteria Task Force. 
  • 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. 
  • 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. 
  • 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. 
  • 2017 ACC/AHA/HFSA/ISHLT/ACP Advanced Training Statement on Advanced Heart Failure and Transplant Cardiology (Revision of the ACCF/AHA/ACP/HFSA/ISHLT 2010 Clinical Competence Statement on Management of Patients With Advanced Heart Failure and Cardiac Transplant): A Report of the ACC Competency Management Committee. 
  • 2017 ACC/AHA/HFSA/ISHLT/ACP Advanced Training Statement on Advanced Heart Failure and Transplant Cardiology (Revision of the ACCF/AHA/ACP/HFSA/ISHLT 2010 Clinical Competence Statement on Management of Patients With Advanced Heart Failure and Cardiac Transplant): A Report of the ACC Competency Management Committee. 
  • 2017 ACC/AHA/HFSA/ISHLT/ACP Advanced Training Statement on Advanced Heart Failure and Transplant Cardiology (Revision of the ACCF/AHA/ACP/HFSA/ISHLT 2010 Clinical Competence Statement on Management of Patients With Advanced Heart Failure and Cardiac Transplant): A Report of the ACC Competency Management Committee. 
  • 2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. 
  • 2020 ACC/HFSA/ISHLT Lifelong Learning Statement for Advanced Heart Failure and Transplant Cardiology Specialists: A Report of the ACC Competency Management Committee. 
  • 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. 
  • 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. 
  • 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. 
  • 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. 
  • 2022 American College of Cardiology/American Heart Association/Heart Failure Society of America Guideline for the Management of Heart Failure: Executive Summary. 
  • 21st Century Cures: A Step Forward for Patients With Heart Failure. 
  • 3-Deazaguanine: report of a phase I trial and drug-related cardiac toxicity. 
  • A "Trapped Heart" in an Octopus Pot: Takotsubo Cardiomyopathy; Review of a Rare Clinical Syndrome Following Solid-Organ Transplant. 
  • A Balancing Act: Preserving Renal Function and the Need for Decongestion. 
  • A Bayesian Model to Predict Survival After Left Ventricular Assist Device Implantation. 
  • A Biomarker Approach to Understanding HFpEF. 
  • A Call for Change: Level of Statistical Significance. 
  • A Call to Move From Point-in-Time Toward Comprehensive Dynamic Risk Prediction in Critically Ill Patients With Heart Failure. 
  • A Canadian context for the Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure (ASCEND-HF) trial. 
  • A Comprehensive Appraisal of Risk Prediction Models for Cardiogenic Shock. 
  • A Contemporary Picture of Congestion in Heart Failure: from Dropsy Impression to Multifaceted Reality. 
  • A Critical Appraisal of Short-Term End Points in Acute Heart Failure Clinical Trials. 
  • A Critical Evaluation of the Representation of Black Patients With Heart Failure and Preserved Ejection Fraction in Clinical Trials: A Literature Review. 
  • A Decade With Editorial Mentors: The Day They Dropped the Mic. 
  • A Fully Magnetically Levitated Circulatory Pump for Advanced Heart Failure. 
  • A Fully Magnetically Levitated Left Ventricular Assist Device - Final Report. 
  • A Generation Passed; A Generation Forward: Why Joseph C. Greenfield, Chairman of Medicine, Duke University, Matters Today (1931 to 2020). 
  • A Gordian knot: disentangling comorbidities in heart failure. 
  • A Hospital Level Analysis of 30-Day Readmission Performance for Heart Failure Patients and Long-Term Survival: Findings from Get With The Guidelines-Heart Failure. 
  • A Hospital and Postdischarge Quality Improvement Intervention and Outcomes and Care for Patients With Heart Failure With Reduced Ejection Fraction-Reply. 
  • A Machine Learning Methodology for Identification and Triage of Heart Failure Exacerbations. 
  • A Machine Without an Owner's Manual. 
  • A Minimally Invasive Approach to HeartMate 3 Implantation for Systemic Ventricular Failure Following the Mustard Procedure for Transposition of the Great Arteries. 
  • A Multicenter Trial of a Shared Decision Support Intervention for Patients and Their Caregivers Offered Destination Therapy for Advanced Heart Failure: DECIDE-LVAD: Rationale, Design, and Pilot Data. 
  • A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial. 
  • A Novel In-hospital Congestion Score to Risk Stratify Patients Admitted for Worsening Heart Failure (from ASCEND-HF). 
  • A Novel Rehabilitation Intervention for Older Patients With Acute Decompensated Heart Failure: The REHAB-HF Pilot Study. 
  • A Phase 1 Randomized Study of Single Intravenous Infusions of the Novel Nitroxyl Donor BMS-986231 in Healthy Volunteers. 
  • A Prospective Pilot Study of Pocket-Carried Ultrasound Pre- and Postdischarge Inferior Vena Cava Assessment for Prediction of Heart Failure Rehospitalization. 
  • A Randomized Controlled Trial of Mobile Health Intervention in Patients With Heart Failure and Diabetes. 
  • A Standardized and Regionalized Network of Care for Cardiogenic Shock. 
  • A Test in Context: Critical Evaluation of Natriuretic Peptide Testing in Heart Failure. 
  • A Young Woman With Heart Failure and Altered Mental Status--The Answer in the Electrocardiogram. 
  • A bridge for the 21st century in heart transplantation? 
  • A call for collaboration: the evolving heart failure apprenticeship network. 
  • A caravanning cardiomyopathy. 
  • A care pathway for the cardiovascular complications of COVID-19: Insights from an institutional response. 
  • A combined clinical and biomarker approach to predict diuretic response in acute heart failure. 
  • A comparative evaluation of hemodynamic and neurohumoral effects of nitroglycerin and nifedipine in congestive heart failure. 
  • A comparison of the costs of and quality of life after coronary angioplasty or coronary surgery for multivessel coronary artery disease. Results from the Emory Angioplasty Versus Surgery Trial (EAST). 
  • A comparison of two spirituality instruments and their relationship with depression and quality of life in chronic heart failure. 
  • A contemporary review of mechanical circulatory support. 
  • A cooperative multicenter study of captopril in congestive heart failure: hemodynamic effects and long-term response. 
  • A cooperative network of trained sites for the conduct of a complex clinical trial: a new concept in multicenter clinical research. 
  • A current and future outlook on upcoming technologies in remote monitoring of patients with heart failure. 
  • A double-blind, randomized, controlled, multicenter study to assess the safety and cardiovascular effects of skeletal myoblast implantation by catheter delivery in patients with chronic heart failure after myocardial infarction. 
  • A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial. 
  • A global rank end point for clinical trials in acute heart failure. 
  • A global ranking approach to end points in trials of mechanical circulatory support devices. 
  • A moment-adjusted imputation method for measurement error models. 
  • A mouse model of heart failure with preserved ejection fraction due to chronic infusion of a low subpressor dose of angiotensin II. 
  • A multicenter analysis of clinical hemolysis in patients supported with durable, long-term left ventricular assist device therapy. 
  • A multicenter analysis of the ED diagnosis of pneumonia. 
  • A multicenter program for electronic health record screening for patients with heart failure with preserved ejection fraction: Lessons from the DELIVER-EHR initiative. 
  • A multimarker multi-time point-based risk stratification strategy in acute heart failure: results from the RELAX-AHF trial. 
  • A network analysis to compare biomarker profiles in patients with and without diabetes mellitus in acute heart failure. 
  • A normothermic ex vivo organ perfusion delivery method for cardiac transplantation gene therapy. 
  • A novel approach for measuring residential socioeconomic factors associated with cardiovascular and metabolic health. 
  • A novel link between G6PD deficiency and hemolysis in patients with continuous-flow left ventricular assist devices. 
  • A pharmacogenetic investigation of intravenous furosemide in decompensated heart failure: a meta-analysis of three clinical trials. 
  • A pilot study examining activity monitor use in older adults with heart failure during and after hospitalization. 
  • A practical use of theory to study adherence. 
  • A proteomic surrogate for cardiovascular outcomes that is sensitive to multiple mechanisms of change in risk. 
  • A qualitative descriptive study of the work of adherence to a chronic heart failure regimen: patient and physician perspectives. 
  • A qualitative, grounded theory exploration of the determinants of self-care behavior among Indian patients with a lived experience of chronic heart failure. 
  • A randomized controlled trial of renin-angiotensin-aldosterone system inhibitor management in patients admitted in hospital with COVID-19. 
  • A randomized trial of ecadotril versus placebo in patients with mild to moderate heart failure: the U.S. ecadotril pilot safety study. 
  • A rare case of isolated congenital right ventricular inflow obstruction due to the presence of an intraventricular muscular shelf. 
  • A reappraisal of loop diuretic choice in heart failure patients. 
  • A reduced transferrin saturation is independently associated with excess morbidity and mortality in older adults with heart failure and incident anemia. 
  • A reevaluation of the costs of heart failure and its implications for allocation of health resources in the United States. 
  • A review of dyspnea in acute heart failure syndromes. 
  • A scoring system derived from electronic health records to identify patients at high risk for noninvasive ventilation failure. 
  • A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment. 
  • A smoker's paradox in patients hospitalized for heart failure: findings from OPTIMIZE-HF. 
  • A standardized definition of ischemic cardiomyopathy for use in clinical research. 
  • A systematic review of randomized trials of disease management programs in heart failure. 
  • A validated risk score for in-hospital mortality in patients with heart failure from the American Heart Association get with the guidelines program. 
  • ACC/AHA/ASE 2003 Guideline Update for the Clinical Application of Echocardiography: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). 
  • ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities. 
  • ACCF/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2013 multimodality appropriate use criteria for the detection and risk assessment of stable ischemic heart disease: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons. 
  • ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 Appropriate Use Criteria for Echocardiography. A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance Endorsed by the American College of Chest Physicians. 
  • ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013 appropriate use criteria for implantable cardioverter-defibrillators and cardiac resynchronization therapy: a report of the American College of Cardiology Foundation appropriate use criteria task force, Heart Rhythm Society, American Heart Association, American Society of Echocardiography, Heart Failure Society of America, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. 
  • ACP Journal Club. Review: in patients with heart failure, β-blockers reduce mortality but do not differ from each other. 
  • ACP Journal Club: pooled RCTs: β-blockers reduce mortality in heart failure patients with sinus rhythm but not in those with AF. 
  • ACR Appropriateness Criteria® Dyspnea-Suspected Cardiac Origin. 
  • ACR Appropriateness Criteria® Suspected New-Onset and Known Nonacute Heart Failure. 
  • Ability of heart rate variability to predict prognosis in patients with advanced congestive heart failure. 
  • Ablation Versus Drug Therapy for Atrial Fibrillation in Heart Failure: Results From the CABANA Trial. 
  • Abnormal liver function tests in acute heart failure: relationship with clinical characteristics and outcome in the PROTECT study. 
  • Abnormalities of cardiac sympathetic function in pacing-induced heart failure as assessed by [123I]metaiodobenzylguanidine scintigraphy. 
  • Absence of effect of cardiac denervation and induced right ventricular failure on canine myocardial norepinephrine binding sites. 
  • Accelerating therapeutic discoveries for heart failure: a new public-private partnership. 
  • Accelerometer-Measured Daily Activity in Heart Failure With Preserved Ejection Fraction: Clinical Correlates and Association With Standard Heart Failure Severity Indices. 
  • Accessory atrioventricular pathway in an infant: prediction of location with body surface maps and ablation with cryosurgery. 
  • Accuracy of Seattle Heart Failure Model and HeartMate II Risk Score in Non-Inotrope-Dependent Advanced Heart Failure Patients: Insights From the ROADMAP Study (Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients). 
  • Achieving a Maximally Tolerated β-Blocker Dose in Heart Failure Patients: Is There Room for Improvement? 
  • Activation delay-induced mechanical dyssynchrony in single-ventricle heart disease. 
  • Acute Decompensated Heart Failure in the Setting of Acute Coronary Syndrome. 
  • Acute Decompensated Heart Failure: Is There a Path Forward? 
  • Acute Diuretic-Sparing Effects of Sacubitril-Valsartan: Staying in the Loop. 
  • Acute Heart Failure and Atrial Fibrillation: Insights From the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) Trial. 
  • Acute Heart Failure in a 39-Year-Old Man. 
  • Acute Heart Failure: Alternatives to Hospitalization. 
  • Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study. 
  • Acute decompensated heart failure patients admitted to critical care units: insights from ASCEND-HF. 
  • Acute decompensated heart failure: update on new and emerging evidence and directions for future research. 
  • Acute decompensation after removing a central line: practical approaches to increasing safety in the intensive care unit. 
  • Acute effect of percutaneous MitraClip therapy in patients with haemodynamic decompensation. 
  • Acute heart failure associated with high admission blood pressure--a distinct vascular disorder? 
  • Acute heart failure in elderly patients: worse outcomes and differential utility of standard prognostic variables. Insights from the PROTECT trial. 
  • Acute heart failure in the elderly: differences in clinical characteristics, outcomes, and prognostic factors in the VERITAS Study. 
  • Acute heart failure in the emergency department: short and long-term outcomes of elderly patients with heart failure. 
  • Acute heart failure in the young: Clinical characteristics and biomarker profiles. 
  • Acute heart failure: multiple clinical profiles and mechanisms require tailored therapy. 
  • Acute heart failure: perspectives from a randomized trial and a simultaneous registry. 
  • Acute kidney injury and 1-year mortality after left ventricular assist device implantation. 
  • Acute myocardial beta-adrenergic receptor dysfunction after cardiopulmonary bypass in patients with cardiac valve disease. Duke Heart Center Perioperative Desensitization Group. 
  • Ad hoc percutaneous coronary intervention in patients with stable coronary artery disease: A report from the National Cardiovascular Data Registry CathPCI Registry. 
  • Adaptive mechanisms that preserve cardiac function in mice without myoglobin. 
  • Adaptive servo-ventilation reduces atrial fibrillation burden in patients with heart failure and sleep apnea. 
  • Adding Troponin to the Puzzle of Heart Failure With Preserved Ejection Fraction: Marker or Mediator? 
  • Adding to the Denominator: A Case Report of Neuraxial Anesthesia for Cesarean Delivery in the Setting of Hemolysis, Elevated Liver Enzyme, Low Platelet, Thrombocytopenia, and Pulmonary Hypertension. 
  • Addressing Orthostatic Hypotension in Heart Failure: Pathophysiology, Clinical Implications and Perspectives. 
  • Adenosine improves post-procedural coronary flow but not clinical outcomes in patients with acute coronary syndrome: a meta-analysis of randomized trials. 
  • Adequate health literacy is associated with higher heart failure knowledge and self-care confidence in hospitalized patients. 
  • Adherence and persistence in the use of warfarin after hospital discharge among patients with heart failure and atrial fibrillation. 
  • Adherence to guideline-recommended adjunctive heart failure therapies among outpatient cardiology practices (findings from IMPROVE HF). 
  • Adherence to medication according to sex and age in the CHARM programme. 
  • Adherence-adjustment in placebo-controlled randomized trials: An application to the candesartan in heart failure randomized trial. 
  • Adiposity and Incident Heart Failure and its Subtypes: MESA (Multi-Ethnic Study of Atherosclerosis). 
  • Adjudicated Heart Failure in HIV-Infected and Uninfected Men and Women. 
  • Adjunctive agents in systemic chemotherapy. 
  • Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. 
  • Admission heart rate and in-hospital outcomes in patients hospitalized for heart failure in sinus rhythm and in atrial fibrillation. 
  • Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF). 
  • Admission to the intensive care unit and well-being in patients with advanced chronic illness. 
  • Admission, discharge, or change in B-type natriuretic peptide and long-term outcomes: data from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) linked to Medicare claims. 
  • Adoption of Sacubitril/Valsartan Among Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The Get With The Guidelines-Heart Failure Registry. 
  • Adrenergic CaV1.2 Activation via Rad Phosphorylation Converges at α1C I-II Loop. 
  • Adrenomedullin, endothelin, neuropeptide Y, atrial, brain, and C-natriuretic prohormone peptides compared as early heart failure indicators. 
  • Advanced (stage D) heart failure: a statement from the Heart Failure Society of America Guidelines Committee. 
  • Advanced Heart Failure: Epidemiology, Diagnosis, and Therapeutic Approaches. 
  • Advanced Practice Provider Versus Physician-Only Outpatient Follow-Up After Acute Myocardial Infarction. 
  • Advanced heart failure patients supported with ambulatory inotropic therapy: What defines success of therapy? 
  • Advanced heart failure treated with continuous-flow left ventricular assist device. 
  • Advanced heart failure. 
  • Advanced heart failure: a call to action. 
  • Advanced therapies for end-stage heart failure. 
  • Advances in the surgical treatment of heart failure. 
  • Advancing Our Common Purpose Through "Coopetition". 
  • Advancing Research on the Complex Interrelations Between Atrial Fibrillation and Heart Failure: A Report From a US National Heart, Lung, and Blood Institute Virtual Workshop. 
  • Advancing Value-Based Models for Heart Failure: A Call to Action From the Value in Healthcare Initiative's Value-Based Models Learning Collaborative. 
  • Advancing care for acute heart failure--no time to relax. 
  • Advancing the #WordsMatter Movement: Changing Chief Complaint to Chief Concern. 
  • Adverse Renal Response to Decongestion in the Obese Phenotype of Heart Failure With Preserved Ejection Fraction. 
  • Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. 
  • Aerobic exercise training and general health status in ambulatory heart failure patients with a reduced ejection fraction-Findings from the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION)trial. 
  • Aetiology, timing and clinical predictors of early vs. late readmission following index hospitalization for acute heart failure: insights from ASCEND-HF. 
  • African Americans With Advanced Heart Failure Are More Likely to Die in a Health Care Facility Than at Home or in Hospice: An Analysis From the PAL-HF Trial. 
  • After-hour ventricular assist device coverage: what level of expertise is required? 
  • Age Differences in Effects of Sacubitril/Valsartan on Cardiac Remodeling, Biomarkers, and Health Status. 
  • Age differences in the use of implantable cardioverter-defibrillators among older patients hospitalized with heart failure. 
  • Age- and gender-related differences in quality of care and outcomes of patients hospitalized with heart failure (from OPTIMIZE-HF). 
  • Age-Dependent Association Between Modifiable Risk Factors and Incident Cardiovascular Disease. 
  • Age-Dependent Relationship of Hypertension Subtypes With Incident Heart Failure. 
  • Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction. 
  • Age-Related Divergence of Risk-Benefit Relationship of Spironolactone Treatment for Heart Failure With Preserved Ejection Fraction. 
  • Age-dependent augmentation of cardiac endothelial NOS in a genetic rat model of heart failure. 
  • Air Pollution in Patients With Heart Failure: Lessons From a Mechanistic Pilot Study of a Filter Intervention. 
  • Albuminuria and Heart Failure: JACC State-of-the-Art Review. 
  • Albuminuria in chronic heart failure: prevalence and prognostic importance. 
  • Aldosterone antagonists--last man standing? 
  • Aldosterone: Behind the Scenes of Depression and Heart Failure? 
  • Alirocumab after acute coronary syndrome in patients with a history of heart failure. 
  • All rise! Orthostatic hypotension in heart failure. Letter regarding the article 'Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients'. 
  • All-Cause Mortality and Cardiovascular Outcomes With Non-Vitamin K Oral Anticoagulants Versus Warfarin in Patients With Heart Failure in the Food and Drug Administration Adverse Event Reporting System. 
  • Alpha 1-adrenoceptor activity in arterial smooth muscle following congestive heart failure. 
  • Alpha-1 adrenoceptor-angiotensin II type 1 receptor cross-talk and its relevance in clinical medicine. 
  • Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy. 
  • Alterations in left ventricular diastolic function in conscious dogs with pacing-induced heart failure. 
  • Alterations in serum sodium in relation to atrial natriuretic factor and other neuroendocrine variables in experimental pacing-induced heart failure. 
  • Altered expression of myosin heavy chain in human skeletal muscle in chronic heart failure. 
  • Alternative pay-for-performance scoring methods: implications for quality improvement and patient outcomes. 
  • America and Apple Pie: How Do We Change the American Health Care System? 
  • American Association for Thoracic Surgery/International Society for Heart and Lung Transplantation guidelines on selected topics in mechanical circulatory support. 
  • American Association for Thoracic Surgery/International Society for Heart and Lung Transplantation guidelines on selected topics in mechanical circulatory support. 
  • Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. 
  • Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality. 
  • Amlodipine in chronic heart failure. 
  • Amrinone therapy for congestive heart failure in outpatients with idiopathic dilated cardiomyopathy. 
  • Amrinone: its effect on vascular resistance and capacitance in human subjects. 
  • An ECG index of myocardial scar enhances prediction of defibrillator shocks: an analysis of the Sudden Cardiac Death in Heart Failure Trial. 
  • An N-ethyl-N-nitrosourea mutagenesis recessive screen identifies two candidate regions for murine cardiomyopathy that map to chromosomes 1 and 15. 
  • An aetiology-based subanalysis of the Telerehabilitation in Heart Failure Patients (TELEREH-HF) trial. 
  • An evaluation of torsemide in patients with heart failure and renal disease. 
  • An interesting finding during transesophageal echocardiographic assessment of the mitral valve. 
  • An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry. 
  • Anaemia and coronary artery disease severity in patients with heart failure. 
  • Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved. 
  • Analysis of Temporal Trends and Variation in the Use of Defibrillation Testing in Contemporary Practice. 
  • Analysis of transcriptome complexity through RNA sequencing in normal and failing murine hearts. 
  • Analysis of ventricular activation using surface electrocardiography to predict left ventricular reverse volumetric remodeling during cardiac resynchronization therapy. 
  • Anatomy of the obesity paradox in heart failure. 
  • Anemia and associated clinical outcomes in patients with heart failure due to reduced left ventricular systolic function. 
  • Anemia as a risk factor and therapeutic target in heart failure. 
  • Anemia in patients with heart failure and preserved systolic function. 
  • Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. 
  • Anesthetic management of the patient with a ventricular assist device. 
  • Anesthetic management of the patient with extracorporeal membrane oxygenator support. 
  • Angina and Future Cardiovascular Events in Stable Patients With Coronary Artery Disease: Insights From the Reduction of Atherothrombosis for Continued Health (REACH) Registry. 
  • Angiographic and clinical outcomes associated with direct versus conventional stenting among patients treated with fibrinolytic therapy for ST-elevation acute myocardial infarction. 
  • Angiotensin II antagonism is associated with reduced risk for gastrointestinal bleeding caused by arteriovenous malformations in patients with left ventricular assist devices. 
  • Angiotensin II type 1 receptor-associated protein is an endogenous inhibitor of angiotensin II type 1 receptor action in cardiac hypertrophy: role in check and balance. 
  • Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists. 
  • Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction. 
  • Angiotensin as local modulating factor in ventricular dysfunction and failure due to coronary artery disease. 
  • Angiotensin converting enzyme inhibitors and the cardiovascular system. 
  • Angiotensin receptor neprilysin inhibition in heart failure: mechanistic action and clinical impact. 
  • Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. 
  • Angiotensin-Neprilysin Inhibition in Black Americans: Data From the PIONEER-HF Trial. 
  • Angiotensin-converting enzyme inhibitor dosing in heart failure: what is optimal? 
  • Animal models of heart failure: a scientific statement from the American Heart Association. 
  • Annexin A1 is a Potential Novel Biomarker of Congestion in Acute Heart Failure. 
  • Another reason to embrace quadruple medical therapy for heart failure: medications enabling tolerance of each other. 
  • Anti-beta(1)-adrenergic receptor antibodies and heart failure: causation, not just correlation. 
  • Anti-inflammatory effect of physical training in heart failure: role of TNF-alpha and IL-10. 
  • Anticoagulant therapy and outcomes in patients with prior or acute heart failure and acute coronary syndromes: Insights from the APixaban for PRevention of Acute ISchemic Events 2 trial. 
  • Anticoagulation in heart failure: current status and future direction. 
  • Antidepressant use, depression, and survival in patients with heart failure. 
  • Antihyperglycemic Medication Use Among Medicare Beneficiaries With Heart Failure, Diabetes Mellitus, and Chronic Kidney Disease. 
  • Antihyperglycemic Therapies to Treat Patients With Heart Failure and Diabetes Mellitus. 
  • Antiplatelet and anticoagulant agents in heart failure: current status and future perspectives. 
  • Antithrombotic Strategies and Device Thrombosis. 
  • Antithrombotic therapy for atrial fibrillation and coronary artery disease in older patients. 
  • Aortic Insufficiency During Contemporary Left Ventricular Assist Device Support: Analysis of the INTERMACS Registry. 
  • Aortic valve ring annuloplasty is an option in left ventricular assist device patients. 
  • Apolipoprotein E Polymorphism, Cardiac Remodeling, and Heart Failure in the ARIC Study. 
  • Apoptosis and heart failure. 
  • Application of Diagnostic Algorithms for Heart Failure With Preserved Ejection Fraction to the Community. 
  • Application of the Seattle Heart Failure Model in ambulatory patients presented to an advanced heart failure therapeutics committee. 
  • Approaches to decongestion in patients with acute decompensated heart failure. 
  • Appropriate baseline laboratory testing following ACEI or ARB initiation by Medicare FFS beneficiaries. 
  • Appropriateness of therapy with angiotensin-converting-enzyme inhibitors in elderly outpatients. 
  • Are We Approaching Chronotropy (In)competently? 
  • Are We Getting Any Closer to Understanding Congestion? 
  • Are existing and emerging biomarkers associated with cardiorespiratory fitness in patients with chronic heart failure? 
  • Are models better than cardiologists?: An analysis of risk prediction in heart failure. 
  • Are racial/ethnic gaps in the use of cardiac resynchronization therapy narrowing?: an analysis of 107,096 patients from the National Cardiovascular Data Registry's ICD Registry. 
  • Are there negative responders to exercise training among heart failure patients? 
  • Are we targeting the right metric for heart failure? Comparison of hospital 30-day readmission rates and total episode of care inpatient days. 
  • Arrival by ambulance in acute heart failure: insights into the mode of presentation from Acute Studies of Nesiritide in Decompensated Heart Failure (ASCEND-HF). 
  • Arterial stiffness and cardiovascular events: the Framingham Heart Study. 
  • Arterial-venous nitroglycerin gradient during intravenous infusion in man. 
  • Ascending aorta to main pulmonary artery fistula following orthotopic heart transplantation: successful percutaneous closure employing an Amplatzer Duct Occluder. 
  • Ascertaining Death Events in a Pragmatic Clinical Trial: Insights From the TRANSFORM-HF Trial. 
  • Aspirin and left ventricular assist devices: rationale and design for the international randomized, placebo-controlled, non-inferiority ARIES HM3 trial. 
  • Aspirin use and outcomes in a community-based cohort of 7352 patients discharged after first hospitalization for heart failure. 
  • Assessing Frailty in Patients Undergoing Destination Therapy Left Ventricular Assist Device: Observations from Interagency Registry for Mechanically Assisted Circulatory Support. 
  • Assessing prognosis in heart failure: is hepatocyte growth factor the next B-type natriuretic peptide? 
  • Assessing race and ethnicity differences in outcomes based on GDMT and target NT-proBNP in patients with heart failure with reduced ejection fraction: An analysis of the GUIDE-IT study. 
  • Assessing the Quality and Comparative Effectiveness of Team-Based Care for Heart Failure: Who, What, Where, When, and How. 
  • Assessing the Role of Rare Genetic Variation in Patients With Heart Failure. 
  • Assessing the appropriateness of ICD use "appropriately". 
  • Assessment of ECG during hybrid comprehensive telerehabilitation in heart failure patients-Subanalysis of the Telerehabilitation in Heart Failure Patients (TELEREH-HF) randomized clinical trial. 
  • Assessment of Heart Transplant Waitlist Time and Pre- and Post-transplant Failure: A Mixed Methods Approach. 
  • Assessment of Limitations to Optimization of Guideline-Directed Medical Therapy in Heart Failure From the GUIDE-IT Trial: A Secondary Analysis of a Randomized Clinical Trial. 
  • Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure: A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical Trial. 
  • Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. 
  • Assessment of dyspnea in acute decompensated heart failure: insights from ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) on the contributions of peak expiratory flow. 
  • Assessment of filling pressures and fluid overload in heart failure: an updated perspective. 
  • Assessment of left ventricular function in older Medicare beneficiaries with newly diagnosed heart failure. 
  • Assessment of left ventricular mechanical dyssynchrony by phase analysis of ECG-gated SPECT myocardial perfusion imaging. 
  • Assessment of regional wall motion abnormalities with real-time 3-dimensional echocardiography. 
  • Association Between Angiotensin Receptor-Neprilysin Inhibition, Cardiovascular Biomarkers, and Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction. 
  • Association Between Comorbidities and Outcomes in Heart Failure Patients With and Without an Implantable Cardioverter-Defibrillator for Primary Prevention. 
  • Association Between Hospital Private Equity Acquisition and Outcomes of Acute Medical Conditions Among Medicare Beneficiaries. 
  • Association Between Hospital Volume, Processes of Care, and Outcomes in Patients Admitted With Heart Failure: Insights From Get With The Guidelines-Heart Failure. 
  • Association Between Regional Adipose Tissue Distribution and Risk of Heart Failure Among Blacks. 
  • Association Between Sacubitril/Valsartan Initiation and Health Status Outcomes in Heart Failure With Reduced Ejection Fraction. 
  • Association Between Sacubitril/Valsartan Initiation and Mitral Regurgitation Severity in Heart Failure With Reduced Ejection Fraction: The PROVE-HF Study. 
  • Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial. 
  • Association Between a Prolonged PR Interval and Outcomes of Cardiac Resynchronization Therapy: A Report From the National Cardiovascular Data Registry. 
  • Association between Respiratory Failure and Clinical Outcomes in Patients with Acute Heart Failure: Analysis of 5 Pooled Clinical Trials. 
  • Association between adrenergic receptor genotypes and beta-blocker dose in heart failure patients: analysis from the HF-ACTION DNA substudy. 
  • Association between beta-blocker use and mortality/morbidity in older patients with heart failure with reduced ejection fraction. A propensity score-matched analysis from the Swedish Heart Failure Registry. 
  • Association between body surface area and prescribed doses of guideline-directed medications among international patients with heart failure and reduced ejection fraction. 
  • Association between frequency of atrial and ventricular ectopic beats and biventricular pacing percentage and outcomes in patients with cardiac resynchronization therapy. 
  • Association between glycated haemoglobin levels and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the TECOS randomized clinical trial. 
  • Association between hemoglobin level and cardiopulmonary performance in heart failure: insights from the HF-ACTION study. 
  • Association between left ventricular ejection fraction post-cardiac resynchronization treatment and subsequent implantable cardioverter defibrillator therapy for sustained ventricular tachyarrhythmias. 
  • Association between myocardial substrate, implantable cardioverter defibrillator shocks and mortality in MADIT-CRT. 
  • Association between natriuretic peptides and mortality among patients admitted with myocardial infarction: a report from the ACTION Registry(R)-GWTG™. 
  • Association between performance measures and clinical outcomes for patients hospitalized with heart failure. 
  • Association between potassium level and outcomes in heart failure with reduced ejection fraction: a cohort study from the Swedish Heart Failure Registry. 
  • Association between prophylactic implantable cardioverter-defibrillators and survival in patients with left ventricular ejection fraction between 30% and 35%. 
  • Association between resting heart rate, chronotropic index, and long-term outcomes in patients with heart failure receiving β-blocker therapy: data from the HF-ACTION trial. 
  • Association between systolic ejection time and outcomes in heart failure by ejection fraction. 
  • Association between the timing of surgery for complicated, left-sided infective endocarditis and survival. 
  • Association between valvular surgery and mortality among patients with infective endocarditis complicated by heart failure. 
  • Association between vectorcardiographic QRS area and incident heart failure diagnosis and mortality among patients with left bundle branch block: A register-based cohort study. 
  • Association of 30-Day Readmission Metric for Heart Failure Under the Hospital Readmissions Reduction Program With Quality of Care and Outcomes. 
  • Association of Arterial Pulse Pressure With Long-Term Clinical Outcomes in Patients With Heart Failure. 
  • Association of Blood Pressure Classification Using the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline With Risk of Heart Failure and Atrial Fibrillation. 
  • Association of Cardiac Injury and Malignant Left Ventricular Hypertrophy With Risk of Heart Failure in African Americans: The Jackson Heart Study. 
  • Association of Changes in Heart Failure Treatment With Patients' Health Status: Real-World Evidence From CHAMP-HF. 
  • Association of Clinical Outcomes With Left Ventricular Assist Device Use by Bridge to Transplant or Destination Therapy Intent: The Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3 (MOMENTUM 3) Randomized Clinical Trial. 
  • Association of Dual Eligibility for Medicare and Medicaid With Heart Failure Quality and Outcomes Among Get With The Guidelines-Heart Failure Hospitals. 
  • Association of Early Blood Pressure Decrease and Renal Function With Prognosis in Acute Heart Failure. 
  • Association of Electronic Health Record Use With Quality of Care and Outcomes in Heart Failure: An Analysis of Get With The Guidelines-Heart Failure. 
  • Association of Heart Failure With Outcomes Among Patients With Peripheral Artery Disease: Insights From EUCLID. 
  • Association of Hospital Performance Based on 30-Day Risk-Standardized Mortality Rate With Long-term Survival After Heart Failure Hospitalization: An Analysis of the Get With The Guidelines-Heart Failure Registry. 
  • Association of Implantable Device Measured Physical Activity With Hospitalization for Heart Failure. 
  • Association of Left Atrial Structure and Function With Heart Failure in Older Adults. 
  • Association of Pulmonary Hypertension With Clinical Outcomes of Transcatheter Mitral Valve Repair. 
  • Association of Renin-Angiotensin Inhibitor Treatment With Mortality and Heart Failure Readmission in Patients With Transcatheter Aortic Valve Replacement. 
  • Association of Smoking Status With Long-Term Mortality and Health Status After Transcatheter Aortic Valve Replacement: Insights From the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. 
  • Association of Tricuspid Regurgitation With Transcatheter Aortic Valve Replacement Outcomes: A Report From The Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. 
  • Association of Visit-to-Visit Variability in Kidney Function and Serum Electrolyte Indexes With Risk of Adverse Clinical Outcomes Among Patients With Heart Failure With Preserved Ejection Fraction. 
  • Association of a 4-Tiered Classification of LV Hypertrophy With Adverse CV Outcomes in the General Population. 
  • Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. 
  • Association of beta-blocker use and selectivity with outcomes in patients with heart failure and chronic obstructive pulmonary disease (from OPTIMIZE-HF). 
  • Association of chronic congestive heart failure in humans with an intrinsic upregulation in skeletal muscle sarcoplasmic reticulum calcium ion adenosine triphosphatase activity. 
  • Association of circulating cardiac biomarkers with electrocardiographic abnormalities in chronic kidney disease. 
  • Association of comorbidity burden with abnormal cardiac mechanics: findings from the HyperGEN study. 
  • Association of depression and survival in patients with chronic heart failure over 12 Years. 
  • Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. 
  • Association of left ventricular ejection fraction with worsening renal function in patients with acute heart failure: insights from the RELAX-AHF-2 study. 
  • Association of liver fibrosis risk scores with clinical outcomes in patients with heart failure with preserved ejection fraction: findings from TOPCAT. 
  • Association of parental heart failure with risk of heart failure in offspring. 
  • Association of post-discharge specialty outpatient visits with readmissions and mortality in high-risk heart failure patients. 
  • Association of prolonged QRS duration with death in a clinical trial of pacemaker therapy for sinus node dysfunction. 
  • Association of race/ethnicity with clinical risk factors, quality of care, and acute outcomes in patients hospitalized with heart failure. 
  • Association of readmission penalty amount with subsequent 30-day risk standardized readmission and mortality rates among patients hospitalized with heart failure: An analysis of get with the guidelines - heart failure participating centers. 
  • Association of serum triiodothyronine with B-type natriuretic peptide and severe left ventricular diastolic dysfunction in heart failure with preserved ejection fraction. 
  • Association of the Affordable Care Act's Medicaid Expansion With Care Quality and Outcomes for Low-Income Patients Hospitalized With Heart Failure. 
  • Association of the Hospital Readmissions Reduction Program Implementation With Readmission and Mortality Outcomes in Heart Failure. 
  • Association of the Novel Inflammatory Marker GlycA and Incident Heart Failure and Its Subtypes of Preserved and Reduced Ejection Fraction: The Multi-Ethnic Study of Atherosclerosis. 
  • Association of the frontal QRS-T angle with adverse cardiac remodeling, impaired left and right ventricular function, and worse outcomes in heart failure with preserved ejection fraction. 
  • Association of weight change with subsequent outcomes in patients hospitalized with acute decompensated heart failure. 
  • Associations Between Blood Pressure and Outcomes Among Blacks in the Jackson Heart Study. 
  • Associations between Seattle Heart Failure Model scores and health utilities: findings from HF-ACTION. 
  • Associations between aldosterone antagonist therapy and risks of mortality and readmission among patients with heart failure and reduced ejection fraction. 
  • Associations between anticoagulation therapy and risks of mortality and readmission among patients with heart failure and atrial fibrillation. 
  • Associations between atrial fibrillation and early outcomes of patients with heart failure and reduced or preserved ejection fraction. 
  • Associations between hemoglobin level, resource use, and medical costs in patients with heart failure: findings from HF-ACTION. 
  • Associations between outpatient heart failure process-of-care measures and mortality. 
  • Associations between published quality ratings of skilled nursing facilities and outcomes of medicare beneficiaries with heart failure. 
  • Associations between seattle heart failure model scores and medical resource use and costs: findings from HF-ACTION. 
  • Associations between understanding of current treatment intent, communication with healthcare providers, preferences for invasive life-sustaining interventions and decisional conflict: results from a survey of patients with advanced heart failure in Singapore. 
  • Associations between use of the hospitalist model and quality of care and outcomes of older patients hospitalized for heart failure. 
  • Associations between worsening renal function and 30-day outcomes among Medicare beneficiaries hospitalized with heart failure. 
  • Associations between β-blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease. 
  • Associations of Body Mass Index With Laboratory and Biomarkers in Patients With Acute Heart Failure. 
  • Associations of gender and etiology with outcomes in heart failure with systolic dysfunction: a pooled analysis of 5 randomized control trials. 
  • Associations of patient demographic characteristics and regional physician density with early physician follow-up among medicare beneficiaries hospitalized with heart failure. 
  • Atherosclerotic cardiovascular disease and heart failure: Determinants of risk and outcomes in patients with diabetes. 
  • Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection Fraction. 
  • Atrial Fibrillation and Heart Failure: In This Challenge Lies Opportunity. 
  • Atrial Fibrillation and Ischemic Stroke With the Amyloidogenic V122I Transthyretin Variant Among Black Americans. 
  • Atrial Natriuretic Peptide and Treatment With Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction. 
  • Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. 
  • Atrial fibrillation and sudden cardiac death: is heart failure the middleman? 
  • Atrial fibrillation burden and heart failure: Data from 39,710 individuals with cardiac implanted electronic devices. 
  • Atrial fibrillation in heart failure: what should we do? 
  • Atrial fibrillation is an independent risk factor for heart failure hospitalization in heart failure with preserved ejection fraction. 
  • Atrial fibrillation management strategies and early mortality after myocardial infarction: results from the Valsartan in Acute Myocardial Infarction (VALIANT) Trial. 
  • Atrial fibrillation or flutter on initial electrocardiogram is associated with worse outcomes in patients admitted for worsening heart failure with reduced ejection fraction: findings from the EVEREST Trial. 
  • Atrial fibrillation patterns and risks of subsequent stroke, heart failure, or death in the community. 
  • Atrial natriuretic factor: pharmacokinetics and cyclic GMP response in relation to biologic effects in severe heart failure. 
  • Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial. 
  • Atrioventricular and ventricular-to-ventricular programming in patients with cardiac resynchronization therapy: results from ALTITUDE. 
  • Augmenting outcomes in patients with advanced heart failure. 
  • Authorship in a multicenter clinical trial: The Heart Failure-A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) Authorship and Publication (HAP) scoring system results. 
  • Autocrine and paracrine mechanisms in the pathophysiology of heart failure. 
  • Autonomic Modulation for the Treatment of Ventricular Arrhythmias: Therapeutic Use of Percutaneous Stellate Ganglion Blocks. 
  • Aviation Emergencies for Heart Failure Cardiologists: A New Twist to the Heart Team. 
  • Axial Muscle Size as a Strong Predictor of Death in Subjects With and Without Heart Failure. 
  • B-type natriuretic peptide - a biomarker for all seasons? 
  • B-type natriuretic peptide assessment in ambulatory heart failure patients: insights from IMPROVE HF. 
  • B-type natriuretic peptide level and postdischarge thrombotic events in older patients hospitalized with heart failure: insights from the Acute Decompensated Heart Failure National Registry. 
  • BIN1 is reduced and Cav1.2 trafficking is impaired in human failing cardiomyocytes. 
  • BNP-guided heart failure therapy in older patients. 
  • BNP-guided therapy for heart failure. 
  • BRG1 and BRM SWI/SNF ATPases redundantly maintain cardiomyocyte homeostasis by regulating cardiomyocyte mitophagy and mitochondrial dynamics in vivo. 
  • Back to the Future With Intravenous Diuretics: Reinvigorating an Old Treatment Through New Care Settings. 
  • Baroreceptor function in congestive heart failure: effect on neurohumoral activation and regional vascular resistance. 
  • Baroreflex activation therapy with the Barostim™ device in patients with heart failure with reduced ejection fraction: a patient level meta-analysis of randomized controlled trials. 
  • Baroreflex regulation of regional blood flow in congestive heart failure. 
  • Barriers to enrollment in a randomized controlled trial of hydrocortisone for cardiovascular insufficiency in term and late preterm newborn infants. 
  • Baseline Characteristics Predict the Presence of Amyloid on Endomyocardial Biopsy. 
  • Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial. 
  • Baseline Hemodynamics and Response to Contrast Media During Diagnostic Cardiac Catheterization Predict Adverse Events in Heart Failure Patients. 
  • Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. 
  • Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF). 
  • Baseline clinical characteristics of patients recruited into the assessment of treatment with lisinopril and survival study. 
  • Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial. 
  • Basic and Translational Research in Cardiac Repair and Regeneration: JACC State-of-the-Art Review. 
  • Behavioral Benefits of COVID Lockdown for Heart Failure Patients: A New Therapeutic Intervention? 
  • Benefit of cardiopoietic mesenchymal stem cell therapy on left ventricular remodelling: results from the Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) study. 
  • Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme. 
  • Benefits of a novel percutaneous ventricular assist device for right heart failure: The prospective RECOVER RIGHT study of the Impella RP device. 
  • Beta adrenoceptor recovery after heart failure in the dog. 
  • Beta-Blockers for Primary Therapy of Heart Failure With Preserved Ejection Fraction: An Idea Whose Time Has Gone? 
  • Beta-adrenergic axis and heart disease. 
  • Beta-adrenergic receptor desensitization in cardiac hypertrophy and heart failure. 
  • Beta-arrestin-mediated signaling in the heart. 
  • Beta-blocker and ACE-inhibitor dosing as a function of body surface area: From the HF-ACTION trial. 
  • Beta-blocker therapy for heart failure: the evidence is in, now the work begins. 
  • Beta-blocker therapy in advanced heart failure: clinical characteristics and long-term outcomes. 
  • Beta-blocker use and outcomes among hospitalized heart failure patients. 
  • Better Quality of Life Over More Quantity of Life: How We View Time Trade-Off. 
  • Between Scylla and Charybdis: The choice of inotropic agent for decompensated heart failure. 
  • Beyond drug therapy: nonpharmacologic care of the patient with advanced heart failure. 
  • Beyond pharmacological treatment: an insight into therapies that target specific aspects of heart failure pathophysiology. 
  • Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF). 
  • Biatrial appendage hypertrophy but not ventricular hypertrophy: a unique feature of canine pacing-induced heart failure. 
  • Biomarker Profile of Left Atrial Myopathy in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial. 
  • Biomarker Profiles of Acute Heart Failure Patients With a Mid-Range Ejection Fraction. 
  • Biomarker guided therapy for heart failure: focus on natriuretic peptides. 
  • Biomarker-based risk prediction in the community. 
  • Biomarker-guided therapies in heart failure: a forum for unified strategies. 
  • Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. 
  • Biomarkers and heart failure events in patients with atrial fibrillation in the ARISTOTLE trial evaluated by a multi-state model. 
  • Biomarkers as surrogate end points in heart failure trials. 
  • Biomarkers for the Prevention of Heart Failure: Are We There Yet? 
  • Biomarkers in Advanced Heart Failure: Implications for Managing Patients With Mechanical Circulatory Support and Cardiac Transplantation. 
  • Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction. 
  • Biomarkers of Congestion: Emerging Tools in the Management of Heart Failure? 
  • Biomarkers, mineralocorticoid receptor antagonism, and cardiorenal remodeling. 
  • Bleeding and thrombosis associated with ventricular assist device therapy. 
  • Bleeding complications and blood product utilization with left ventricular assist device implantation. 
  • Blood Pressure Response during Cardiopulmonary Exercise Testing in Heart Failure. 
  • Blood Pressure and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: DELIVER. 
  • Blood Pressure and Safety Events With Vericiguat in the VICTORIA Trial. 
  • Blood pressure reactivity to psychological stress is associated with clinical outcomes in patients with heart failure. 
  • Blood urea nitrogen-to-creatinine ratio in the general population and in patients with acute heart failure. 
  • Blood volume and chronic kidney disease in heart failure - Can volume expansion help balance the Cardio-Renal Axis for better clinical outcomes? 
  • Blood-gas and hemodynamic responses to oxygen in acute myocardial infarction. 
  • Bloodless HeartMate 3 explantation and orthotopic heart transplant in a heart failure patient refusing blood products. 
  • Blunted cyclic variation of heart rate predicts mortality risk in post-myocardial infarction, end-stage renal disease, and chronic heart failure patients. 
  • Body Composition, Natriuretic Peptides, and Adverse Outcomes in Heart Failure With Preserved and Reduced Ejection Fraction. 
  • Body Mass Index From Early-, Mid-, and Older-Adulthood and Risk of Heart Failure and Atherosclerotic Cardiovascular Disease: MESA. 
  • Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes: Findings From the ASCEND-HF Trial. 
  • Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. 
  • Body surface area and medication dosing in patients with heart failure with reduced ejection fraction. 
  • Boosting cardiac contractility with genes. 
  • Brain Natriuretic Peptide Treatment and Heart Failure Prevention: Reliving the Mistakes of the Past or Charting a New Course for the Future? 
  • Branched chain amino acid metabolic reprogramming in heart failure. 
  • Branched-chain amino acid metabolism in heart disease: an epiphenomenon or a real culprit? 
  • Branched-chain amino acids in cardiovascular disease. 
  • Breaking Bad: The Heartbreak of Drug Abuse. 
  • Breaking Clinical Inertia in Heart Failure Management. 
  • Breaking the vicious circle of fatigue in patients with chronic heart failure. 
  • Bridge-to-decision therapy with a continuous-flow external ventricular assist device in refractory cardiogenic shock of various causes. 
  • Bringing cardiovascular cell-based therapy to clinical application: perspectives based on a National Heart, Lung, and Blood Institute Cell Therapy Working Group meeting. 
  • Bronchodilators in heart failure patients with COPD: is it time for a clinical trial? 
  • Bucindolol Decreases Atrial Fibrillation Burden in Patients With Heart Failure and the ADRB1 Arg389Arg Genotype. 
  • Bucindolol for the Maintenance of Sinus Rhythm in a Genotype-Defined HF Population: The GENETIC-AF Trial. 
  • Bucindolol hydrochloride in atrial fibrillation and concomitant heart failure. 
  • Bucindolol: new hopes from reviewing past data. 
  • Building a Heart Failure Clinic: A Practical Guide from the Heart Failure Society of America. 
  • Building the Foundation for a New Era of Quadruple Therapy in Heart Failure. 
  • Building the case for aerobic exercise in ambulatory patients with heart failure and a reduced ejection fraction. 
  • Bundle Up for Value-Based Heart Failure Care. 
  • Burden of medical co-morbidities and benefit from surgical revascularization in patients with ischaemic cardiomyopathy. 
  • C-Reactive Protein Levels Predict Outcomes in Continuous-Flow Left Ventricular Assist Device Patients: An INTERMACS Analysis. 
  • CABG Improves Outcomes in Patients With Ischemic Cardiomyopathy: 10-Year Follow-Up of the STICH Trial. 
  • CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis. 
  • COAPTing Heart Failure Physicians, Interventional Cardiologists, and CardioThoracic Surgeons: A New Opportunity for Patients. 
  • COPD in heart failure: are there long-term implications following acute heart failure hospitalization? 
  • CT angiography in the detection of carotid body enlargement in patients with hypertension and heart failure. 
  • CYP3A4 genotype is associated with sildenafil concentrations in patients with heart failure with preserved ejection fraction. 
  • Ca2+/calmodulin-dependent protein kinase II (CaMKII) regulates cardiac sodium channel NaV1.5 gating by multiple phosphorylation sites. 
  • Calcineurin signaling in human cardiac hypertrophy. 
  • Calcium antagonists: new therapy for congestive heart failure? 
  • Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial. 
  • Calculated Estimates of Plasma Volume in Patients With Chronic Heart Failure-Comparison With Measured Volumes. 
  • Can 2 Pills a Day Keep Readmission Away?: Sacubitril/Valsartan to Reduce 30-Day Heart Failure Readmissions. 
  • Can Vaccinations Improve Heart Failure Outcomes?: Contemporary Data and Future Directions. 
  • Can catheter ablation of atrial fibrillation reverse heart failure with preserved ejection fraction? 
  • Can walking patients with heart failure and preserved ejection fraction tell us who should walk also to the catheterization laboratory or just walk home? 
  • Can we prevent heart failure with exercise? 
  • Can we prevent infections in patients with left ventricular assist devices? 
  • Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators. 
  • Cannulation strategy for centrifugal-flow ventricular assist device implantation late after arterial switch operation. 
  • Capillary density of skeletal muscle: a contributing mechanism for exercise intolerance in class II-III chronic heart failure independent of other peripheral alterations. 
  • Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. 
  • Cardiac Dysfunction and Heart Failure in Hematopoietic Cell Transplantation Survivors: Emerging Paradigms in Pathophysiology, Screening, and Prevention. 
  • Cardiac I-1c overexpression with reengineered AAV improves cardiac function in swine ischemic heart failure. 
  • Cardiac Index Declines During Long-Term Left Ventricular Device Support. 
  • Cardiac Myosin Activator Omecamtiv Mecarbil Improves Left Ventricular Myocardial Deformation in Chronic Heart Failure: The COSMIC-HF Trial. 
  • Cardiac Rehabilitation After Ventricular Assist Device Implantation: A Worthwhile Exercise? 
  • Cardiac Rehabilitation in Older Adults with Heart Failure: Fitting a Square Peg in a Round Hole. 
  • Cardiac Resynchronization Therapy With or Without Defibrillation in Patients With Nonischemic Cardiomyopathy: A Systematic Review and Meta-Analysis. 
  • Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer. 
  • Cardiac arrest complicating acute myocardial infarction: predictability and prognosis. 
  • Cardiac contractility modulation: the next cardiac resynchronization therapy or another renal sympathetic denervation? 
  • Cardiac evaluation of mitoxantrone. 
  • Cardiac fibroblasts in pressure overload hypertrophy: the enemy within? 
  • Cardiac function in genetically engineered mice with altered adrenergic receptor signaling. 
  • Cardiac imaging to identify patients at risk for developing heart failure after myocardial infarction. 
  • Cardiac pacing strategies and post-implantation risk of atrial fibrillation and heart failure events in sinus node dysfunction patients: a collaborative analysis of over 6000 patients. 
  • Cardiac potentials on body surface of infants with anomalous left coronary artery (myocardial infarction). 
  • Cardiac resynchronization therapy in chronic heart failure with moderately reduced left ventricular ejection fraction: Lessons from the Multicenter InSync Randomized Clinical Evaluation MIRACLE EF study. 
  • Cardiac resynchronization therapy in heart failure patients with less severe left ventricular dysfunction. 
  • Cardiac resynchronization therapy in heart failure patients: an update. 
  • Cardiac resynchronization therapy in patients with renal dysfunction: keep calm and carry on. 
  • Cardiac resynchronization therapy outcomes with left ventricular lead concordant with latest mechanical activation: A meta-analysis. 
  • Cardiac resynchronization therapy reduces the risk of hospitalizations in patients with advanced heart failure: results from the Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) trial. 
  • Cardiac resynchronization therapy utilization for heart failure: findings from IMPROVE HF. 
  • Cardiac rhabdomyosarcoma presenting as hypereosinophilic syndrome. 
  • Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer. 
  • Cardiac tamponade. 
  • Cardiac transplantation following ACORN CorCap device implantation. 
  • Cardiac troponins in congestive heart failure. 
  • Cardiac-resynchronization therapy for the prevention of heart-failure events. 
  • Cardiogenic Shock From Heart Failure Versus Acute Myocardial Infarction: Clinical Characteristics, Hospital Course, and 1-Year Outcomes. 
  • Cardiogenic shock and heart failure post-percutaneous coronary intervention in ST-elevation myocardial infarction: observations from "Assessment of Pexelizumab in Acute Myocardial Infarction". 
  • Cardiohepatic interactions in heart failure: an overview and clinical implications. 
  • Cardiologists' Perspectives on BiDil and the Use of Race in Drug Prescribing. 
  • Cardiomyocyte-Specific Human Bcl2-Associated Anthanogene 3 P209L Expression Induces Mitochondrial Fragmentation, Bcl2-Associated Anthanogene 3 Haploinsufficiency, and Activates p38 Signaling. 
  • Cardiopoietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial. 
  • Cardioprotective and antiapoptotic effects of heme oxygenase-1 in the failing heart. 
  • Cardiopulmonary Emergencies in Older Adults. 
  • Cardiopulmonary exercise and 6-min walk tests as predictors of quality of life and long-term mortality among patients with heart failure due to Chagas disease. 
  • Cardiorenal Interactions. 
  • Cardiorenal interactions: insights from the ESCAPE trial. 
  • Cardiorenal rescue study in acute decompensated heart failure: rationale and design of CARRESS-HF, for the Heart Failure Clinical Research Network. 
  • Cardiothoracic Morphology Measures in Heart Failure Patients to Inform Device Designs. 
  • Cardiovascular Complications of HIV in Endemic Countries. 
  • Cardiovascular Disease Risk Among Cancer Survivors: The Atherosclerosis Risk In Communities (ARIC) Study. 
  • Cardiovascular Events and Long-Term Risk of Sudden Death Among Stabilized Patients After Acute Coronary Syndrome: Insights From IMPROVE-IT. 
  • Cardiovascular Outcomes Assessment of the MitraClip in Patients with Heart Failure and Secondary Mitral Regurgitation: Design and rationale of the COAPT trial. 
  • Cardiovascular Outcomes With Minute Ventilation-Targeted Adaptive Servo-Ventilation Therapy in Heart Failure: The CAT-HF Trial. 
  • Cardiovascular Risk Factors and Clinical Outcomes among Patients Hospitalized with COVID-19: Findings from the World Heart Federation COVID-19 Study. 
  • Cardiovascular Risk of Isolated Systolic or Diastolic Hypertension in Young Adults. 
  • Cardiovascular biology: heart fails without pump partner. 
  • Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial. 
  • Cardiovascular critical event pathways for the progression of heart failure; a report from the ATLAS study. 
  • Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). 
  • Cardiovascular imaging utilization: boom or bust? 
  • Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study. 
  • Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease. 
  • Care Coordination Processes in Transitional Care for Patients With Heart Failure: An Integrative Review Through a Social Network Lens. 
  • Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart Failure: Rationale and design of CONNECT-HF. 
  • Care and outcomes of Hispanic patients admitted with heart failure with preserved or reduced ejection fraction: findings from get with the guidelines-heart failure. 
  • Care of the patient with cardiovascular disease undergoing general surgery. 
  • Caregiver Health-Related Quality of Life, Burden, and Patient Outcomes in Ambulatory Advanced Heart Failure: A Report From REVIVAL. 
  • Caregivers of Patients Considering a Destination Therapy Left Ventricular Assist Device and a Shared Decision-Making Intervention: The DECIDE-LVAD Trial. 
  • Caring for patients with chronic heart failure: The trajectory model. 
  • Carvedilol use at discharge in patients hospitalized for heart failure is associated with improved survival: an analysis from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). 
  • Case reports of heart failure after therapy with a tumor necrosis factor antagonist. 
  • Case study: heart transplantation--increased incidence of acute rejection in female recipients. 
  • Catabolic Defect of Branched-Chain Amino Acids Promotes Heart Failure. 
  • Catabolism of branched-chain amino acids in heart failure: insights from genetic models. 
  • Catheter ablation of atrial fibrillation in patients with heart failure and preserved ejection fraction. 
  • Catheter ablation of atrial fibrillation with heart failure: An updated meta-analysis of randomized trials. 
  • Catheter-Based Management of Heart Failure: Pathophysiology and Contemporary Data. 
  • Cause of Death in Patients With Acute Heart Failure: Insights From RELAX-AHF-2. 
  • Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program. 
  • Cell therapy for heart failure: the need for a new therapeutic strategy. 
  • Cellular and functional defects in a mouse model of heart failure. 
  • Cerebrovascular insufficiency and amyloidogenic signaling in Ossabaw swine with cardiometabolic heart failure. 
  • Challenges with Percent Predicted Maximal V˙O2 in Patients with Heart Failure. 
  • Change Is Not Always Good. 
  • Change Is the Only Constant in Heart Failure. 
  • Change in Cardiac Biomarkers and Risk of Incident Heart Failure and Atrial Fibrillation in CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study. 
  • Change in intrathoracic impedance measures during acute decompensated heart failure admission: results from the Diagnostic Data for Discharge in Heart Failure Patients (3D-HF) Pilot Study. 
  • Change the management of patients with heart failure: Rationale and design of the CHAMP-HF registry. 
  • Changes in Care Delivery for Patients With Heart Failure During the COVID-19 Pandemic: Results of a Multicenter Survey. 
  • Changes in Dyspnea Status During Hospitalization and Postdischarge Health-Related Quality of Life in Patients Hospitalized for Heart Failure: Findings From the EVEREST Trial. 
  • Changes in Use of Left Ventricular Assist Devices as Bridge to Transplantation With New Heart Allocation Policy. 
  • Changes in inferior vena cava area represent a more sensitive metric than changes in filling pressures during experimental manipulation of intravascular volume and tone. 
  • Changes in pulmonary artery pressure before and after left ventricular assist device implantation in patients utilizing remote haemodynamic monitoring. 
  • Changes in the optimal cardiac resynchronization therapy pacing configuration during physiologic stress. 
  • Changing Demographics, Temporal Trends in Waitlist, and Posttransplant Outcomes After Heart Transplantation in the United States: Analysis of the UNOS Database 1991-2019. 
  • Changing U.S. Heart Failure Research Culture: Part 2-Recognizing Frontline Investigators and Coordinators. 
  • Changing preferences for survival after hospitalization with advanced heart failure. 
  • Changing the Carburetor Without Changing the Plugs: The Intersection of Stock Car Racing With Mechanically Assisted Circulation. 
  • Changing the Research Culture in the United States. 
  • Channeling a new focus for heart failure: insights into ion channels. 
  • Characteristics and Outcomes of COVID-19 in Patients on Left Ventricular Assist Device Support. 
  • Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction After a Recent Worsening Heart Failure Event. 
  • Characteristics and Treatments of Patients Enrolled in the CHAMP-HF Registry Compared With Patients Enrolled in the PARADIGM-HF Trial. 
  • Characteristics and in-hospital outcomes for nonadherent patients with heart failure: findings from Get With The Guidelines-Heart Failure (GWTG-HF). 
  • Characteristics and outcomes of patients with heart failure and discordant findings by right-sided heart catheterization and cardiopulmonary exercise testing. 
  • Characteristics of Acute Heart Failure Hospitalizations Based on Presenting Severity. 
  • Characteristics of Heart Failure Trials Associated With Under-Representation of Women as Lead Authors. 
  • Characteristics of depression remission and its relation with cardiovascular outcome among patients with chronic heart failure (from the SADHART-CHF Study). 
  • Characteristics of strokes associated with centrifugal flow left ventricular assist devices. 
  • Characteristics, Treatments, and Outcomes of Hospitalized Heart Failure Patients Stratified by Etiologies of Cardiomyopathy. 
  • Characteristics, quality of care, and in-hospital outcomes of Asian-American heart failure patients: Findings from the American Heart Association Get With The Guidelines-Heart Failure Program. 
  • Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. 
  • Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial. 
  • Characterization of Mineralocorticoid Receptor Antagonist Therapy Initiation in High-Risk Patients With Heart Failure. 
  • Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial. 
  • Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM. 
  • Characterization of heart failure patients with preserved ejection fraction: a comparison between ADHERE-US registry and ADHERE-International registry. 
  • Characterization of hemodynamically stable acute heart failure patients requiring a critical care unit admission: Derivation, validation, and refinement of a risk score. 
  • Characterization of the Obese Phenotype of Heart Failure With Preserved Ejection Fraction: A RELAX Trial Ancillary Study. 
  • Characterization of the Progression From Ambulatory to Hospitalized Heart Failure With Preserved Ejection Fraction. 
  • Characterizing functional stem cell-cardiomyocyte interactions. 
  • Charting a roadmap for heart failure biomarker studies. 
  • Chest pain in patients with heart failure: why history may matter. 
  • Cheyne-Stokes respiration: poor prognostic sign in a patient with heart failure. 
  • Cholesterol levels and in-hospital mortality in patients with acute decompensated heart failure. 
  • Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. 
  • Chronic counterpulsation devices for heart failure. 
  • Chronic mechanical circulatory support for inotrope-dependent heart failure patients who are not transplant candidates: results of the INTrEPID Trial. 
  • Chronic oral amrinone therapy in congestive heart failure: a double-blind placebo-controlled withdrawal study. 
  • Cigarette Smoking and Incident Heart Failure: Insights From the Jackson Heart Study. 
  • Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes. 
  • Circadian rhythm and sudden death in heart failure: results from Prospective Randomized Amlodipine Survival Trial. 
  • Circulating Cardiac Troponin I Levels Measured by a Novel Highly Sensitive Assay in Acute Decompensated Heart Failure: Insights From the ASCEND-HF Trial. 
  • Circulating Kidney Injury Molecule-1 Levels in Acute Heart Failure: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). 
  • Circulating Neprilysin in Patients With Heart Failure and Preserved Ejection Fraction. 
  • Circulating long chain acylcarnitines and outcomes in diabetic heart failure: an HF-ACTION clinical trial substudy. 
  • Classifying Heart Failure in the 21st Century: Matching Taxonomy With Science. 
  • Classifying heart failure based on ejection fraction: imperfect but enduring. 
  • Clinical Correlates and Prognostic Value of Proenkephalin in Acute and Chronic Heart Failure. 
  • Clinical Effectiveness of Hydralazine-Isosorbide Dinitrate Therapy in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the Get With The Guidelines-Heart Failure Registry. 
  • Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. 
  • Clinical Experience of HeartMate II to HeartWare Left Ventricular Assist Device Exchange: A Multicenter Experience. 
  • Clinical Heart Failure Among Patients With and Without Severe Mental Illness and the Association With Long-Term Outcomes. 
  • Clinical Implications of Cluster Analysis-Based Classification of Acute Decompensated Heart Failure and Correlation with Bedside Hemodynamic Profiles. 
  • Clinical Implications of Serum Albumin Levels in Acute Heart Failure: Insights From DOSE-AHF and ROSE-AHF. 
  • Clinical Implications of the New York Heart Association Classification. 
  • Clinical Outcomes With Metformin and Sulfonylurea Therapies Among Patients With Heart Failure and Diabetes. 
  • Clinical Outcomes and Quality of Life With an Ambulatory Counterpulsation Pump in Advanced Heart Failure Patients: Results of the Multicenter Feasibility Trial. 
  • Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event: Insights From the VICTORIA Trial. 
  • Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial. 
  • Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease: A Systematic Review. 
  • Clinical Phenotypes in Patients With Type 2 Diabetes Mellitus: Characteristics, Cardiovascular Outcomes and Treatment Strategies. 
  • Clinical Prediction Models for Heart Failure Hospitalization in Type 2 Diabetes: A Systematic Review and Meta-Analysis. 
  • Clinical Significance of Early Fluid and Weight Change During Acute Heart Failure Hospitalization. 
  • Clinical and Echocardiographic Characteristics of Patients Hospitalized With Acute Versus Chronic Heart Failure With Preserved Ejection Fraction (From the ARIC Study). 
  • Clinical and Research Considerations for Patients With Hypertensive Acute Heart Failure: A Consensus Statement from the Society for Academic Emergency Medicine and the Heart Failure Society of America Acute Heart Failure Working Group. 
  • Clinical and Research Considerations for Patients With Hypertensive Acute Heart Failure: A Consensus Statement from the Society of Academic Emergency Medicine and the Heart Failure Society of America Acute Heart Failure Working Group. 
  • Clinical and angiographic correlates of short- and long-term mortality in patients undergoing coronary artery bypass grafting. 
  • Clinical applications of machine learning in the diagnosis, classification, and prediction of heart failure. 
  • Clinical assessment of acute heart failure syndromes: emergency department through the early post-discharge period. 
  • Clinical characteristics and long-term outcome of patients in whom congestive heart failure develops after thrombolytic therapy for acute myocardial infarction: development of a predictive model. 
  • Clinical characteristics and long-term outcomes of patients with heart failure and preserved systolic function. 
  • Clinical characteristics and outcomes of patients with and without diabetes in the Surgical Treatment for Ischemic Heart Failure (STICH) trial. 
  • Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme. 
  • Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity). 
  • Clinical characteristics associated with poor long-term survival among patients with diabetes mellitus undergoing saphenous vein graft interventions. 
  • Clinical characteristics, response to exercise training, and outcomes in patients with heart failure and chronic obstructive pulmonary disease: findings from Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing (HF-ACTION). 
  • Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. 
  • Clinical course of atrial fibrillation in older adults: the importance of cardiovascular events beyond stroke. 
  • Clinical determinants and prognostic significance of hypocapnia in acute heart failure. 
  • Clinical development of pharmacologic agents for acute heart failure syndromes: a proposal for a mechanistic translational phase. 
  • Clinical effectiveness of CRT and ICD therapy in heart failure patients by racial/ethnic classification: insights from the IMPROVE HF registry. 
  • Clinical effectiveness of anticoagulation therapy among older patients with heart failure and without atrial fibrillation: findings from the ADHERE registry linked to Medicare claims. 
  • Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. 
  • Clinical effectiveness of cardiac resynchronization and implantable cardioverter-defibrillator therapy in men and women with heart failure: findings from IMPROVE HF. 
  • Clinical effectiveness of cardiac resynchronization therapy versus medical therapy alone among patients with heart failure: analysis of the ICD Registry and ADHERE. 
  • Clinical effectiveness of implantable cardioverter-defibrillators among medicare beneficiaries with heart failure. 
  • Clinical factors related to morbidity and mortality in high-risk heart failure patients: the GUIDE-IT predictive model and risk score. 
  • Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. 
  • Clinical implications of differences between real world and clinical trial usage of left ventricular assist devices for end stage heart failure. 
  • Clinical inertia and medical therapy for heart failure: the unintended harms of 'first, do no harm'. 
  • Clinical judgment and statistics. Lessons from a simulated randomized trial in coronary artery disease. 
  • Clinical lessons learned from experimental heart failure. 
  • Clinical management of continuous-flow left ventricular assist devices in advanced heart failure. 
  • Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. 
  • Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program. 
  • Clinical outcomes after implantation of a centrifugal flow left ventricular assist device and concurrent cardiac valve procedures. 
  • Clinical outcomes and healthcare expenditures in the real world with left ventricular assist devices - The CLEAR-LVAD study. 
  • Clinical outcomes at 1 year following transcatheter aortic valve replacement. 
  • Clinical outcomes in patients on beta-blocker therapy admitted with worsening chronic heart failure. 
  • Clinical outcomes with β-blockers for myocardial infarction: a meta-analysis of randomized trials. 
  • Clinical pathway to screen for cardiac amyloidosis in heart failure with preserved ejection fraction. 
  • Clinical performance and quality measures for heart failure management in China: the China-Heart Failure registry study. 
  • Clinical pharmacology considerations for children supported with ventricular assist devices. 
  • Clinical problem-solving. A key miscommunication--an 81-year-old woman presented to the emergency department with increasing abdominal distention, nausea, and vomiting. 
  • Clinical problem-solving. Undercover and overlooked. 
  • Clinical profile and prognostic significance of natriuretic peptide trajectory following hospitalization for worsening chronic heart failure: findings from the ASTRONAUT trial. 
  • Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trial. 
  • Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial. 
  • Clinical profiles in acute heart failure: an urgent need for a new approach. 
  • Clinical response to angiotensin-converting enzyme inhibition in cardiac failure. 
  • Clinical study of the cardiac findings in patients on chronic maintenance hemodialysis: the relationship to coronary risk factors. 
  • Clinical trajectory of patients with a worsening heart failure event and reduced ventricular ejection fraction. 
  • Clinical trial evidence for treatment of depression in heart failure. 
  • Clinical trials in Japan and the United States. 
  • Clinical trials in acute decompensated heart failure--over 50 years of research. 
  • Clinical trials in hospitalized heart failure patients: targeting interventions to optimal phenotypic subpopulations. 
  • Clinical trials in mechanical circulatory support. 
  • Clinical trials of pharmacological therapies in acute heart failure syndromes: lessons learned and directions forward. 
  • Clinical update on nursing home medicine: 2014. 
  • Clinical utility of the platelet function analyzer (PFA-100) for the assessment of the platelet status in patients with congestive heart failure (EPCOT trial). 
  • Clinical value of pre-discharge bio-adrenomedullin as a marker of residual congestion and high risk of heart failure hospital readmission. 
  • Clinician and Algorithmic Application of the 2019 and 2022 Society of Cardiovascular Angiography and Intervention Shock Stages in the Critical Care Cardiology Trials Network Registry. 
  • Cluster-Randomized Trial of Personalized Site Performance Feedback in Get With The Guidelines-Heart Failure. 
  • Coagulation Abnormalities in Heart Failure: Pathophysiology and Therapeutic Implications. 
  • Coapting Cost and Clinical Outcomes in Transcatheter Intervention for Secondary Mitral Regurgitation. 
  • Coenzyme Q10 and Heart Failure: A State-of-the-Art Review. 
  • Coenzyme Q10 and statins in heart failure: the dog that didn't bark. 
  • Cognition, Physical Function, and Quality of Life in Older Patients With Acute Decompensated Heart Failure. 
  • Combating Acute Heart Failure in the Arena: Lessons From the ROPA-DOP Trial. 
  • Combination decongestion therapy in hospitalized heart failure: loop diuretics, mineralocorticoid receptor antagonists and vasopressin antagonists. 
  • Combination of loop diuretics with thiazide-type diuretics in heart failure. 
  • Combinatorial pharmacogenetic interactions of bucindolol and β1, α2C adrenergic receptor polymorphisms. 
  • Combined heart failure device diagnostics identify patients at higher risk of subsequent heart failure hospitalizations: results from PARTNERS HF (Program to Access and Review Trending Information and Evaluate Correlation to Symptoms in Patients With Heart Failure) study. 
  • Combined modality therapy for advanced, diffuse lymphocytic and histiocytic lymphomas. 
  • Combined neprilysin and renin-angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis. 
  • Combined treatment with vessel dilator and kaliuretic hormone in persons with congestive heart failure. 
  • Combining Diuretic Response and Hemoconcentration to Predict Rehospitalization After Admission for Acute Heart Failure. 
  • Combining baseline clinical descriptors and real-time response to therapy: the incremental prognostic value of continuous ST-segment monitoring in acute myocardial infarction. 
  • Commentary: Following the guidelines: Life in the real world. 
  • Commentary: Managing the native heart in patients supported with durable left ventricular assist devices. 
  • Comorbidities and the decision to undergo or forego destination therapy left ventricular assist device implantation: An analysis from the Trial of a Shared Decision Support Intervention for Patients and their Caregivers Offered Destination Therapy for End-Stage Heart Failure (DECIDE-LVAD) study. 
  • Comorbidities in Heart Failure: Are There Gender Differences? 
  • Comparative Effect of Angiotensin Receptor Neprilysin Inhibition on B-type Natriuretic Peptide Levels Measured by Three Different Assays: The PROVE-HF Study. 
  • Comparative Effectiveness of CRT-D Versus Defibrillator Alone in HF Patients With Moderate-to-Severe Chronic Kidney Disease. 
  • Comparative Effectiveness of Cardiac Resynchronization Therapy Among Patients With Heart Failure and Atrial Fibrillation: Findings From the National Cardiovascular Data Registry's Implantable Cardioverter-Defibrillator Registry. 
  • Comparative Effectiveness of Dosing of Medical Therapy for Heart Failure: From the CHAMP-HF Registry. 
  • Comparative Effectiveness of Implantable Cardioverter Defibrillators for Primary Prevention in Women. 
  • Comparative Effectiveness of Primary Prevention Implantable Cardioverter-Defibrillators in Older Heart Failure Patients With Diabetes Mellitus. 
  • Comparative assessment of short-term adverse events in acute heart failure with cystatin C and other estimates of renal function: results from the ASCEND-HF trial. 
  • Comparative cardiovascular safety of dementia medications: a cross-national study. 
  • Comparative effectiveness of angiotensin-converting-enzyme inhibitors: is an ACE always an ace? 
  • Comparative effectiveness of beta-blockers in elderly patients with heart failure. 
  • Comparative effectiveness of cardiac resynchronization therapy with an implantable cardioverter-defibrillator versus defibrillator therapy alone: a cohort study. 
  • Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial. 
  • Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. 
  • Comparative prognostic significance of simultaneous versus independent resolution of ST segment depression relative to ST segment elevation during acute myocardial infarction. 
  • Comparing New York Heart Association Class and Patient-Reported Outcomes Among Patients Hospitalized for Heart Failure. 
  • Comparing the Benefit of Novel Therapies Across Clinical Trials: Insights From the VICTORIA Trial. 
  • Comparing the Palliative Care Needs of Those With Cancer to Those With Common Non-Cancer Serious Illness. 
  • Comparing three life-limiting diseases: does diagnosis matter or is sick, sick? 
  • Comparing unmet needs between community-based palliative care patients with heart failure and patients with cancer. 
  • Comparing willingness to pay for telemedicine across a chronic heart failure and hypertension population. 
  • Comparison of 2-Year Outcomes of Extended Criteria Cardiac Transplantation Versus Destination Left Ventricular Assist Device Therapy Using Continuous Flow. 
  • Comparison of Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction With Versus Without Hyperuricemia or Gout. 
  • Comparison of Dyspnea Measurement Instruments in Acute Heart Failure: The DYSPNEA-AHF Pilot Study. 
  • Comparison of Frequency of Frailty and Severely Impaired Physical Function in Patients ≥60 Years Hospitalized With Acute Decompensated Heart Failure Versus Chronic Stable Heart Failure With Reduced and Preserved Left Ventricular Ejection Fraction. 
  • Comparison of Hydralazine/Nitrate and Angiotensin Receptor Neprilysin Inhibitor Use Among Black Versus Nonblack Americans With Heart Failure and Reduced Ejection Fraction (from CHAMP-HF). 
  • Comparison of New York Heart Association Class and Patient-Reported Outcomes for Heart Failure With Reduced Ejection Fraction. 
  • Comparison of coronary artery bypass grafting versus medical therapy on long-term outcome in patients with ischemic cardiomyopathy (a 25-year experience from the Duke Cardiovascular Disease Databank). 
  • Comparison of dyssynchrony parameters for VV-optimization in CRT patients. 
  • Comparison of hand-carried ultrasound assessment of the inferior vena cava and N-terminal pro-brain natriuretic peptide for predicting readmission after hospitalization for acute decompensated heart failure. 
  • Comparison of heart failure in children with enterovirus 71 rhombencephalitis and cats with norepinephrine cardiotoxicity. 
  • Comparison of hospital costing methods in an economic evaluation of a multinational clinical trial. 
  • Comparison of impedance cardiography with invasive hemodynamic measurements in patients with heart failure secondary to ischemic or nonischemic cardiomyopathy. 
  • Comparison of major and minor depression in older medical inpatients with chronic heart and pulmonary disease. 
  • Comparison of medical therapy dosing in outpatients cared for in cardiology practices with heart failure and reduced ejection fraction with and without device therapy: report from IMPROVE HF. 
  • Comparison of myocardial reperfusion in patients undergoing percutaneous coronary intervention in ST-segment elevation acute myocardial infarction with versus without diabetes mellitus (from the EMERALD Trial). 
  • Comparison of older depressed hospitalized patients with and without heart failure/pulmonary disease. 
  • Comparison of survival after mitral valve replacement with biologic and mechanical valves in 1139 patients. 
  • Comparison of treatment options for depression in heart failure: A network meta-analysis. 
  • Comparison of vessel dilator and long-acting natriuretic peptide in the treatment of congestive heart failure. 
  • Compensatory hypertrophy induced by ventricular cardiomyocyte-specific COX-2 expression in mice. 
  • Complete LVOT obstruction following aortic valve replacement after HeartMate II implantation. 
  • Complexity in congestive heart failure: A time-frequency approach. 
  • Compliance with clinical pathways for inpatient care in Chinese public hospitals. 
  • Complications and Mortality Following CRT-D Versus ICD Implants in Older Medicare Beneficiaries With Heart Failure. 
  • Composite End Points in Acute Heart Failure Research: Data Simulations Illustrate the Limitations. 
  • Computed tomography angiogram for left ventricular assist device thrombosis: When does it help? 
  • Concealed mechanical bradycardia: an indication for permanent pacemaker implantation. 
  • Concomitant Thoracic Aortobifemoral Bypass With Left Ventricular Assist Device Implantation. 
  • Concomitant tricuspid valve surgery during implantation of continuous-flow left ventricular assist devices: a Society of Thoracic Surgeons database analysis. 
  • Concomitant use of a positive inotropic agent to create a bridge to the successful initiation of beta-blocker therapy in patients with heart failure: a proposal for a trial. 
  • Conduct of clinical trials in acute heart failure: regional differences in heart failure clinical trials. 
  • Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). 
  • Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) trial design. 
  • Congestive heart failure patients' perceptions of quality of life: the integration of physical and psychosocial factors. 
  • Congestive heart failure. 
  • Congestive heart failure: Dx and Rx in the elderly. 
  • Connecting the pieces of the cardiovascular care puzzle in Canada. 
  • Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure. 
  • Consideration of ICD-9 code-derived disease-specific safety indicators in CKD. 
  • Considering the duration of heart failure: using the past to predict the future. 
  • Consistency of Laboratory Monitoring During Initiation of Mineralocorticoid Receptor Antagonist Therapy in Patients With Heart Failure. 
  • Contemplation from Our Hearts: A Call to Shift From Failure to Function. 
  • Contemporary Applications of Machine Learning for Device Therapy in Heart Failure. 
  • Contemporary Burden of Primary Versus Secondary Heart Failure Hospitalizations in the United States. 
  • Contemporary Nationwide Heart Transplantation and Left Ventricular Assist Device Outcomes in Patients with Histories of Bariatric Surgery. 
  • Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HFrEF: The CHAMP-HF Registry. 
  • Contemporary Use of Venoarterial Extracorporeal Membrane Oxygenation: Insights from the Multicenter RESCUE Registry. 
  • Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry. 
  • Contemporary outpatient management of patients with worsening heart failure with reduced ejection fraction: Rationale and design of the CHART-HF study. 
  • Contextualizing Risk Among Patients With Heart Failure. 
  • Continuous flow left ventricular assist device improves functional capacity and quality of life of advanced heart failure patients. 
  • Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). 
  • Continuous versus bolus dosing of Furosemide for patients hospitalized for heart failure. 
  • Contrast nephrotoxicity: a randomized controlled trial of a nonionic and an ionic radiographic contrast agent. 
  • Contrast-enhanced anatomic imaging as compared to contrast-enhanced tissue characterization for detection of left ventricular thrombus. 
  • Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure. 
  • Contribution of individual components to composite end points in contemporary cardiovascular randomized controlled trials. 
  • Contributions of hemodynamic monitoring to the treatment of chronic congestive heart failure. 
  • Contributions of neuroendocrine and local autocrine-paracrine mechanisms to the pathophysiology and pharmacology of congestive heart failure. 
  • Control beliefs and risk for 4-year mortality in older adults: a prospective cohort study. 
  • Controlling axillary intra-aortic balloon pump inflation is a viable option for turning an acute heart failure patient into a chronic one. 
  • Controversies and Challenges of Ventricular Assist Device Therapy. 
  • Convalescence From COVID Research: Lessons From the Heart Failure Community. 
  • Convergences of Life Sciences and Engineering in Understanding and Treating Heart Failure. 
  • Coping effectively with heart failure (COPE-HF): design and rationale of a telephone-based coping skills intervention. 
  • Coping styles in heart failure patients with depressive symptoms. 
  • Coronary Artery Calcification and Risk of Cardiovascular Disease and Death Among Patients With Chronic Kidney Disease. 
  • Coronary artery disease in patients with heart failure: incidental, coincidental, or a target for therapy? 
  • Coronary bypass surgery with or without surgical ventricular reconstruction. 
  • Coronary cyclic flow variations following primary angioplasty is associated with poor short-term prognosis. 
  • Coronary intervention for persistent occlusion after myocardial infarction. 
  • Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy. 
  • Coronary-artery bypass surgery in patients with left ventricular dysfunction. 
  • Correction of anemia with epoetin alfa in chronic kidney disease. 
  • Corrections needed to 2016 ESC and AHA guidelines on heart failure. 
  • Correlates and impact on outcomes of worsening renal function in patients > or =65 years of age with heart failure. 
  • Correlation between peak expiratory flow rate and NT-proBNP in patients with acute heart failure. An analysis from ASCEND-HF trial. 
  • Correlation of impedance cardiography with invasive hemodynamic measurements in patients with advanced heart failure: the BioImpedance CardioGraphy (BIG) substudy of the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) Trial. 
  • Correlations between physician-perceived functional status, patient-perceived health status, and cardiopulmonary exercise results in hypertrophic cardiomyopathy. 
  • Cost and Value in Contemporary Heart Failure Clinical Guidance Documents. 
  • Cost of ventricular assist devices: can we afford the progress? 
  • Cost-Effectiveness of the International Late Effects of Childhood Cancer Guideline Harmonization Group Screening Guidelines to Prevent Heart Failure in Survivors of Childhood Cancer. 
  • Cost-effectiveness analysis of continuous-flow left ventricular assist devices as destination therapy. 
  • Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). 
  • Cost-effectiveness of implantable cardioverter defibrillators in patients >or=65 years of age. 
  • Cost-effectiveness of screening for asymptomatic left ventricular dysfunction in childhood cancer survivors. 
  • Costs for heart failure with normal vs reduced ejection fraction. 
  • Costs of inpatient care among Medicare beneficiaries with heart failure, 2001 to 2004. 
  • Covariate adjustment in heart failure randomized controlled clinical trials: a case analysis of the HF-ACTION trial. 
  • Creatine kinase-mediated improvement of function in failing mouse hearts provides causal evidence the failing heart is energy starved. 
  • Creation of a quantitative recipient risk index for mortality prediction after cardiac transplantation (IMPACT). 
  • Current and novel pharmacologic approaches in advanced heart failure. 
  • Current and novel pharmacologic approaches in advanced heart failure. 
  • Current best practices and guidelines. Assessment and management of complications in infective endocarditis. 
  • Current trends in the management of heart failure. 
  • Currently Available Options for Mechanical Circulatory Support for the Management of Cardiogenic Shock. 
  • Cytoskeletal regulation of TRPC channels in the cardiorenal system. 
  • DNA Methylation Indicates Susceptibility to Isoproterenol-Induced Cardiac Pathology and Is Associated With Chromatin States. 
  • DUCCS and SWANS: when U.S. site-based research was highly successful. 
  • Dangerous diuretics or death defying drugs? 
  • Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial. 
  • Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. 
  • Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. 
  • Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial. 
  • Dapagliflozin for heart failure according to body mass index: the DELIVER trial. 
  • Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. 
  • Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction. 
  • Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial. 
  • Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial. 
  • Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan. 
  • Dapagliflozin-Does Cost Make 4-Pillar Heart Failure Therapy Too Herculean a Labor for Medicine? 
  • Data Sharing From the Editors' Perspective: Our Hope With Limitations. 
  • Data sources for heart failure comparative effectiveness research. 
  • Day of admission and clinical outcomes for patients hospitalized for heart failure: findings from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF). 
  • Day vs night: Does time of presentation matter in acute heart failure? A secondary analysis from the RELAX-AHF trial. 
  • Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program. 
  • De Novo vs Acute-on-Chronic Presentations of Heart Failure-Related Cardiogenic Shock: Insights from the Critical Care Cardiology Trials Network Registry. 
  • Dead letter office. 
  • Death during coronary angiography in a woman with cardiac amyloidosis. 
  • Death of the Heart Failure Clinical Investigator: Molecules and Receptors Win Nobel Prizes, Clinical Investigation Improves Survival. 
  • Death: The Simple Clinical Trial Endpoint. 
  • Decision Aid Implementation among Left Ventricular Assist Device Programs Participating in the DECIDE-LVAD Stepped-Wedge Trial. 
  • Decision making in advanced heart failure: a scientific statement from the American Heart Association. 
  • Decision-Making of Patients With Implantable Cardioverter-Defibrillators at End of Life: Family Members' Experiences. 
  • Decision-making regarding primary prevention implantable cardioverter-defibrillators among older adults. 
  • Declining Risk of Sudden Death in Heart Failure. 
  • Declining in-hospital mortality and increasing heart failure incidence in elderly patients with first myocardial infarction. 
  • Decoding the noncoding transcripts in human heart failure. 
  • Deconditioning fails to explain peripheral skeletal muscle alterations in men with chronic heart failure. 
  • Decongestion in acute heart failure. 
  • Decongestion strategies and renin-angiotensin-aldosterone system activation in acute heart failure. 
  • Defects in cardiomyocyte function: role of beta-adrenergic receptor dysfunction. 
  • Defibrillators: Selecting the Right Device for the Right Patient. 
  • Defining Optimal Outcomes in Patients with Left Ventricular Assist Devices. 
  • Defining and refining heart failure risk stratification to optimize patient selection for cardiac transplantation. 
  • Defining heart failure end points in ST-segment elevation myocardial infarction trials: integrating past experiences to chart a path forward. 
  • Delivering heart failure disease management in 3 tertiary care centers: key clinical components and venues of care. 
  • Delivery risks and outcomes associated with grand multiparity. 
  • Demographic and Regional Trends of Heart Failure-Related Mortality in Young Adults in the US, 1999-2019. 
  • Demographic and Regional Trends of Hypertrophic Cardiomyopathy-Related Mortality in the United States, 1999 to 2019. 
  • Demographics, clinical characteristics, and outcomes of patients hospitalized for decompensated heart failure: observations from the IMPACT-HF registry. 
  • Depression and clinical outcomes in heart failure: an OPTIMIZE-HF analysis. 
  • Depression and heart failure in patients with a new myocardial infarction. 
  • Depression and heart failure: the lonely comorbidity. 
  • Depression and major outcomes in older patients with heart failure. 
  • Depression in Heart Failure: Beyond a SADHART. 
  • Depression in hospitalized older patients with congestive heart failure. 
  • Depression in male and female patients undergoing cardiac surgery. 
  • Depression outcome in inpatients with congestive heart failure. 
  • Depression: are we ignoring an important comorbidity in heart failure? 
  • Depressive Symptoms and Incident Heart Failure in the Jackson Heart Study: Differential Risk Among Black Men and Women. 
  • Design Elements and Enrollment Patterns of Contemporary Trials in Heart Failure With Preserved Ejection Fraction: A Systematic Review. 
  • Design and rationale of a retrospective clinical effectiveness study of aldosterone antagonist therapy in patients with heart failure. 
  • Design and rationale of the B-lines lung ultrasound guided emergency department management of acute heart failure (BLUSHED-AHF) pilot trial. 
  • Design and rationale of the PROTECT study: a placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function. 
  • Design considerations and proposed template for clinical trials in hospitalized patients with decompensated chronic heart failure. 
  • Design of a "Lean" Case Report Form for Heart Failure Therapeutic Development. 
  • Design of a phase 2b trial of intracoronary administration of AAV1/SERCA2a in patients with advanced heart failure: the CUPID 2 trial (calcium up-regulation by percutaneous administration of gene therapy in cardiac disease phase 2b). 
  • Design of design papers. 
  • Design of the RELAXin in acute heart failure study. 
  • Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial. 
  • Designing effective drug and device development programs for hospitalized heart failure: a proposal for pretrial registries. 
  • Detection of tricuspid regurgitation with two-dimensional echocardiography and peripheral vein injections. 
  • Determinants of Diuretic Responsiveness and Associated Outcomes During Acute Heart Failure Hospitalization: An Analysis From the NHLBI Heart Failure Network Clinical Trials. 
  • Determinants of variable exercise performance among patients with severe left ventricular dysfunction. 
  • Determination of hospitalization type by investigator case report form or adjudication committee in a large heart failure clinical trial (β-Blocker Evaluation of Survival Trial [BEST]). 
  • Developing Breakthrough Drugs for Heart Failure: Lessons Learned From the Cystic Fibrosis Experience. 
  • Developing New Treatments for Heart Failure: Focus on the Heart. 
  • Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction. 
  • Developing therapies for heart failure with preserved ejection fraction: current state and future directions. 
  • Development and Validation of Machine Learning-Based Race-Specific Models to Predict 10-Year Risk of Heart Failure: A Multicohort Analysis. 
  • Development and validation of a risk model for in-hospital worsening heart failure from the Acute Decompensated Heart Failure National Registry (ADHERE). 
  • Development of Acute Decompensated Heart Failure Therapies: Is the Journey Over? 
  • Development of a Metastatic Spinal Tumor Frailty Index (MSTFI) Using a Nationwide Database and Its Association with Inpatient Morbidity, Mortality, and Length of Stay After Spine Surgery. 
  • Development of a Pediatric Cardiac Mechanical Support Program. 
  • Development of a method to risk stratify patients with heart failure for 30-day readmission using implantable device diagnostics. 
  • Developments in Exercise Capacity Assessment in Heart Failure Clinical Trials and the Rationale for the Design of METEORIC-HF. 
  • Device Development in the Gray Zone: One Step Forward. 
  • Device Therapy for Heart Failure with Preserved Ejection Fraction. 
  • Device Therapy in Chronic Heart Failure: JACC State-of-the-Art Review. 
  • Device therapy in heart failure patients with chronic kidney disease. 
  • Diabetes and heart failure in the crosshairs: where is the target? 
  • Diabetes, quality of care, and in-hospital outcomes in patients hospitalized with heart failure. 
  • Diabetic retinopathy and risk of heart failure. 
  • Diagnosing heart failure with preserved ejection fraction in 2019: the search for a gold standard. 
  • Diagnostic characteristics of combining phonocardiographic third heart sound and systolic time intervals for the prediction of left ventricular dysfunction. 
  • Diagnostic monitoring strategies in heart failure management. 
  • Diagnostic usefulness and prognostic implications of the mitral E/E' ratio in patients with heart failure and severe secondary mitral regurgitation. 
  • Diaphragmatic Function in Cardiovascular Disease: JACC Review Topic of the Week. 
  • Diastolic Dysfunction in Patients With Human Immunodeficiency Virus Receiving Antiretroviral Therapy: Results From the CHART Study. 
  • Diastolic Function in Heart Failure With Reduced Ejection Fraction: The Overlooked Prognosticator? 
  • Diastolic dysfunction: old dog, new tricks. 
  • Diastolic heart failure and continuous hemodynamic monitoring. 
  • Dichotomous Relationship Between Age and 30-Day Death or Rehospitalization in Heart Failure Patients Admitted With Acute Decompensated Heart Failure: Results From the ASCEND-HF Trial. 
  • Diet and Exercise for Obese Patients With Heart Failure--Reply. 
  • Dietary interventions and nutritional supplements for heart failure: a systematic appraisal and evidence map. 
  • Differences Between Patients Enrolled Early and Late During Clinical Trial Recruitment: Insights From the HF-ACTION Trial. 
  • Differences between depressed patients with heart failure and those with pulmonary disease. 
  • Differences in NT-proBNP Response and Prognosis in Men and Women With Heart Failure With Reduced Ejection Fraction. 
  • Differences in health care use and outcomes by the timing of in-hospital worsening heart failure. 
  • Differences in treatment, outcomes, and quality of life among patients with heart failure in Canada and the United States. 
  • Differential Response to Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Reduced or Preserved Ejection Fraction: Results From the ROSE AHF Trial (Renal Optimization Strategies Evaluation in Acute Heart Failure). 
  • Differential effects of captopril and enalapril on tissue renin-angiotensin systems in experimental heart failure. 
  • Differential effects of exercise training in men and women with chronic heart failure. 
  • Differential gene expression and genomic patient stratification following left ventricular assist device support. 
  • Digoxin Use and Subsequent Outcomes Among Patients in a Contemporary Atrial Fibrillation Cohort. 
  • Digoxin and Mortality in Patients With Atrial Fibrillation. 
  • Digoxin measurements following plasma ultrafiltration in two patients with digoxin toxicity treated with specific Fab fragments. 
  • Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). 
  • Diminishment of respiratory sinus arrhythmia foreshadows doxorubicin-induced cardiomyopathy. 
  • Direct visualization of cardiac transcription factories reveals regulatory principles of nuclear architecture during pathological remodeling. 
  • Discharge heart rate and β-blocker dose in patients hospitalized with heart failure: Findings from the OPTIMIZE-HF registry. 
  • Discharge to a skilled nursing facility and subsequent clinical outcomes among older patients hospitalized for heart failure. 
  • Discontinuation and non-publication of heart failure randomized controlled trials: a call to publish all trial results. 
  • Discordance between patient-predicted and model-predicted life expectancy among ambulatory patients with heart failure. 
  • Discordance of Pressure and Volume: Potential Implications for Pressure-Guided Remote Monitoring in Heart Failure. 
  • Discordant Perceptions of Prognosis and Treatment Options Between Physicians and Patients With Advanced Heart Failure. 
  • Discovery of Genetic Variation on Chromosome 5q22 Associated with Mortality in Heart Failure. 
  • Discriminating clinical features of heart failure with preserved vs. reduced ejection fraction in the community. 
  • Disease management interventions to improve outcomes in congestive heart failure. 
  • Disease management of congestive heart failure. 
  • Disease management produces limited quality-of-life improvements in patients with congestive heart failure: evidence from a randomized trial in community-dwelling patients. 
  • Disparities in access to left ventricular assist device therapy. 
  • Disparity Between Indications for and Utilization of Implantable Cardioverter Defibrillators in Asian Patients With Heart Failure. 
  • Disrupted junctional membrane complexes and hyperactive ryanodine receptors after acute junctophilin knockdown in mice. 
  • Dissociation between hemodynamic changes and symptom improvement in patients with advanced congestive heart failure. 
  • Dissociation of the prostaglandin and renin angiotensin systems during captopril therapy for chronic congestive heart failure secondary to coronary artery disease. 
  • Distinct renin/aldosterone activity profiles correlate with renal function, natriuretic response, decongestive ability and prognosis in acute heart failure. 
  • Diuretic Changes, Health Care Resource Utilization, and Clinical Outcomes for Heart Failure With Reduced Ejection Fraction: From the Change the Management of Patients With Heart Failure Registry. 
  • Diuretic Therapy for Patients With Heart Failure: JACC State-of-the-Art Review. 
  • Diuretic Treatment in Heart Failure. 
  • Diuretic Treatment in Heart Failure. 
  • Diuretic management in heart failure. 
  • Diuretic resistance predicts mortality in patients with advanced heart failure. 
  • Diuretic response in acute heart failure-an analysis from ASCEND-HF. 
  • Diuretic response in acute heart failure: clinical characteristics and prognostic significance. 
  • Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome--an analysis from RELAX-AHF. 
  • Diuretic strategies in patients with acute decompensated heart failure. 
  • Diuretics and ultrafiltration in acute decompensated heart failure. 
  • Diverse cardiopulmonary diseases are associated with distinct xenon magnetic resonance imaging signatures. 
  • Do Women and Men Respond Similarly to Therapies in Contemporary Heart Failure Clinical Trials? 
  • Do cardiac troponins provide prognostic insight in hemodialysis patients? 
  • Do countries or hospitals with longer hospital stays for acute heart failure have lower readmission rates?: Findings from ASCEND-HF. 
  • Do evidence-based treatments provide incremental benefits to patients with congestive heart failure already receiving angiotensin-converting enzyme inhibitors? A secondary analysis of one-year outcomes from the Assessment of Treatment with Lisinopril and Survival (ATLAS) study. 
  • Do heart failure disease management programs make financial sense under a bundled payment system? 
  • Do physicians' attitudes toward implantable cardioverter defibrillator therapy vary by patient age, gender, or race? 
  • Do we really need more biomarkers? 
  • Does Age Influence Cardiac Resynchronization Therapy Use and Outcome? 
  • Does Favorable Selection Among Medicare Advantage Enrollees Affect Measurement of Hospital Readmission Rates? 
  • Does Guideline-Directed Medical Therapy for Heart Failure Offer Benefits After LVAD Placement?-A Call for a Randomized Clinical Trial. 
  • Does Institutional Memory Matter? 
  • Does Survival on the Heart Transplant Waiting List Depend on the Underlying Heart Disease? 
  • Does a hypertonic saline load predict fluid retention in pacing induced heart failure? 
  • Does aspirin use adversely influence intermediate-term postdischarge outcomes for hospitalized patients who are treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers? Findings from Organized Program to Facilitate Life-Saving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). 
  • Does heart failure etiology, New York Heart Association class, or ejection fraction affect the ability of clopidogrel to inhibit heightened platelet activity? 
  • Does increased access to primary care reduce hospital readmissions? Veterans Affairs Cooperative Study Group on Primary Care and Hospital Readmission. 
  • Does low bone mineral density cause a broken heart? 
  • Does method of sternal repair influence long-term outcome of postoperative mediastinitis? 
  • Does the Implantable Cardioverter-Defibrillator Benefit Vary With the Estimated Proportional Risk of Sudden Death in Heart Failure Patients? 
  • Doing the wrong thing for the right reasons: The demise of the HVAD. 
  • Domain Management Approach to Heart Failure in the Geriatric Patient: Present and Future. 
  • Don't Be So Fast to Discard That Clean Catch! 
  • Donation After Circulatory Death in Heart Transplantation: History, Outcomes, Clinical Challenges, and Opportunities to Expand the Donor Pool. 
  • Donor and recipient age matching in heart transplantation: analysis of the UNOS Registry. 
  • Door-to-Furosemide Therapy in the ED: New Quality Metric or Just a Piece of the Puzzle? 
  • Doppler-detected valve movement in aortic stenosis: a predictor of adverse outcome. 
  • Dose Response of β-Blockers in Adrenergic Receptor Polymorphism Genotypes. 
  • Dose of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Outcomes in Heart Failure: A Meta-Analysis. 
  • Dose-Response to Sacubitril/Valsartan in Patients With Heart Failure and Reduced Ejection Fraction. 
  • Dosing of beta-blocker therapy before, during, and after hospitalization for heart failure (from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure). 
  • Dosing recommendations and prescribing patterns for depressed medically ill hospitalized older patients. 
  • Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). 
  • Dronedarone for the treatment of atrial fibrillation with concomitant heart failure with preserved and mildly reduced ejection fraction: a post-hoc analysis of the ATHENA trial. 
  • Dronedarone in high-risk permanent atrial fibrillation. 
  • Drug Development for Heart Failure With Preserved Ejection Fraction: What Pieces Are Missing From the Puzzle? 
  • Drugs of Abuse and Heart Failure. 
  • Dual natriuretic peptide system in experimental heart failure. 
  • Dual renin-angiotensin system blockade in heart failure. 
  • Dumping adherence: a person-centred response for primary care. 
  • Durability and Efficacy of Tricuspid Valve Repair in Patients Undergoing Left Ventricular Assist Device Implantation. 
  • Durability and clinical impact of tricuspid valve procedures in patients receiving a continuous-flow left ventricular assist device. 
  • Durable mechanical circulatory support devices. 
  • Duration of Trastuzumab. In matters of the heart, one size may not fit all? 
  • Dynamic regulation of phosphoinositide 3-kinase-gamma activity and beta-adrenergic receptor trafficking in end-stage human heart failure. 
  • Dysglycemia and incident heart failure among blacks: The jackson heart study. 
  • Dysphagia in the setting of left ventricular assist device hemolysis. 
  • Dyspnea and pain frequently co-occur among Medicare managed care recipients. 
  • Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study. 
  • Dyspnoea in patients with acute heart failure: an analysis of its clinical course, determinants, and relationship to 60-day outcomes in the PROTECT pilot study. 
  • ECG quantification of myocardial scar and risk stratification in MADIT-II. 
  • ECMO as a Bridge to Left Ventricular Assist Device or Heart Transplantation. 
  • EXPANDing the Donor Pool: Quantifying the Potential Impact of a Portable Organ-Care System for Expanded Criteria Heart Donation. 
  • Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction: Insights From Get With the Guidelines-Heart Failure (GWTG-HF). 
  • Early Ambulation Among Hospitalized Heart Failure Patients Is Associated With Reduced Length of Stay and 30-Day Readmissions. 
  • Early Identification of Patients at Risk for Incident Heart Failure With Preserved Ejection Fraction: Novel Approach to Echocardiographic Trends. 
  • Early Impedance-Guided Intervention Improves Long-Term Outcome in Patients With Heart Failure. 
  • Early Increased Physical Activity, Cardiac Rehabilitation, and Survival After Implantable Cardioverter-Defibrillator Implantation. 
  • Early adaptive chromatin remodeling events precede pathologic phenotypes and are reinforced in the failing heart. 
  • Early and long-term outcomes of heart failure in elderly persons, 2001-2005. 
  • Early diuretic strategies and the association with In-hospital and Post-discharge outcomes in acute heart failure. 
  • Early drop in systolic blood pressure and worsening renal function in acute heart failure: renal results of Pre-RELAX-AHF. 
  • Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study. 
  • Early fetal hypoxia leads to growth restriction and myocardial thinning. 
  • Early impact of guideline publication on angiotensin-receptor neprilysin inhibitor use among patients hospitalized for heart failure. 
  • Early intravenous heart failure therapy and outcomes among older patients hospitalized for acute decompensated heart failure: findings from the Acute Decompensated Heart Failure Registry Emergency Module (ADHERE-EM). 
  • Early management of patients with acute heart failure: state of the art and future directions--a consensus document from the SAEM/HFSA acute heart failure working group. 
  • Early management of patients with acute heart failure: state of the art and future directions. A consensus document from the society for academic emergency medicine/heart failure society of America acute heart failure working group. 
  • Early outcomes with durable left ventricular assist device replacement using the HeartMate 3. 
  • Early planned institution of biventricular mechanical circulatory support results in improved outcomes compared with delayed conversion of a left ventricular assist device to a biventricular assist device. 
  • Early recovery from heart failure: insights into the pathogenesis of experimental chronic pacing-induced heart failure. 
  • Early versus late readmission during the vulnerable phase following hospitalization for heart failure: reply. 
  • Early vs. late worsening heart failure during acute heart failure hospitalization: insights from the PROTECT trial. 
  • Early worsening heart failure in patients admitted with acute heart failure--a new outcome measure associated with long-term prognosis? 
  • Easy to Predict, Difficult to Prevent. 
  • Echocardiographic documentation of vegetative lesions in infective endocarditis: clinical implications. 
  • Echocardiography in the Management of Patients with Left Ventricular Assist Devices: Recommendations from the American Society of Echocardiography. 
  • Economic Evaluation of Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure With Reduced Ejection Fraction. 
  • Economic Outcomes of Rehabilitation Therapy in Older Patients With Acute Heart Failure in the REHAB-HF Trial: A Secondary Analysis of a Randomized Clinical Trial. 
  • Economic and Quality-of-Life Outcomes of Natriuretic Peptide-Guided Therapy for Heart Failure. 
  • Economic burden of heart failure in the elderly. 
  • Economic effects of beta-blocker therapy in patients with heart failure. 
  • Economic evaluation of the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) randomized controlled trial: an exercise training study of patients with chronic heart failure. 
  • Economics of treating heart failure. 
  • Editorial Commentary: Determining the cost-effectiveness of mechanical circulatory support. 
  • Editorial Privilege. 
  • Educational attainment has a limited impact on disease management outcomes in heart failure. 
  • Educational videos to reduce racial disparities in ICD therapy via innovative designs (VIVID): a randomized clinical trial. 
  • Effect of Age and Renal Function on Survival After Left Ventricular Assist Device Implantation. 
  • Effect of Atrial Fibrillation on Mortality, Stroke Risk, and Quality-of-Life Scores in Patients With Heart Failure (from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF]). 
  • Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis. 
  • Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial. 
  • Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial. 
  • Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF. 
  • Effect of Heart Failure With Preserved Ejection Fraction on Perioperative Outcomes in Patients Undergoing Hip Fracture Surgery. 
  • Effect of Heart Rate Reserve on Exercise Capacity in Patients Treated with a Continuous Left Ventricular Assist Device. 
  • Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease: A Randomized Clinical Trial. 
  • Effect of Inorganic Nitrite vs Placebo on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: The INDIE-HFpEF Randomized Clinical Trial. 
  • Effect of Intensive Blood Pressure Treatment on Heart Failure Events in the Systolic Blood Pressure Reduction Intervention Trial. 
  • Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. 
  • Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction: The METEORIC-HF Randomized Clinical Trial. 
  • Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial. 
  • Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial. 
  • Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. 
  • Effect of Smoking on Outcomes of Primary PCI in Patients With STEMI. 
  • Effect of Socioeconomic Status on Patients Supported with Contemporary Left Ventricular Assist Devices. 
  • Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure : A Randomized Trial. 
  • Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure: The TRANSFORM-HF Randomized Clinical Trial. 
  • Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. 
  • Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure. 
  • Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial. 
  • Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial. 
  • Effect of a Hospital and Postdischarge Quality Improvement Intervention on Clinical Outcomes and Quality of Care for Patients With Heart Failure With Reduced Ejection Fraction: The CONNECT-HF Randomized Clinical Trial. 
  • Effect of admission oral diuretic dose on response to continuous versus bolus intravenous diuretics in acute heart failure: an analysis from diuretic optimization strategies in acute heart failure. 
  • Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial. 
  • Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. 
  • Effect of amlodipine on mode of death among patients with advanced heart failure in the PRAISE trial. Prospective Randomized Amlodipine Survival Evaluation. 
  • Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. 
  • Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRAISE-2 study (prospective randomized amlodipine survival evaluation 2). 
  • Effect of an Early Palliative Care Telehealth Intervention vs Usual Care on Patients With Heart Failure: The ENABLE CHF-PC Randomized Clinical Trial. 
  • Effect of angiotensin-converting enzyme inhibitors, beta blockers, statins, and aspirin on C-reactive protein levels in outpatients with heart failure. 
  • Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation. 
  • Effect of candesartan on New York Heart Association functional class. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. 
  • Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. 
  • Effect of cardiac resynchronization therapy and implantable cardioverter defibrillator on quality of life in patients with heart failure: a meta-analysis. 
  • Effect of defibrillation threshold testing on heart failure hospitalization or death in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). 
  • Effect of exercise training on ventricular function, dyssynchrony, resting myocardial perfusion, and clinical outcomes in patients with heart failure: a nuclear ancillary study of Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing (HF-ACTION); design and rationale. 
  • Effect of increasing pump speed during exercise on peak oxygen uptake in heart failure patients supported with a continuous-flow left ventricular assist device. A double-blind randomized study. 
  • Effect of nesiritide in patients with acute decompensated heart failure. 
  • Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. 
  • Effect of patient-centered transitional care services on patient-reported outcomes in heart failure: sex-specific analysis of the PACT-HF randomized controlled trial. 
  • Effect of peripheral arterial disease on functional and clinical outcomes in patients with heart failure (from HF-ACTION). 
  • Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. 
  • Effect of sensitization in US heart transplant recipients bridged with a ventricular assist device: update in a modern cohort. 
  • Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. 
  • Effect of serelaxin on mode of death in acute heart failure: results from the RELAX-AHF study. 
  • Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials. 
  • Effect on Mortality of Higher Versus Lower β-Blocker (Metoprolol Succinate or Carvedilol) Dose in Patients With Heart Failure. 
  • Effectiveness of Cardiac Resynchronization Therapy by QRS Morphology in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). 
  • Effectiveness of Telemedicine Visits in Reducing 30-Day Readmissions Among Patients With Heart Failure During the COVID-19 Pandemic. 
  • Effectiveness of a telephone-delivered psycho-behavioural intervention on depression in elderly with chronic heart failure: rationale and design of a randomized controlled trial. 
  • Effectiveness of an Intervention Supporting Shared Decision Making for Destination Therapy Left Ventricular Assist Device: The DECIDE-LVAD Randomized Clinical Trial. 
  • Effectiveness of percutaneous balloon mitral valvotomy during pregnancy. 
  • Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the American Heart Association. 
  • Effects of BG9928, an adenosine A₁ receptor antagonist, in patients with congestive heart failure. 
  • Effects of Coping Skills Training on Quality of Life, Disease Biomarkers, and Clinical Outcomes in Patients With Heart Failure: A Randomized Clinical Trial. 
  • Effects of Dapagliflozin According to the Heart Failure Collaboratory Medical Therapy Score: Insights From DAPA-HF. 
  • Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial. 
  • Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial. 
  • Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. 
  • Effects of Liraglutide on Worsening Renal Function Among Patients With Heart Failure With Reduced Ejection Fraction: Insights From the FIGHT Trial. 
  • Effects of Omecamtiv Mecarbil on Symptoms and Health-Related Quality of Life in Patients With Chronic Heart Failure: Results From the COSMIC-HF Study. 
  • Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction. 
  • Effects of Serelaxin in Patients with Acute Heart Failure. 
  • Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study. 
  • Effects of a 9-Week Hybrid Comprehensive Telerehabilitation Program on Long-term Outcomes in Patients With Heart Failure: The Telerehabilitation in Heart Failure Patients (TELEREH-HF) Randomized Clinical Trial. 
  • Effects of a Novel Nitroxyl Donor in Acute Heart Failure: The STAND-UP AHF Study. 
  • Effects of a structured heart failure program on quality of life and frequency of hospital admission in Saudi Arabia. 
  • Effects of admission to a teaching hospital on the cost and quality of care for Medicare beneficiaries. 
  • Effects of amino acid supplementation on left ventricular remodeling in patients with chronic heart failure with decreased systolic function and diabetes mellitus: rationale and design of a magnetic resonance imaging study. 
  • Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. 
  • Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. 
  • Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. 
  • Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. 
  • Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. 
  • Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial. 
  • Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial. 
  • Effects of exercise training on depressive symptoms in patients with chronic heart failure: the HF-ACTION randomized trial. 
  • Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial. 
  • Effects of hybrid comprehensive telerehabilitation on cardiopulmonary capacity in heart failure patients depending on diabetes mellitus: subanalysis of the TELEREH-HF randomized clinical trial. 
  • Effects of kaliuretic peptide on sodium and water excretion in persons with congestive heart failure. 
  • Effects of left ventricular assist device support on biomarkers of cardiovascular stress, fibrosis, fluid homeostasis, inflammation, and renal injury. 
  • Effects of mindfulness training programmes delivered by a self-directed mobile app and by telephone compared with an education programme for survivors of critical illness: a pilot randomised clinical trial. 
  • Effects of nesiritide and predictors of urine output in acute decompensated heart failure: results from ASCEND-HF (acute study of clinical effectiveness of nesiritide and decompensated heart failure). 
  • Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial. 
  • Effects of propranolol treatment on left ventricular function and intracellular calcium regulation in rats with postinfarction heart failure. 
  • Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF. 
  • Effects of serelaxin in patients admitted for acute heart failure: a meta-analysis. 
  • Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF. 
  • Effects of serelaxin on the outcome of patients with or without substantial peripheral edema: A subgroup analysis from the RELAX-AHF trial. 
  • Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. 
  • Effects of the Novel Long-Acting GLP-1 Agonist, Albiglutide, on Cardiac Function, Cardiac Metabolism, and Exercise Capacity in Patients With Chronic Heart Failure and Reduced Ejection Fraction. 
  • Effects of the adenosine A1 receptor antagonist rolofylline on renal function in patients with acute heart failure and renal dysfunction: results from PROTECT (Placebo-Controlled Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function). 
  • Effects of the chymase inhibitor fulacimstat on adverse cardiac remodeling after acute myocardial infarction-Results of the Chymase Inhibitor in Adverse Remodeling after Myocardial Infarction (CHIARA MIA) 2 trial. 
  • Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. 
  • Effects of vericiguat in heart failure with reduced ejection fraction: do not forget sST2. Reply. 
  • Efficacy and Safety of Antithrombotic Therapy in Patients With Atrial Fibrillation, Recent Acute Coronary Syndrome, or Percutaneous Coronary Intervention and a History of Heart Failure: Insights From the AUGUSTUS Trial. 
  • Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial. 
  • Efficacy and Safety of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Age: The DELIVER Trial. 
  • Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial. 
  • Efficacy and Safety of Sacubitril/Valsartan in High-Risk Patients in the PIONEER-HF Trial. 
  • Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial. 
  • Efficacy and Safety of Tolvaptan in Patients Hospitalized With Acute Heart Failure. 
  • Efficacy and durability of central oversewing for treatment of aortic insufficiency in patients with continuous-flow left ventricular assist devices. 
  • Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analysis. 
  • Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programme. 
  • Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial. 
  • Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. 
  • Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. 
  • Efficacy and safety of nesiritide in patients with acute decompensated heart failure. 
  • Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF. 
  • Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis. 
  • Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial. 
  • Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial. 
  • Efficacy of Intravenous Furosemide Versus a Novel, pH-Neutral Furosemide Formulation Administered Subcutaneously in Outpatients With Worsening Heart Failure. 
  • Efficacy of azimilide for the maintenance of sinus rhythm in patients with paroxysmal atrial fibrillation in the presence and absence of structural heart disease. 
  • Efficacy of signal-averaged electrocardiography in the young orthotopic heart transplant patient to detect allograft rejection. 
  • Efficacy of zoniporide, an Na/H exchange ion inhibitor, for reducing perioperative cardiovascular events in vascular surgery patients. 
  • Ejection fraction assessment and survival: an analysis of the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). 
  • Electrical storm in patients with left ventricular assist devices: Risk factors, incidence, and impact on survival. 
  • Electrocardiographic QRS duration and the risk of congestive heart failure: the Framingham Heart Study. 
  • Electromechanical associations. 
  • Electronic health records and quality of care for heart failure. 
  • Elevated Uric Acid Prevalence and Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction: Insights from RELAX. 
  • Eligibility for sacubitril/valsartan in heart failure across the ejection fraction spectrum: real-world data from the Swedish Heart Failure Registry. 
  • Eligibility of sodium-glucose co-transporter-2 inhibitors among patients with diabetes mellitus admitted for heart failure. 
  • Emergence of coagulase-negative staphylococci as a cause of native valve endocarditis. 
  • Emergency Department Visits Versus Hospital Readmissions Among Patients Hospitalized for Heart Failure. 
  • Emerging Implantable-Device Technology for Patients at the Intersection of Electrophysiology and Heart Failure Interdisciplinary Care. 
  • Emerging Therapies for Congestive Heart Failure. 
  • Emerging role of the tissue renin-angiotensin systems in congestive heart failure. 
  • Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes. 
  • Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial. 
  • Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. 
  • Empirically Based Guidelines for Selecting Vagus Nerve Stimulation Parameters in Epilepsy and Heart Failure. 
  • Empower the Future… Even Oprah Had a Mentor! 
  • Enalapril in infants with single ventricle: results of a multicenter randomized trial. 
  • End point selection in acute decompensated heart failure clinical trials: economic end points. 
  • End points for clinical trials in acute heart failure syndromes. 
  • End-of-life Heart Failure Care in the United States. 
  • End-of-life care in patients with implantable cardioverter defibrillators: a MADIT-II substudy. 
  • Endomyocardial Biopsy Characterization of Heart Failure With Preserved Ejection Fraction and Prevalence of Cardiac Amyloidosis. 
  • Endothelial Stromal PD-L1 (Programmed Death Ligand 1) Modulates CD8+ T-Cell Infiltration After Heart Transplantation. 
  • Endothelial nitric oxide synthase increases in left atria of dogs with pacing-induced heart failure. 
  • Endothelium modulation of the effects of nitroglycerin on blood vessels from dogs with pacing-induced heart failure. 
  • Endothelium-dependent relaxations in canine coronary arteries are enhanced in early heart failure and persist in recovery. 
  • Endovascular ablation of the right greater splanchnic nerve in heart failure with preserved ejection fraction: early results of the REBALANCE-HF trial roll-in cohort. 
  • Endpoints for diuresis: are we there yet? 
  • Endpoints in Heart Failure Drug Development: History and Future. 
  • Endurance training modulates lymphocyte function in rats with post-MI CHF. 
  • Energetics and metabolism in the failing heart: important but poorly understood. 
  • Energy metabolic reprogramming in the hypertrophied and early stage failing heart: a multisystems approach. 
  • Engaging patients and families to create a feasible clinical trial integrating palliative and heart failure care: results of the ENABLE CHF-PC pilot clinical trial. 
  • Enhanced External Counterpulsation (EECP): enough evidence to support this and the next wave? 
  • Enhanced Galphaq signaling: a common pathway mediates cardiac hypertrophy and apoptotic heart failure. 
  • Enhanced access to primary care for patients with congestive heart failure. Veterans Affairs Cooperative Study Group on Primary Care and Hospital Readmission. 
  • Enhanced effect of combining human cardiac stem cells and bone marrow mesenchymal stem cells to reduce infarct size and to restore cardiac function after myocardial infarction. 
  • Enhanced myocardial function in transgenic mice overexpressing the beta 2-adrenergic receptor. 
  • Enhancement of cardiac function after adenoviral-mediated in vivo intracoronary beta2-adrenergic receptor gene delivery. 
  • Enhancing Cardiovascular Care: Global Collaboration Is How It Happens. 
  • Enrollment and events of hospice patients with heart failure vs. cancer. 
  • Enrollment in Heart Failure Clinical Trials: Insights Into Which Entry Criteria Exclude Patients. 
  • Enrollment of Older Patients, Women, and Racial and Ethnic Minorities in Contemporary Heart Failure Clinical Trials: A Systematic Review. 
  • Enterococcal endocarditis in the beginning of the 21st century: analysis from the International Collaboration on Endocarditis-Prospective Cohort Study. 
  • Epidemiology and risk factors for heart failure in the elderly. 
  • Epidemiology of cardiorenal syndrome. 
  • Epidemiology of cardiorenal syndrome. 
  • Epidemiology of drug-disease interactions in older veteran nursing home residents. 
  • Epidemiology of geographic disparities in heart failure among US older adults: a Medicare-based analysis. 
  • Epidemiology of infection in mechanical circulatory support: A global analysis from the ISHLT Mechanically Assisted Circulatory Support Registry. 
  • Epidemiology, management, and outcomes of sustained ventricular arrhythmias after continuous-flow left ventricular assist device implantation. 
  • Epigenomic regulation of heart failure: integrating histone marks, long noncoding RNAs, and chromatin architecture. 
  • Equitable improvement for women and men in the use of guideline-recommended therapies for heart failure: findings from IMPROVE HF. 
  • Equivalence Ratio for Daunorubicin to Doxorubicin in Relation to Late Heart Failure in Survivors of Childhood Cancer. 
  • Escalating and De-escalating Temporary Mechanical Circulatory Support in Cardiogenic Shock: A Scientific Statement From the American Heart Association. 
  • Establishing a pragmatic framework to optimise health outcomes in heart failure and multimorbidity (ARISE-HF): A multidisciplinary position statement. 
  • Estimated Glomerular Filtration Rate Variability in Patients With Heart Failure and Chronic Kidney Disease. 
  • Estimated Long-Term Benefit of Dapagliflozin in Patients With Heart Failure. 
  • Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. 
  • Evaluating Discrimination of Risk Prediction Models: The C Statistic. 
  • Evaluating strict and conventional left bundle branch block criteria using electrocardiographic simulations. 
  • Evaluating the Application of Chronic Heart Failure Therapies and Developing Treatments in Individuals With Recent Myocardial Infarction: A Review. 
  • Evaluating treatment efficacy by multiple end points in phase II acute heart failure clinical trials: analyzing data using a global method. 
  • Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE): design and rationale. 
  • Evaluation and Treatment of Central Sleep Apnea in Patients with Heart Failure. 
  • Evaluation of New-Onset Ascites. 
  • Evaluation of Novel Metrics of Symptom Relief in Acute Heart Failure: The Worst Symptom Score. 
  • Evaluation of a provocative dyspnea severity score in acute heart failure. 
  • Evaluation of heart failure websites for patient education. 
  • Evaluation of indices of left ventricular contractility and relaxation in evolving canine experimental heart failure. 
  • Evaluation of mechanical dyssynchrony and myocardial perfusion using phase analysis of gated SPECT imaging in patients with left ventricular dysfunction. 
  • Evaluation of platelets in heart failure: is platelet activity related to etiology, functional class, or clinical outcomes? 
  • Evaluation of right and left ventricular diastolic filling. 
  • Evaluation of risk indices in continuous-flow left ventricular assist device patients. 
  • Evaluation of the Incremental Prognostic Utility of Increasingly Complex Testing in Chronic Heart Failure. 
  • Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. 
  • Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial. 
  • Evaluation of the role of endomyocardial biopsy in 851 patients with unexplained heart failure from 2000-2009. 
  • Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. 
  • Evidence Builds for Catheter Ablation for Atrial Fibrillation and Heart Failure. 
  • Evidence for tissue-specific activation of renal angiotensinogen mRNA expression in chronic stable experimental heart failure. 
  • Evidence of clinical practice heterogeneity in the use of implantable cardioverter-defibrillators in heart failure and post-myocardial infarction left ventricular dysfunction: Findings from IMPROVE HF. 
  • Evidence-Based Process Performance Measures and Clinical Outcomes in Patients With Incident Heart Failure With Reduced Ejection Fraction: A Danish Nationwide Cohort Study. 
  • Evolution of Left Ventricular Assist Device Therapy for Advanced Heart Failure: A Review. 
  • Evolution of a Geriatric Syndrome: Pathophysiology and Treatment of Heart Failure with Preserved Ejection Fraction. 
  • Evolving Landscape of Clinical Trials in Heart Failure: Patient Populations, Endpoint Selection, and Regions of Enrollment. 
  • Examining the interrelatedness of patient and spousal stress in heart failure: conceptual model and pilot data. 
  • Exception-Status Listing: A Critical Pathway to Heart Transplantation for Adults With Congenital Heart Diseases. 
  • Excess body mass index- and waist circumference-years and incident cardiovascular disease: the CARDIA study. 
  • Exercise Training in Patients With Chronic Heart Failure and Atrial Fibrillation. 
  • Exercise blood pressure response during assisted circulatory support: comparison of the total artificial [corrected] heart with a left ventricular assist device during rehabilitation. 
  • Exercise capacity and mortality in patients with ischemic left ventricular dysfunction randomized to coronary artery bypass graft surgery or medical therapy: an analysis from the STICH trial (Surgical Treatment for Ischemic Heart Failure). 
  • Exercise training and implantable cardioverter-defibrillator shocks in patients with heart failure: results from HF-ACTION (Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing). 
  • Exercise training and pacing status in patients with heart failure: results from HF-ACTION. 
  • Exercise training as therapy for heart failure: current status and future directions. 
  • Exercise training changes IL-10/TNF-alpha ratio in the skeletal muscle of post-MI rats. 
  • Exercise training for chronic heart failure (ExTraMATCH II): protocol for an individual participant data meta-analysis. 
  • Exercise training for prevention and treatment of older adults with heart failure with preserved ejection fraction. 
  • Exercise training of patients with ventricular dysfunction and heart failure. 
  • Exercise-induced angiogenesis-related growth and transcription factors in skeletal muscle, and their modification in muscle pathology. 
  • Exertional dyspnea in heart failure: a symptom unrelated to pulmonary function at rest or during exercise. Duke University Clinical Cardiology Studies (DUCCS) Exercise Group. 
  • Exogenous ketones in the healthy heart: the plot thickens. 
  • Expanded algorithm for managing patients with acute decompensated heart failure. 
  • Expenditure on Heart Failure in the United States: A Rising Tide Lifts All Boats. 
  • Experimental congestive heart failure produced by rapid ventricular pacing in the dog: cardiac effects. 
  • Expert consensus document: Mitochondrial function as a therapeutic target in heart failure. 
  • Exploring Culturally Responsive Religious and Spirituality Health Care Communications among African Americans with Advanced Heart Failure, Their Family Caregivers, and Clinicians. 
  • Exploring New Cardiovascular Pathways: Are Soluble Guanylate Cyclase Stimulators the Right Direction? 
  • Exploring differences between patients who accept, decline, and are deemed ineligible for left ventricular assist device implantation as destination therapy. 
  • Exploring the role of the beta-adrenergic receptor kinase in cardiac disease using gene-targeted mice. 
  • Expression of a beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. 
  • Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. 
  • Extent of coronary artery disease as a predictor of outcomes in acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. 
  • Extra-cardiac targets in the management of cardiometabolic disease: Device-based therapies. 
  • Extracardiac Abnormalities of Preload Reserve: Mechanisms Underlying Exercise Limitation in Heart Failure with Preserved Ejection Fraction, Autonomic Dysfunction, and Liver Disease. 
  • Extracorporeal Membrane Oxygenation in Pediatric Trisomy 21: 30 Years of Experience from the Extracorporeal Life Support Organization Registry. 
  • Extracorporeal membrane oxygenation support and post-heart transplant outcomes among United States adults. 
  • Extreme Acetylation of the Cardiac Mitochondrial Proteome Does Not Promote Heart Failure. 
  • FDA in the 21st Century: Focus on Tobacco Policies and Heart Failure Prevention. 
  • FGF21-FGFR4 signaling in cardiac myocytes promotes concentric cardiac hypertrophy in mouse models of diabetes. 
  • Factors Associated With Racial and Ethnic Diversity Among Heart Failure Trial Participants: A Systematic Bibliometric Review. 
  • Factors Associated With and Prognostic Implications of Cardiac Troponin Elevation in Decompensated Heart Failure With Preserved Ejection Fraction: Findings From the American Heart Association Get With The Guidelines-Heart Failure Program. 
  • Factors and outcomes associated with improved left ventricular systolic function in patients with cardiomyopathy. 
  • Factors associated with improvement in ejection fraction in clinical practice among patients with heart failure: findings from IMPROVE HF. 
  • Factors associated with improvement in guideline-based use of ICDs in eligible heart failure patients. 
  • Factors associated with improvement in utilization of cardiac resynchronization therapy in eligible heart failure patients: findings from IMPROVE HF. 
  • Factors associated with isolated right heart failure in women: a pilot study from western Kenya. 
  • Factors associated with non-use and sub-target dosing of medical therapy for heart failure with reduced ejection fraction. 
  • Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF. 
  • Factors related to morbidity and mortality in patients with chronic heart failure with systolic dysfunction: the HF-ACTION predictive risk score model. 
  • Failure of platelet parameters and biomarkers to correlate platelet function to severity and etiology of heart failure in patients enrolled in the EPCOT trial. With special reference to the Hemodyne hemostatic analyzer. Whole Blood Impedance Aggregometry for the Assessment of Platelet Function in Patients with Congestive Heart Failure. 
  • Familial aggregation of left ventricular geometry and association with parental heart failure: the Framingham Heart Study. 
  • Family history of dilated cardiomyopathy among patients with heart failure from the HF-ACTION genetic ancillary study. 
  • Family income and cardiovascular disease risk in American adults. 
  • Fatigability, Exercise Intolerance, and Abnormal Skeletal Muscle Energetics in Heart Failure. 
  • Feasibility and safety of moderate hypothermia after massive hemispheric infarction. 
  • Feasibility of Cardiac Rehabilitation Models in Kenya. 
  • Feasibility of a Randomized Clinical Trial of Cardiac Resynchronization Therapy With or Without an Implantable Defibrillator in Older Patients. 
  • Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. 
  • Fibroblast Growth Factor 23 and Exercise Capacity in Heart Failure with Preserved Ejection Fraction. 
  • Fibroblast Growth Factor-23, Heart Failure Risk, and Renin-Angiotensin-Aldosterone-System Blockade in Hypertension: The MESA Study. 
  • Fibroblast growth factor-23 and cardiovascular events in CKD. 
  • Financial difficulties and patient-reported outcomes among patients with advanced heart failure. 
  • Financial implications of a model heart failure disease management program for providers, hospital, healthcare systems, and payer perspectives. 
  • Finding the road to recovery: therapeutic and clinical trial implications of dysfunctional viable myocardium in heart failure with reduced ejection fraction. 
  • Finerenone in heart failure: walking a fine line. 
  • Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial. 
  • First successful bridge to cardiac transplantation using direct mechanical ventricular actuation. 
  • First-degree AV block-an entirely benign finding or a potentially curable cause of cardiac disease? 
  • Fluid Resuscitation in Septic Patients With Comorbid Heart Failure. 
  • Fluid dynamics of ventricular filling in heart failure: overlooked problems of RV/LV chamber dilatation. 
  • Fluid removal in acute heart failure: diuretics versus devices. 
  • Focused cardiac ultrasound as a predictor of readmission in acute decompensated heart failure. 
  • Following Our Hearts: Prioritizing Self-care and Wellness. 
  • Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. 
  • Fostering Belonging at JCF. 
  • Frailty Among Older Decompensated Heart Failure Patients: Prevalence, Association With Patient-Centered Outcomes, and Efficient Detection Methods. 
  • Frailty Status Modifies the Efficacy of Exercise Training Among Patients With Chronic Heart Failure and Reduced Ejection Fraction: An Analysis From the HF-ACTION Trial. 
  • Frailty in the End-Stage Lung Disease or Heart Failure Patient: Implications for the Perioperative Transplant Clinician. 
  • Frailty, Guideline-Directed Medical Therapy, and Outcomes in HFrEF: From the GUIDE-IT Trial. 
  • Frequency, patient characteristics, and outcomes of mild-to-moderate heart failure complicating ST-segment elevation acute myocardial infarction: lessons from 4 international fibrinolytic therapy trials. 
  • From Clinical Trials to Communities: The 5 C's of Ensuring Equitable Delivery of Heart Failure Therapies. 
  • From Theory to Practice: The Use of Real-World Data to Evaluate New Heart Failure Therapies. 
  • Function Follows Form. 
  • Functional aging in health and heart failure: the COmPLETE Study. 
  • Functional and Symptomatic Clinical Trial Endpoints: The HFC-ARC Scientific Expert Panel. 
  • Functional status in left ventricular assist device-supported patients: a literature review. 
  • Further aspects of anemia, heart failure, and erythropoietin. 
  • Fusion of aortic valve commissures in patients supported by a continuous axial flow left ventricular assist device. 
  • Future research prioritization in cardiac resynchronization therapy. 
  • G protein-coupled receptor signalling in in vivo cardiac overload. 
  • G-Protein-Coupled Receptors in Heart Disease. 
  • G-protein-coupled receptor function in heart failure. 
  • GLP-1 agonist therapy for advanced heart failure with reduced ejection fraction: design and rationale for the functional impact of GLP-1 for heart failure treatment study. 
  • Gadolinium cardiovascular magnetic resonance predicts reversible myocardial dysfunction and remodeling in patients with heart failure undergoing beta-blocker therapy. 
  • Galectin-3 and mineralocorticoid receptor antagonist use in patients with chronic heart failure due to left ventricular systolic dysfunction. 
  • Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study. 
  • Galectin-3 in heart failure: more answers or more questions? 
  • Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. 
  • Gender does not affect postdischarge outcomes in patients hospitalized for worsening heart failure with reduced ejection fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan [EVEREST] Trial). 
  • Gene delivery approaches to heart failure treatment. 
  • Gene expression analysis of cardiovascular diseases: novel insights into biology and clinical applications. 
  • Gene therapy and genomic strategies for cardiovascular surgery: The emerging field of surgiomics. 
  • Generalizability and longitudinal outcomes of a national heart failure clinical registry: Comparison of Acute Decompensated Heart Failure National Registry (ADHERE) and non-ADHERE Medicare beneficiaries. 
  • Generalizability of the CASTLE-AF trial: Catheter ablation for patients with atrial fibrillation and heart failure in routine practice. 
  • Genetic Dissection of Cardiac Remodeling in an Isoproterenol-Induced Heart Failure Mouse Model. 
  • Genetic variants are not associated with outcome in patients with coronary artery disease and left ventricular dysfunction: results of the Genetic Substudy of the Surgical Treatment for Ischemic Heart Failure (STICH) trials. 
  • Genetics of common forms of heart failure: challenges and potential solutions. 
  • Genomics and the circulation. 
  • Genomics and the pathophysiology of heart failure. 
  • Geographic Differences in Patients in a Global Acute Heart Failure Clinical Trial (from the ASCEND-HF Trial). 
  • Get With The Guidelines program participation, process of care, and outcome for Medicare patients hospitalized with heart failure. 
  • Gi-biased β2AR signaling links GRK2 upregulation to heart failure. 
  • Gleaning physiologic information from the conventional chest radiograph. 
  • Glenn shunt facilitated weaning of right ventricular mechanical support. 
  • Global Variations in Patient Populations and Outcomes in Heart Failure Clinical Trials. 
  • Global perspectives in hospitalized heart failure: regional and ethnic variation in patient characteristics, management, and outcomes. 
  • Global representation of heart failure clinical trial leaders, collaborators, and enrolled participants: a bibliometric review 2000-20. 
  • Global variation in clinical profile, management, and post-discharge outcomes among patients hospitalized for worsening chronic heart failure: findings from the ASTRONAUT trial. 
  • Global variation in quality of care among patients hospitalized with acute heart failure in an international trial: findings from the acute study clinical effectiveness of nesiritide in decompensated heart failure trial (ASCEND-HF). 
  • Globalization of heart failure clinical trials: a systematic review of 305 trials conducted over 16 years. 
  • Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization. 
  • Glycated Hemoglobin and Outcomes of Heart Failure (from Get With the Guidelines-Heart Failure). 
  • Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes. 
  • Glycemic status and the association of change in blood pressure with incident cardiovascular disease. 
  • Glycogen-branching enzyme deficiency leads to abnormal cardiac development: novel insights into glycogen storage disease IV. 
  • Grassroots marketing in a global era: more lessons from BiDil. 
  • Greater Splanchnic Nerve Stimulation in Heart Failure With Preserved Ejection Fraction. 
  • Growth differentiation factor 15 (GDF-15) in patients admitted for acute heart failure: results from the RELAX-AHF study. 
  • Growth differentiation factor 15 and cardiovascular risk: individual patient meta-analysis. 
  • Growth differentiation factor-15, treatment with liraglutide, and clinical outcomes among patients with heart failure. 
  • Guidance for Timely and Appropriate Referral of Patients With Advanced Heart Failure: A Scientific Statement From the American Heart Association. 
  • Guideline-Appropriate Care and In-Hospital Outcomes in Patients With Heart Failure in Teaching and Nonteaching Hospitals: Findings From Get With The Guidelines-Heart Failure. 
  • Guideline-Directed Medical Therapy and Survival Following Hospitalization in Patients with Heart Failure. 
  • Guideline-Directed Medical Therapy Clinics: A Call to Action for the Heart Failure Team. 
  • Guideline-directed therapies for comorbidities and clinical outcomes among individuals with atrial fibrillation. 
  • HCV Positive Allograft Use in Heart Transplant: A Silver Lining to an Epidemic. 
  • HFSA 2010 Comprehensive Heart Failure Practice Guideline. 
  • HFpEF: From Early Observations to Worldwide Awareness. 
  • HVAD: The ENDURANCE Supplemental Trial. 
  • Haemoconcentration during treatment of acute heart failure with cardiorenal syndrome: from the CARRESS-HF trial. 
  • Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. 
  • Haemodynamic effects of rolofylline in the treatment of patients with heart failure and impaired renal function. 
  • Haemodynamic effects of the nitroxyl donor cimlanod (BMS-986231) in chronic heart failure: a randomized trial. 
  • Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction. 
  • Haplo-insufficiency of Bcl2-associated athanogene 3 in mice results in progressive left ventricular dysfunction, β-adrenergic insensitivity, and increased apoptosis. 
  • Happy 50th Birthday, Cardiac Transplantation: Happy 5th Birthday, JACC: Heart Failure. 
  • Has Public Reporting of Hospital Readmission Rates Affected Patient Outcomes?: Analysis of Medicare Claims Data. 
  • HbA 1c as a risk factor for heart failure in persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) study. 
  • Health Status Disparities by Sex, Race/Ethnicity, and Socioeconomic Status in Outpatients With Heart Failure. 
  • Health Status Variation Across Practices in Outpatients With Heart Failure: Insights From the CHAMP-HF (Change the Management of Patients With Heart Failure) Registry. 
  • Health System-Level Performance in Prescribing Guideline-Directed Medical Therapy for Patients With Heart Failure With Reduced Ejection Fraction: Results From the CONNECT-HF Trial. 
  • Health status and depression remission in patients with chronic heart failure: patient-reported outcomes from the SADHART-CHF trial. 
  • Health-Related Quality of Life in Comorbid Heart Failure With Reduced Ejection Fraction and Diabetes Mellitus. 
  • Healthcare Resource Use and Cost Implications in the MOMENTUM 3 Long-Term Outcome Study. 
  • Healthcare utilization and cost in patients with atrial fibrillation and heart failure undergoing catheter ablation. 
  • Healthy Aging and Cardiovascular Function: Invasive Hemodynamics During Rest and Exercise in 104 Healthy Volunteers. 
  • Heart Failure "End Result Cards": Solid B. 
  • Heart Failure Clinical Trial Operations During the COVID-19 Pandemic: Results From a Multicenter Survey. 
  • Heart Failure Clinical Trials in East and Southeast Asia: Understanding the Importance and Defining the Next Steps. 
  • Heart Failure Collaboratory Statement on Remote Monitoring and Social Distancing in the Landscape of COVID-19. 
  • Heart Failure Complicated by Atrial Fibrillation: Don't Bury the Beta-Blockers Just Yet. 
  • Heart Failure Drug Therapy: New Treatments, New Guidelines. 
  • Heart Failure Duration and Mechanistic Efficacy of Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction. 
  • Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Critical Evaluation of Clinical and Regulatory Issues. 
  • Heart Failure Fake News: How Do We Distinguish the Truth? 
  • Heart Failure Health Care 2018: Challenges and Opportunities. 
  • Heart Failure Is Common and Under-Recognized in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia. 
  • Heart Failure Primary Prevention: What Does SPRINT Add?: Recent Advances in Hypertension. 
  • Heart Failure Site-Based Research in the United States: Results of the Heart Failure Society of America Research Network Survey. 
  • Heart Failure Specific Versus All-cause End Points in Heart Failure Clinical Trials. 
  • Heart Failure Strategically Focused Research Network: Summary of Results and Future Directions. 
  • Heart Failure With Preserved Ejection Fraction Expert Panel Report: Current Controversies and Implications for Clinical Trials. 
  • Heart Failure With Preserved Ejection Fraction and Diabetes: JACC State-of-the-Art Review. 
  • Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes. 
  • Heart Failure With Reduced Ejection Fraction in Human Immunodeficiency Virus Infection: The More Things Stay the Same. 
  • Heart Failure and Hospital Utilization Trajectories Before and After Hip Fracture Surgery. 
  • Heart Failure in Non-Caucasians, Women, and Older Adults: A White Paper on Special Populations From the Heart Failure Society of America Guideline Committee. 
  • Heart Failure in Women. 
  • Heart Failure with Preserved Ejection Fraction in Older Adults. 
  • Heart Failure-Related Cardiogenic Shock: Pathophysiology, Evaluation and Management Considerations: Review of Heart Failure-Related Cardiogenic Shock. 
  • Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association. 
  • Heart Month - A Historical Look and Simple "Walk" of Acknowledgement in the Present. 
  • Heart Rate or Beta-Blocker Dose? Association With Outcomes in Ambulatory Heart Failure Patients With Systolic Dysfunction: Results From the HF-ACTION Trial. 
  • Heart Sound Analysis in Individuals Supported With Left Ventricular Assist Devices. 
  • Heart Transplantation Survival Outcomes of HIV Positive and Negative Recipients. 
  • Heart Transplantation and Mechanical Circulatory Support in Adults with Congenital Heart Disease. 
  • Heart Transplantation: An In-Depth Survival Analysis. 
  • Heart failure after myocardial infarction: A good heart is hard to find. 
  • Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF-alpha antagonists. 
  • Heart failure and a controlled trial investigating outcomes of exercise training (HF-ACTION): design and rationale. 
  • Heart failure and depression. 
  • Heart failure and the elderly: disease diversity, data, and delivery of care. 
  • Heart failure care and outcomes in a Tanzanian emergency department: A prospective observational study. 
  • Heart failure care in the outpatient cardiology practice setting: findings from IMPROVE HF. 
  • Heart failure complicating non-ST-segment elevation acute coronary syndrome: timing, predictors, and clinical outcomes. 
  • Heart failure disease management program experience in 4,545 heart failure admissions to a community hospital. 
  • Heart failure drug treatment. 
  • Heart failure during cardiac pacing. 
  • Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. 
  • Heart failure event definitions in drug trials in patients with type 2 diabetes. 
  • Heart failure hospitalization is more common in pacemaker patients with sinus node dysfunction and a prolonged paced QRS duration. 
  • Heart failure in elderly patients: distinctive features and unresolved issues. 
  • Heart failure in sub-Saharan Africa. 
  • Heart failure medications prescribed at discharge for patients with left ventricular assist devices. 
  • Heart failure oral therapies at discharge are associated with better outcome in acute heart failure: a propensity-score matched study. 
  • Heart failure preserved ejection fraction (HFpEF): an integrated and strategic review. 
  • Heart failure quality of care and in-hospital outcomes during the COVID-19 pandemic: findings from the Get With The Guidelines-Heart Failure registry. 
  • Heart failure severity, inappropriate ICD therapy, and novel ICD programming: a MADIT-RIT substudy. 
  • Heart failure survival score in patients with Chagas disease: correlation with functional variables. 
  • Heart failure therapeutics on the basis of a biased ligand of the angiotensin-2 type 1 receptor. Rationale and design of the BLAST-AHF study (Biased Ligand of the Angiotensin Receptor Study in Acute Heart Failure). 
  • Heart failure treatment and the art of medical decision making. 
  • Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. 
  • Heart failure with mid-range ejection fraction: pro and cons of the new classification of Heart Failure by European Society of Cardiology guidelines. 
  • Heart failure with preserved ejection fraction in the elderly: scope of the problem. 
  • Heart failure with preserved ejection fraction: New approaches to diagnosis and management. 
  • Heart failure with preserved ejection fraction: a heterogenous disorder with multifactorial pathophysiology. 
  • Heart failure with preserved ejection fraction: comparison of patients with and without angina pectoris (from the Duke Databank for Cardiovascular Disease). 
  • Heart failure with preserved left ventricular systolic function among patients with non-ST-segment elevation acute coronary syndromes. 
  • Heart failure: where the paths cross. 
  • Heart rate at hospital discharge in patients with heart failure is associated with mortality and rehospitalization. 
  • Heart rate is associated with progression of atrial fibrillation, independent of rhythm. 
  • Heart rate: a prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering properties. 
  • Heart transplantation for adults with congenital heart disease: analysis of the United network for organ sharing database. 
  • Heartmate III Replacement for Recurring Left Ventricular Assist Device Pump Thrombosis. 
  • Heart Failure Collaboratory Statement on Clinical Trials in the Landscape of COVID-19. 
  • Heart Failure Editorial Emergencies in the COVID-19 Era. 
  • Heart Failure Hospitalization and Guideline-Directed Prescribing Patterns Among Heart Failure With Reduced Ejection Fraction Patients. 
  • Heart Failure Leadership, Culture, and Governance: Lessons Learned From Tom Brady. 
  • Heart Failure Management Under Pressure. 
  • Heart Failure Multidisciplinary Teams and New Zealand Rugby: What Can We Learn From the "All Blacks" Rugby Team? 
  • Heart Failure Outcomes and Associated Factors Among Veterans With Human Immunodeficiency Virus Infection. 
  • Heart Failure Physician Burnout: How Can We Help? 
  • Heart Failure Prevention in Older Patients Using Intensive Blood Pressure Reduction: Potential Role of Diuretics. 
  • Heart Failure and Atrial Fibrillation, Like Fire and Fury. 
  • Hemiazygous coil placement for high-defibrillation thresholds in a patient with a right-sided implantable cardioverter defibrillator. 
  • Hemocompatibility-Related Outcomes in the MOMENTUM 3 Trial at 6 Months: A Randomized Controlled Study of a Fully Magnetically Levitated Pump in Advanced Heart Failure. 
  • Hemoconcentration-guided diuresis in heart failure. 
  • Hemodynamic Predictors of Heart Failure Morbidity and Mortality: Fluid or Flow? 
  • Hemodynamic and Clinical Determinants of Left Atrial Enlargement in Liver Transplant Candidates. 
  • Hemodynamic evaluation of glucagon in symptomatic heart disease. 
  • Hemodynamic profiles of advanced heart failure: association with clinical characteristics and long-term outcomes. 
  • Hemodynamics as surrogate end points for survival in advanced heart failure: an analysis from FIRST. 
  • Hemoglobin and Clinical Outcomes in the Vericiguat Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA). 
  • Hemoglobin, exercise training, and health status in patients with chronic heart failure (from the HF-ACTION randomized controlled trial). 
  • Hemostatic abnormalities in patients with congestive heart failure: diagnostic significance and clinical challenge. 
  • Hepatocyte Growth Factor and Incident Heart Failure Subtypes: The Multi-Ethnic Study of Atherosclerosis (MESA). 
  • Hepatorenal dysfunction identifies high-risk patients with acute heart failure: insights from the RELAX-AHF trial. 
  • Heterogeneity of health status treatment response with sacubitril/valsartan: insights from the CHAMP-HF registry. 
  • Heterogeneous Outcomes of Heart Failure with Better Ejection Fraction. 
  • High Heart Failure Readmission Rates: Is It the Health System's Fault? 
  • High early event rates in patients with questionable eligibility for advanced heart failure therapies: Results from the Medical Arm of Mechanically Assisted Circulatory Support (Medamacs) Registry. 
  • High mortality without ESCAPE: the registry of heart failure patients receiving pulmonary artery catheters without randomization. 
  • High-Density Lipoprotein Particle Subfractions in Heart Failure With Preserved or Reduced Ejection Fraction. 
  • High-Resolution Mapping of Chromatin Conformation in Cardiac Myocytes Reveals Structural Remodeling of the Epigenome in Heart Failure. 
  • High-Sensitivity Troponin I in Hospitalized and Ambulatory Patients With Heart Failure With Preserved Ejection Fraction: Insights From the Heart Failure Clinical Research Network. 
  • High-Sensitivity Troponin in Acute Heart Failure Triage. 
  • High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trial. 
  • High-normal albuminuria and risk of heart failure in the community. 
  • High-sensitivity C-reactive protein in acute heart failure: insights from the ASCEND-HF trial. 
  • High-sensitivity troponin T and N-terminal pro-B-type natriuretic peptide (NT-proBNP) and risk of incident heart failure in patients with CKD: the Chronic Renal Insufficiency Cohort (CRIC) Study. 
  • Highest Obesity Category Associated With Largest Decrease in N-Terminal Pro-B-Type Natriuretic Peptide in Patients Hospitalized With Heart Failure With Preserved Ejection Fraction. 
  • Highlights of the 2007 Scientific Meeting of the Heart Failure Society of America: Washington, DC, September 16-19, 2007. 
  • Highlights of the 2008 Scientific Sessions of the Heart Failure Society of America. Toronto, Ontario, Canada, September 20-23, 2008. 
  • Highlights of the 2010 scientific sessions of the Heart Failure Society of America, San Diego, California, September 12-15, 2010. 
  • Histologic and electron microscopy findings in myocardium of treated Fabry disease. 
  • History of Atrial Fibrillation and Trajectory of Decongestion in Acute Heart Failure. 
  • Home Health Care Use and Post-Discharge Outcomes After Heart Failure Hospitalizations. 
  • Home-Time After Discharge Among Patients Hospitalized With Heart Failure. 
  • Hospice Care for Heart Failure: Challenges Faced by Hospice Staff in a Predominantly Rural Setting. 
  • Hospital use and costs among patients with nonischemic cardiomyopathy in the first prospective randomized amlodipine survival evaluation study. 
  • Hospital variation and characteristics of implantable cardioverter-defibrillator use in patients with heart failure: data from the GWTG-HF (Get With The Guidelines-Heart Failure) registry. 
  • Hospital variation in intravenous inotrope use for patients hospitalized with heart failure: insights from Get With The Guidelines. 
  • Hospital-based quality improvement interventions for patients with heart failure: a systematic review. 
  • Hospitalization Patterns and Impact of a Magnetically-Levitated Left Ventricular Assist Device in the MOMENTUM 3 Trial. 
  • Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure: From the ASCEND-HF Trial. 
  • Hospitalizations and Prognosis in Elderly Patients With Heart Failure and Preserved Ejection Fraction: Time to Treat the Whole Patient. 
  • Hospitalizations for heart failure during the COVID-19 pandemic: making sense of the known knowns, known unknowns, and unknown unknowns. 
  • Hospitalized Heart Failure in the United States: Lessons Learned from Clinical Trial Populations. 
  • How does intermittent pacing modify the response to rapid ventricular pacing in experimental heart failure? 
  • How many patients with heart failure are eligible for cardiac resynchronization? Insights from two prospective cohorts. 
  • How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. Results from the Breathing Not Properly Multinational Study. 
  • Human Immunodeficiency Virus and Heart Failure in Low- and Middle-Income Countries. 
  • Hybrid comprehensive telerehabilitation in heart failure patients (TELEREH-HF): A randomized, multicenter, prospective, open-label, parallel group controlled trial-Study design and description of the intervention. 
  • Hydration for prevention of kidney injury after primary coronary intervention for acute myocardial infarction: a randomised clinical trial. 
  • Hyperkalemia and Treatment With RAAS Inhibitors During Acute Heart Failure Hospitalizations and Their Association With Mortality. 
  • Hyperkalemia in Heart Failure: Probably Not O"K". 
  • Hypertension and heart failure. Roundtable discussion. 
  • Hypertension as a Road to Treatment of Heart Failure with Preserved Ejection Fraction. 
  • Hypertension with acute coronary syndrome and heart failure. 
  • Hypertensive Disorders of Pregnancy and Heart Failure Risk. 
  • Hypertensive Disorders of Pregnancy and Long-Term Heart Failure Risk: A Missed Opportunity for Prevention. 
  • Hypertensive heart failure: patient characteristics, treatment, and outcomes. 
  • Hypertrophic preconditioning: short-term tricks for long-term gain. 
  • Hypochloremia, Diuretic Resistance, and Outcome in Patients With Acute Heart Failure. 
  • Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: findings from propensity-matched studies. 
  • Hyponatraemia in acute heart failure is a marker of increased mortality but not when associated with hyperglycaemia. 
  • Hyponatremia and long-term outcomes in chronic heart failure--an observational study from the Duke Databank for Cardiovascular Diseases. 
  • Hyponatremia in congestive heart failure: implications for neurohumoral activation and responses to orthostasis. 
  • Hypoplastic right lung with systemic blood supply and anomalous pulmonary venous drainage: reversal of pulmonary hypertension with surgical management in infancy. 
  • Hypotension during hospitalization for acute heart failure is independently associated with 30-day mortality: findings from ASCEND-HF. 
  • I Brazilian Registry of Heart Failure - Clinical Aspects, Care Quality and Hospitalization Outcomes. 
  • I Don't Care How Low My BNP Is, I Want to Feel Good. 
  • ICDs Are Still an Effective Therapy to Prevent Sudden Cardiac Death in Heart Failure. 
  • IGF-1 predicts survival in chronic heart failure. Insights from the T.O.S.CA. (Trattamento Ormonale Nello Scompenso CArdiaco) registry. 
  • INDIE-HFpEF (Inorganic Nitrite Delivery to Improve Exercise Capacity in Heart Failure With Preserved Ejection Fraction): Rationale and Design. 
  • INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) Profiling Identifies Ambulatory Patients at High Risk on Medical Therapy After Hospitalizations for Heart Failure. 
  • INTERMACS: interval analysis of registry data. 
  • Identifying Barriers and Practical Solutions to Conducting Site-Based Research in North America: Exploring Acute Heart Failure Trials As a Case Study. 
  • Identifying Treatments for Stage C2 Heart Failure. 
  • Identifying patients at increased risk for poor outcomes from heart failure with reduced ejection fraction: the PROMPT-HF risk model. 
  • Identifying responders to oral iron supplementation in heart failure with a reduced ejection fraction: a post-hoc analysis of the IRONOUT-HF trial. 
  • Identifying, recruiting, and retaining seriously-ill patients and their caregivers in longitudinal research. 
  • Imaging for Temporary Mechanical Circulatory Support Devices. 
  • Imaging surrogate end points in heart failure trials. 
  • Impact of Age on Comorbidities and Outcomes in Heart Failure With Reduced Ejection Fraction. 
  • Impact of Atrial Fibrillation on In-Hospital Mortality and Thromboembolic Complications after Left Ventricular Assist Device Implantation. 
  • Impact of Bridge to Transplantation With Continuous-Flow Left Ventricular Assist Devices on Posttransplantation Mortality. 
  • Impact of Cardiovascular Magnetic Resonance Imaging on Identifying the Etiology of Cardiomyopathy in Patients Undergoing Cardiac Transplantation. 
  • Impact of Continuous Flow Left Ventricular Assist Device Therapy on Chronic Kidney Disease: A Longitudinal Multicenter Study. 
  • Impact of Current Versus Previous Cardiac Resynchronization Therapy Guidelines on the Proportion of Patients With Heart Failure Eligible for Therapy. 
  • Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death: Outcomes at 4 Years From the Reduction of Atherothrombosis for Continued Health (REACH) Registry. 
  • Impact of Ejection Fraction and Aortic Valve Gradient on Outcomes of Transcatheter Aortic Valve Replacement. 
  • Impact of Exercise Rehabilitation on Exercise Capacity and Quality-of-Life in Heart Failure: Individual Participant Meta-Analysis. 
  • Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE-IT. 
  • Impact of Induction Immunosuppression on Post-Transplant Outcomes of Patients Bridged with Contemporary Left Ventricular Assist Devices. 
  • Impact of Intubation Time on Survival following Coronary Artery Bypass Grafting: Insights from the Surgical Treatment for Ischemic Heart Failure (STICH) Trial. 
  • Impact of Non-Infarct-Related Artery Disease on Infarct Size and Outcomes (from the CRISP-AMI Trial). 
  • Impact of Obesity on Ventricular Assist Device Outcomes. 
  • Impact of Percutaneous Coronary Intervention on Outcomes in Patients With Heart Failure: JACC State-of-the-Art Review. 
  • Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial. 
  • Impact of a Formal Advance Care Planning Program on End-of-Life Care for Patients With Heart Failure: Results From a Randomized Controlled Trial. 
  • Impact of a Palliative Care Education Module in Patients With Heart Failure. 
  • Impact of acute beta-blocker therapy for patients with non-ST-segment elevation myocardial infarction. 
  • Impact of advance care planning on the care of patients with heart failure: study protocol for a randomized controlled trial. 
  • Impact of age, sex, therapeutic intent, race and severity of advanced heart failure on short-term principal outcomes in the MOMENTUM 3 trial. 
  • Impact of an expanded hospital recognition program for heart failure quality of care. 
  • Impact of atrial fibrillation on exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study. 
  • Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure. 
  • Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (valsartan in acute myocardial infarction). 
  • Impact of cardiovascular magnetic resonance on management and clinical decision-making in heart failure patients. 
  • Impact of center volume on outcomes of left ventricular assist device implantation as destination therapy: analysis of the Thoratec HeartMate Registry, 1998 to 2005. 
  • Impact of concurrent surgical valve procedures in patients receiving continuous-flow devices. 
  • Impact of congestive heart failure in patients with non-ST-segment elevation acute coronary syndromes. 
  • Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure. 
  • Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. 
  • Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. 
  • Impact of enalapril therapy on in vitro coronary artery responsiveness in pacing-induced heart failure. 
  • Impact of exercise-based cardiac rehabilitation in patients with heart failure (ExTraMATCH II) on mortality and hospitalisation: an individual patient data meta-analysis of randomised trials. 
  • Impact of genetic polymorphisms on heart failure prognosis. 
  • Impact of heart failure drug therapy on rates of gastrointestinal bleeding in LVAD recipients: An INTERMACS analysis. 
  • Impact of heart failure on patients undergoing major noncardiac surgery. 
  • Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failure. 
  • Impact of immortal person-time and time scale in comparative effectiveness research for medical devices: a case for implantable cardioverter-defibrillators. 
  • Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial. 
  • Impact of mitral valve regurgitation evaluated by intraoperative transesophageal echocardiography on long-term outcomes after coronary artery bypass grafting. 
  • Impact of nonfatal myocardial infarction on outcomes in patients with advanced heart failure and the effect of bucindolol therapy. 
  • Impact of serial troponin release on outcomes in patients with acute heart failure: analysis from the PROTECT pilot study. 
  • Impact of specialist follow-up in outpatients with congestive heart failure. 
  • Impact of tricuspid valve regurgitation in patients treated with implantable left ventricular assist devices. 
  • Impact of using a telescoping-support catheter system for left ventricular lead placement on implant success and procedure time of cardiac resynchronization therapy. 
  • Impairment of activities of daily living and incident heart failure in community-dwelling older adults. 
  • Implantable Cardioverter Defibrillator Utilization and Mortality Among Patients ≥65 Years of Age With a Low Ejection Fraction After Coronary Revascularization. 
  • Implantable Cardioverter-Defibrillator Eligibility After Initiation of Sacubitril/Valsartan in Chronic Heart Failure: Insights From PROVE-HF. 
  • Implantable Cardioverter-Defibrillators Have Stood the Test of Time! 
  • Implantable Cardioverter-Defibrillators in Patients With Left Ventricular Assist Devices: On Trial and in Need of a Trial. 
  • Implantable cardioverter defibrillators and cardiac resynchronization therapy in patients with left ventricular dysfunction: randomized trial evidence through 2004. 
  • Implantable cardioverter-defibrillator implementation in acute heart failure syndromes: unanswered questions. 
  • Implantable cardioverter-defibrillator lead revision following left ventricular assist device implantation. 
  • Implantable cardioverter-defibrillator therapy and risk of congestive heart failure or death in MADIT II patients with atrial fibrillation. 
  • Implantable cardioverter-defibrillators in heart failure patients with reduced ejection fraction and diabetes. 
  • Implantable cardioverter-defibrillators in patients hospitalized for heart failure with chronically reduced left ventricular ejection fraction. 
  • Implantable cardioverter-defibrillators. 
  • Implantable left ventricular assist devices: new hope for patients with end-stage heart failure. 
  • Implantation of a HeartMate 3 ventricular assist device in a 21-kg pediatric patient with Fontan failure. 
  • Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice. 
  • Implementation Noise. 
  • Implementation of a Disease Management Program in Adult Patients With Heart Failure. 
  • Implementing Electronic Tablet-Based Education of Acute Care Patients. 
  • Implications of Altered Ketone Metabolism and Therapeutic Ketosis in Heart Failure. 
  • Implications of Alternative Hepatorenal Prognostic Scoring Systems in Acute Heart Failure (from DOSE-AHF and ROSE-AHF). 
  • Implications of Serum Chloride Homeostasis in Acute Heart Failure (from ROSE-AHF). 
  • Implications of Using Different Definitions on Outcomes in Worsening Heart Failure. 
  • Implications of elevated cardiac troponin T in ambulatory patients with heart failure: a prospective analysis. 
  • Implications of peripheral oedema in heart failure with preserved ejection fraction: a heart failure network analysis. 
  • Importance of angina in patients with coronary disease, heart failure, and left ventricular systolic dysfunction: insights from STICH. 
  • Importance of echocardiography in patients with severe nonischemic heart failure: the second Prospective Randomized Amlodipine Survival Evaluation (PRAISE-2) echocardiographic study. 
  • Improved Outcomes in Severe Primary Graft Dysfunction After Heart Transplantation Following Donation After Circulatory Death Compared With Donation After Brain Death. 
  • Improved early survival with a nonsternotomy approach for continuous-flow left ventricular assist device replacement. 
  • Improved outcome in heart failure. 
  • Improved survival in patients enrolled promptly into remote monitoring following cardiac implantable electronic device implantation. 
  • Improvement in Left Ventricular Ejection Fraction in Outpatients With Heart Failure With Reduced Ejection Fraction: Data From CHAMP-HF. 
  • Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial. 
  • Improvement in the function of hibernating myocardium in a patient with heart failure due to coronary artery disease receiving high-dose simvastatin. 
  • Improvement in the mechanical efficiency of walking: an explanation for the "placebo effect" seen during repeated exercise testing of patients with heart failure. Duke University Clinical Cardiology Studies (DUCCS) Exercise Group. 
  • Improvement of Health Status Following Initiation of Sacubitril/Valsartan in Heart Failure and Reduced Ejection Fraction. 
  • Improvements in signs and symptoms during hospitalization for acute heart failure follow different patterns and depend on the measurement scales used: an international, prospective registry to evaluate the evolution of measures of disease severity in acute heart failure (MEASURE-AHF). 
  • Improving Congestive Heart Failure Care with a Clinical Decision Unit. 
  • Improving Enrollment of Underrepresented Racial and Ethnic Populations in Heart Failure Trials: A Call to Action From the Heart Failure Collaboratory. 
  • Improving Heart Failure Therapeutics Development in the United States: The Heart Failure Collaboratory. 
  • Improving In-Hospital Diuretic Therapy for Heart Failure: The Need for High-Quality Evidence. 
  • Improving Value-Based Care for Left Ventricular Assist Device Therapy: Lowering Costs When Stakes Are High. 
  • Improving cardiovascular clinical trials conduct in the United States: recommendation from clinicians, researchers, sponsors, and regulators. 
  • Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF). 
  • Improving heart failure health: is there a secret Swedish sauce? 
  • Improving implementation of evidence-based therapies for heart failure. 
  • Improving outcomes in cardio-renal-metabolic diseases. 
  • Improving the Use of Primary Prevention Implantable Cardioverter-Defibrillators Therapy With Validated Patient-Centric Risk Estimates. 
  • Improving the use of evidence-based heart failure therapies in the outpatient setting: the IMPROVE HF performance improvement registry. 
  • In HF with LVEF ≤ 42.5%, sacubitril-valsartan vs RAS inhibitors reduced a composite of CV death or HF hospitalization. 
  • In HFpEF, the benefit of empagliflozin on a composite of CV death or HF hospitalization at 26 mo did not vary by diabetes status. 
  • In Reply: B-type natriuretic peptide level and postdischarge thrombotic events in older patients hospitalized with heart failure: Insights from the ADHERE registry. 
  • In heart failure, automatic implant-based telemonitoring reduced a composite of cardiac events and mortality. 
  • In vivo inhibition of elevated myocardial beta-adrenergic receptor kinase activity in hybrid transgenic mice restores normal beta-adrenergic signaling and function. 
  • In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Reduced Ejection Fraction. 
  • In-Hospital Therapy for Heart Failure With Reduced Ejection Fraction in the United States. 
  • In-Hospital and Postdischarge Mortality Among Patients With Acute Decompensated Heart Failure Hospitalizations Ending on the Weekend Versus Weekday: The ARIC Study Community Surveillance. 
  • In-Hospital and Three-Year Outcomes of Heart Failure Patients in South India: The Trivandrum Heart Failure Registry. 
  • In-hospital initiation of quadruple medical therapy for heart failure: making the post-discharge vulnerable phase far less vulnerable. 
  • In-hospital initiation of sacubitril/valsartan in acute decompensated heart failure: being in the right place at the right time. 
  • In-hospital management of patients with atrial flutter. 
  • In-hospital outcomes after bariatric surgery in patients with heart failure. 
  • In-hospital resource use and medical costs in the last year of life by mode of death (from the HF-ACTION randomized controlled trial). 
  • In-hospital worsening heart failure and associations with mortality, readmission, and healthcare utilization. 
  • In-hospital worsening heart failure. 
  • Inactivation of the Glucose-Dependent Insulinotropic Polypeptide Receptor Improves Outcomes following Experimental Myocardial Infarction. 
  • Incidence and Diagnostic Challenges of Bowel Ischemia after Continuous-flow Left Ventricular Assist Device Therapy. 
  • Incidence and Outcomes of Acute Heart Failure With Preserved Versus Reduced Ejection Fraction in SPRINT. 
  • Incidence and impact of primary graft dysfunction in adult heart transplant recipients: A systematic review and meta-analysis. 
  • Incidence and outcomes associated with early heart failure pharmacotherapy in patients with ongoing cardiogenic shock. 
  • Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program. 
  • Incidence and prevalence of heart failure in elderly persons, 1994-2003. 
  • Incidence and survival of hospitalized acute decompensated heart failure in four US communities (from the Atherosclerosis Risk in Communities Study). 
  • Incidence of heart failure and mortality after acute coronary syndromes. 
  • Incidence, Management, and Outcomes of Trauma in Patients with a Left Ventricular Assist Device in North Carolina. 
  • Incidence, Predictors, and Outcomes of Permanent Pacemaker Implantation Following Transcatheter Aortic Valve Replacement: Analysis From the U.S. Society of Thoracic Surgeons/American College of Cardiology TVT Registry. 
  • Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. 
  • Incident Cardiovascular Disease Among Adults With Blood Pressure <140/90 mm Hg. 
  • Incident anaemia in older adults with heart failure: rate, aetiology, and association with outcomes. 
  • Incorporating Patient Preferences Into Hospital Quality Metrics for Heart Failure. 
  • Incorporating patient preferences into clinical trial design: results of the opinions of patients on treatment implications of new studies (OPTIONS) project. 
  • Incorporation of Retinal Arteriolosclerosis into Risk Stratification of Blood Pressure Category According to the 2017 ACC/AHA Blood Pressure Guideline. 
  • Increased Opportunities for Transplantation for Women in the New Heart Allocation System. 
  • Increased ketone body oxidation provides additional energy for the failing heart without improving cardiac efficiency. 
  • Increased levels of uric acid predict haemodynamic compromise in patients with heart failure independently of B-type natriuretic peptide levels. 
  • Increased mortality with elevated plasma endothelin-1 in acute heart failure: an ASCEND-HF biomarker substudy. 
  • Increasing the United States heart transplant donor pool with donation after circulatory death. 
  • Incremental prognostic value of echocardiography of left ventricular remodeling and diastolic function in STICH trial. 
  • Incremental value of clinical data beyond claims data in predicting 30-day outcomes after heart failure hospitalization. 
  • Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. 
  • Independent prognostic value of echocardiography and N-terminal pro-B-type natriuretic peptide in patients with heart failure. 
  • Index of contractile asymmetry improves patient selection for CRT: a proof-of-concept study. 
  • Indications and Outcomes for Temporary Mechanical Circulatory Support in Pediatric Patients with Cardiac Failure. 
  • Indications for cardiac resynchronization therapy: 2011 update from the Heart Failure Society of America Guideline Committee. 
  • Individual prediction of heart failure among childhood cancer survivors. 
  • Induction of SENP1 in myocardium contributes to abnormities of mitochondria and cardiomyopathy. 
  • Infarct Size, Shock, and Heart Failure: Does Reperfusion Strategy Matter in Early Presenting Patients With ST-Segment Elevation Myocardial Infarction? 
  • Infection and noncardiovascular death in the elderly-Heart failure's dirty little secret. 
  • Inflammation Markers and Major Depressive Disorder in Patients With Chronic Heart Failure: Results From the Sertraline Against Depression and Heart Disease in Chronic Heart Failure Study. 
  • Inflammatory biomarkers in heart failure. 
  • Influence of Baseline Characteristics, Operative Conduct, and Postoperative Course on 30-Day Outcomes of Coronary Artery Bypass Grafting Among Patients With Left Ventricular Dysfunction: Results From the Surgical Treatment for Ischemic Heart Failure (STICH) Trial. 
  • Influence of Baseline Physical Activity Level on Exercise Training Response and Clinical Outcomes in Heart Failure: The HF-ACTION Trial. 
  • Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). 
  • Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. 
  • Influence of Patient Goals of Care on Performance Measures in Patients Hospitalized for Heart Failure: An Analysis of the Enhanced Feedback For Effective Cardiac Treatment (EFFECT) Registry. 
  • Influence of a performance-improvement initiative on quality of care for patients hospitalized with heart failure: results of the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF). 
  • Influence of age on the management of heart failure: findings from Get With the Guidelines-Heart Failure (GWTG-HF). 
  • Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial. 
  • Influence of atrial fibrillation on post-discharge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the ASTRONAUT trial. 
  • Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program. 
  • Influence of coronary angiography on the utilization of therapies in patients with acute heart failure syndromes: findings from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). 
  • Influence of coronary artery disease and coronary revascularization status on outcomes in patients with acute heart failure syndromes: a report from OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure). 
  • Influence of dedicated heart failure clinics on delivery of recommended therapies in outpatient cardiology practices: findings from the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF). 
  • Influence of diabetes mellitus on the clinical manifestations and prognosis of infective endocarditis: a report from the International Collaboration on Endocarditis-Merged Database. 
  • Influence of diabetes on characteristics and outcomes in patients hospitalized with heart failure: a report from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). 
  • Influence of documented history of coronary artery disease on outcomes in patients admitted for worsening heart failure with reduced ejection fraction in the EVEREST trial. 
  • Influence of donor brain death duration on outcomes following heart transplantation: A United Network for Organ Sharing Registry analysis. 
  • Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. 
  • Influence of exercise training on T-wave alternans assessed during exercise test in heart failure patients. 
  • Influence of global region on outcomes in heart failure β-blocker trials. 
  • Influence of heart failure symptoms and ejection fraction on short- and long-term outcomes for older patients with non-ST-segment elevation myocardial infarction. 
  • Influence of hospital length of stay for heart failure on quality of care. 
  • Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. 
  • Influence of imprecision on ROC curve analysis for cardiac markers. 
  • Influence of life-course socioeconomic position on incident heart failure in blacks and whites: the Atherosclerosis Risk in Communities Study. 
  • Influence of mitral regurgitation repair on survival in the surgical treatment for ischemic heart failure trial. 
  • Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. 
  • Influence of patient age and sex on delivery of guideline-recommended heart failure care in the outpatient cardiology practice setting: findings from IMPROVE HF. 
  • Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction. 
  • Influence of renal function on the use of guideline-recommended therapies for patients with heart failure. 
  • Influence of skin site on bioavailability of nitroglycerin ointment in congestive heart failure. 
  • Influenza Vaccination in Patients With Heart Failure. 
  • Inhaled nitric oxide after left ventricular assist device implantation: a prospective, randomized, double-blind, multicenter, placebo-controlled trial. 
  • Inherited restrictive cardiomyopathy in a 74-year-old woman: a case of Fabry's disease. 
  • Inhibition of Dipeptidyl Peptidase-4 Impairs Ventricular Function and Promotes Cardiac Fibrosis in High Fat-Fed Diabetic Mice. 
  • Inhibition of receptor-localized PI3K preserves cardiac beta-adrenergic receptor function and ameliorates pressure overload heart failure. 
  • Inhibitory role of the coronary arterial endothelium to alpha-adrenergic stimulation in experimental heart failure. 
  • Initial Experience of Left Ventricular Assist Device Support for Adult Patients with Transposition of the Great Vessels. 
  • Initial Invasive Versus Conservative Management of Stable Ischemic Heart Disease in Patients With a History of Heart Failure or Left Ventricular Dysfunction: Insights From the ISCHEMIA Trial. 
  • Initial United States experience with the Paracor HeartNet myocardial constraint device for heart failure. 
  • Initial assessment of a new instrument to measure quality of life at the end of life. 
  • Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial. 
  • Initiation, Continuation, Switching, and Withdrawal of Heart Failure Medical Therapies During Hospitalization. 
  • Initiation, Continuation, or Withdrawal of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction. 
  • Innovations in Heart Transplantation: A Review. 
  • Inotropes in the management of acute heart failure. 
  • Inotropic drugs and neurohormonal antagonists in the treatment of HF in the elderly. 
  • Inotropic therapy for heart failure: an evidence-based approach. 
  • Inpatient Management of Heart Failure: Are We Shooting at the Right Target? 
  • Inpatient Unit Heart Failure Discharge Volume Predicts All-cause 30-Day Hospital Readmission. 
  • Insights into the contemporary epidemiology and outpatient management of congestive heart failure. 
  • Instability in End-of-Life Care Preference Among Heart Failure Patients: Secondary Analysis of a Randomized Controlled Trial in Singapore. 
  • Instability in Preference for Place of Death Among Patients With Symptoms of Advanced Heart Failure. 
  • Insufficient reduction in heart rate during hospitalization despite beta-blocker treatment in acute decompensated heart failure: insights from the ASCEND-HF trial. 
  • Insulin Growth Factor Phenotypes in Heart Failure With Preserved Ejection Fraction, an INSPIRE Registry and CATHGEN Study. 
  • Insulin resistance in heart failure: widening the divide between reduced and preserved ejection fraction? 
  • Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction. 
  • Insulin-Like Growth Factor-Binding Protein-7 as a Biomarker of Diastolic Dysfunction and Functional Capacity in Heart Failure With Preserved Ejection Fraction: Results From the RELAX Trial. 
  • Intact negative feedback of four cardiac hormones in congestive heart failure. 
  • Integrated electrophysiology care for patients with heart failure: An envisioned future. 
  • Intensity and focus of heart failure disease management after hospital discharge. 
  • Interaction between digoxin and dronedarone in the PALLAS trial. 
  • Interaction of Blood Pressure and Glycemic Status in Developing Cardiovascular Disease: Analysis of a Nationwide Real-World Database. 
  • Interaction of Body Mass Index on the Association Between N-Terminal-Pro-b-Type Natriuretic Peptide and Morbidity and Mortality in Patients With Acute Heart Failure: Findings From ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). 
  • Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) analysis of pump thrombosis in the HeartMate II left ventricular assist device. 
  • Interatrial Stent to Treat Stiff Left Atrium Syndrome. 
  • Intercountry Differences in Guideline-Directed Medical Therapy and Outcomes Among Patients With Heart Failure. 
  • Interleukin-1 Blockade in Recently Decompensated Systolic Heart Failure: Results From REDHART (Recently Decompensated Heart Failure Anakinra Response Trial). 
  • Interleukin-6 and Outcomes in Acute Heart Failure: An ASCEND-HF Substudy. 
  • International Collaborations in Heart Failure: JCF in Latin America. 
  • International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better short-term outcomes in patients enrolled in Eastern Europe and Russia in the PROTECT trial. 
  • International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. 
  • International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS. 
  • International variation in use of oral anticoagulation among heart failure patients with atrial fibrillation. 
  • Intersection of atrial fibrillation and heart failure with mildly reduced and preserved ejection fraction in >400 000 participants in the Get With The Guidelines-Heart Failure Registry. 
  • Intervention Adherence in REHAB-HF: Predictors and Relationship With Physical Function, Quality of Life, and Clinical Events. 
  • Intracellular protein aggregation is a proximal trigger of cardiomyocyte autophagy. 
  • Intramyocardial Injection of Mesenchymal Precursor Cells and Successful Temporary Weaning From Left Ventricular Assist Device Support in Patients With Advanced Heart Failure: A Randomized Clinical Trial. 
  • Intrapericardial Left Ventricular Assist Device for Advanced Heart Failure. 
  • Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing-induced heart failure. 
  • Intravenous nisoldipine in severe congestive heart failure. 
  • Intrinsic myocyte dysfunction and tyrosine kinase pathway activation underlie the impaired wall thickening of adjacent regions during postinfarct left ventricular remodeling. 
  • Introduction of the Tools for Economic Analysis of Patient Management Interventions in Heart Failure Costing Tool: a user-friendly spreadsheet program to estimate costs of providing patient-centered interventions. 
  • Introduction: Vasopressin therapy. 
  • Introduction: exercise in patients with chronic heart failure. 
  • Invited commentary. 
  • Invited commentary. 
  • Iodine-123 MIBG imaging before treatment of heart failure with carvedilol to predict improvement of left ventricular function and exercise capacity. 
  • Is Discordance Between Recommended and Actual Postacute Discharge Setting a Risk Factor for Readmission in Patients With Congestive Heart Failure? 
  • Is Resistance Futile?: Addressing Diuretic Resistance During Hospitalization for Heart Failure. 
  • Is Salt Bad for You? 
  • Is There Still a Role for Digoxin in the Management of Atrial Fibrillation? 
  • Is Time From Last Hospitalization for Heart Failure to Placement of a Primary Prevention Implantable Cardioverter-Defibrillator Associated With Patient Outcomes? 
  • Is Time of the Essence? The Impact of Time of Hospital Presentation in Acute Heart Failure: Insights From ASCEND-HF Trial. 
  • Is an Admission for Decompensated Heart Failure Inevitable? 
  • Is heart failure guideline adherence being underestimated? The impact of therapeutic contraindications. 
  • Is it Time to Get More Aggressive With Aortic Valve Insufficiency During LVAD Implantation? 
  • Is lack of health insurance a predictor of worsening of heart failure among adult patients attending referral hospitals in Northwestern Tanzania? 
  • Is optimal angiotensin-converting enzyme inhibitor dosing neglected in elderly patients with heart failure? 
  • Is plasma renin activity associated with worse outcomes in acute heart failure? A secondary analysis from the BLAST-AHF trial. 
  • Is rhythm control superior to rate control in patients with atrial fibrillation and congestive heart failure? 
  • Is specialty care associated with improved survival of patients with congestive heart failure? 
  • Is the affordable care act medicaid expansion associated with receipt of heart failure guideline-directed medical therapy by race and ethnicity? 
  • Is there a rationale for antiplatelet therapy in acute heart failure? 
  • Is there a role for albumin and C-reactive protein levels for prognostication in acute heart failure? 
  • Is there a role for upper-extremity intra-aortic balloon counterpulsation as a bridge-to-recovery or a bridge-to-transplant in the treatment of end-stage heart failure? 
  • Is thrombosis a contributor to heart failure pathophysiology? Possible mechanisms, therapeutic opportunities, and clinical investigation challenges. 
  • Ischaemic stroke in heart failure: back to basics? 
  • Isolated hormone receptors: physiologic and clinical implications. 
  • Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. 
  • It Is Time to Discuss Dying. 
  • It is time to exercise change for heart failure. 
  • IxCELL-DCM: rejuvenation for cardiac regenerative therapy? 
  • JACC: Heart Failure Series: FDA in the 21st Century: Focus on Nutrition and Heart Failure Prevention. 
  • JACC: Heart Failure fellows program: training the next generation. 
  • JCF Heart Failure Year-In-Review 2022… The Best is Yet to Come! 
  • Junctophilin-2 is necessary for T-tubule maturation during mouse heart development. 
  • Kidney Function and Outcomes in Patients Hospitalized With Heart Failure. 
  • LVAD Outflow Graft Role in Pump Thrombosis. 
  • Lack of Association Between Anemia and Intrinsic Left Ventricular Diastolic Function or Cardiac Mechanics in Heart Failure With Preserved Ejection Fraction. 
  • Lack of Association Between Heart Failure and Incident Cancer. 
  • Lack of Thy1 defines a pathogenic fraction of cardiac fibroblasts in heart failure. 
  • Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol. 
  • Lack of association between electronic health record systems and improvement in use of evidence-based heart failure therapies in outpatient cardiology practices. 
  • Lack of effect of increased inspired oxygen concentrations on maximal exercise capacity or ventilation in stable heart failure. 
  • Language Matters: Understanding Barriers to Medication Adherence to Better Tailor Heart Failure Care. 
  • Late "adult form" scimitar syndrome presenting with "infant form" complications. 
  • Late Durability of Mitral Repair for Ischemic Versus Nonischemic Functional Mitral Regurgitation. 
  • Late gadolinium enhancement magnetic resonance imaging in the diagnosis and prognosis of endomyocardial fibrosis patients. 
  • Leading from the Heart. 
  • Learning from recent trials and shaping the future of acute heart failure trials. 
  • Learning whether to subtract beta-blockers: it's about time. 
  • Left Atrial Stiffness Index Independently Predicts Exercise Intolerance and Quality of Life in Older, Obese Patients With Heart Failure With Preserved Ejection Fraction. 
  • Left Atrial Structure and Function in Heart Failure with Preserved Ejection Fraction: A RELAX Substudy. 
  • Left Bundle Branch Block: Is it "Unsafe at Any Speed"? 
  • Left Ventricular Assist Devices: A Primer For the General Cardiologist. 
  • Left Ventricular Global Longitudinal Strain Can Reliably Be Measured from a Single Apical Four-Chamber View in Patients with Heart Failure. 
  • Left atrial decompression pump for severe heart failure with preserved ejection fraction: theoretical and clinical considerations. 
  • Left atrial function in heart failure with preserved ejection fraction: a systematic review and meta-analysis. 
  • Left bundle branch block without a typical contraction pattern is associated with increased risk of ventricular arrhythmias in cardiac resynchronization therapy patients. 
  • Left bundle branch block-induced left ventricular remodeling and its potential for reverse remodeling. 
  • Left bundle-branch block is associated with asimilar dyssynchronous phenotype in heart failure patients with normal and reduced ejection fractions. 
  • Left ventricular assist device as destination therapy in doxorubicin-induced cardiomyopathy. 
  • Left ventricular assist device destination therapy versus extended criteria cardiac transplant. 
  • Left ventricular assist device effects on metabolic substrates in the failing heart. 
  • Left ventricular assist device failure due to outflow graft compression by thrombofibrotic exudate. 
  • Left ventricular assist device therapy in advanced heart failure: patient selection and outcomes. 
  • Left ventricular assist devices as destination therapy for end-stage heart failure. 
  • Left ventricular assist devices versus medical management in ambulatory heart failure patients: An analysis of INTERMACS Profiles 4 and 5 to 7 from the ROADMAP study. 
  • Left ventricular assist systems and infection-related outcomes: A comprehensive analysis of the MOMENTUM 3 trial. 
  • Left ventricular diastolic dysfunction and exercise intolerance in obese heart failure with preserved ejection fraction. 
  • Left ventricular dysfunction: causes, natural history, and hopes for reversal. 
  • Left ventricular ejection fraction test rates for Medicare beneficiaries with heart failure. 
  • Left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: outcomes following an acute heart failure hospitalization. 
  • Left ventricular hypertrophy patterns and incidence of heart failure with preserved versus reduced ejection fraction. 
  • Left ventricular lead position and clinical outcome in the multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT) trial. 
  • Left ventricular long axis function assessed during cine-cardiovascular magnetic resonance is an independent predictor of adverse cardiac events. 
  • Left ventricular myocardial blood flow, metabolism, and effects of treatment with enalapril: further insights into the mechanisms of canine experimental pacing-induced heart failure. 
  • Left ventricular remodelling and disparate changes in contractility and relaxation during the development of and recovery from experimental heart failure. 
  • Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation: insights from the ARISTOTLE trial. 
  • Length of hospital stay and 30-day readmission following heart failure hospitalization: insights from the EVEREST trial. 
  • Lessons from the TOPCAT trial. 
  • Lessons learned from a clinical trial: Design, rationale, and insights from The Cardiovascular Improvements with Minute Ventilation-targeted Adaptive Sero-Ventilation (ASV) Therapy in Heart Failure (CAT-HF) Study. 
  • Lessons learned from clinical trials in acute heart failure: phase 3 drug trials. 
  • Letter by Makkar et al regarding article, "Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions". 
  • Letter by Moris et al Regarding Article, "Cardioprotective Role of Myeloid-Derived Suppressor Cells in Heart Failure". 
  • Leukocyte iNOS is required for inflammation and pathological remodeling in ischemic heart failure. 
  • Leveraging Behavioral Economics to Improve Heart Failure Care and Outcomes. 
  • Leveraging Clinical Informatics Tools to Extract Cumulative Anthracycline Exposure, Measure Cardiovascular Outcomes, and Assess Guideline Adherence for Children With Cancer. 
  • Leveraging Multiple Biomarkers to Assess Risk of Acute Heart Failure: Is More Better? 
  • Life-threatening congestive heart failure as the presentation of centronuclear myopathy. 
  • Lifting Coronavirus Disease-19 Shelter-in-Place Restrictions: Impact on Heart Failure Hospitalizations in Northeast Georgia. 
  • Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA. 
  • Link between decisions regarding resuscitation and preferences for quality over length of life with heart failure. 
  • Linkage of familial dilated cardiomyopathy with conduction defect and muscular dystrophy to chromosome 6q23. 
  • Linking inpatient clinical registry data to Medicare claims data using indirect identifiers. 
  • Lipids, statins, and clinical outcomes in heart failure: rethinking the data. 
  • Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial. 
  • Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. 
  • Liver function tests in patients with acute heart failure and associated outcomes: insights from ASCEND-HF. 
  • Liver function, in-hospital, and post-discharge clinical outcome in patients with acute heart failure-results from the relaxin for the treatment of patients with acute heart failure study. 
  • Local contractile and growth modulators in the myocardium. 
  • Long-Chain Omega-3 Fatty Acid Supplements in Depressed Heart Failure Patients: Results of the OCEAN Trial. 
  • Long-Term Cognitive Decline After Newly Diagnosed Heart Failure: Longitudinal Analysis in the CHS (Cardiovascular Health Study). 
  • Long-Term Neurocognitive Outcome in Patients With Continuous Flow Left Ventricular Assist Device. 
  • Long-Term Outcomes of Implantable Cardioverter-Defibrillator Therapy in the SCD-HeFT. 
  • Long-Term Survival in Patients Receiving a Continuous-Flow Left Ventricular Assist Device. 
  • Long-acting natriuretic peptide, vessel dilator, and kaliuretic peptide enhance urinary excretion rate of albumin, total protein, and beta(2)-microglobulin in patients with congestive heart failure. 
  • Long-term ambulatory therapy with prazosin versus placebo for chronic heart failure: relation between clinical response and left ventricular function at rest and during exercise. 
  • Long-term cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer. 
  • Long-term cardiovascular outcomes in patients with atrial fibrillation and atherothrombosis in the REACH Registry. 
  • Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. 
  • Long-term costs and resource use in elderly participants with congestive heart failure in the Cardiovascular Health Study. 
  • Long-term destination therapy with the HeartMate XVE left ventricular assist device: improved outcomes since the REMATCH study. 
  • Long-term effects of percutaneous coronary intervention of the totally occluded infarct-related artery in the subacute phase after myocardial infarction. 
  • Long-term follow-up of continuous flow left ventricular assist devices: complications and predisposing risk factors. 
  • Long-term healthcare and cost outcomes of disease management in a large, randomized, community-based population with heart failure. 
  • Long-term outcomes and costs of ventricular assist devices among Medicare beneficiaries. 
  • Long-term outcomes and management of the heart transplant recipient. 
  • Long-term outcomes for heart failure patients with and without diabetes: From the Get With The Guidelines-Heart Failure Registry. 
  • Long-term outcomes in elderly survivors of in-hospital cardiac arrest. 
  • Long-term outcomes of medicare beneficiaries with worsening renal function during hospitalization for heart failure. 
  • Long-term outcomes of simultaneous heart and kidney transplantation in pediatric recipients. 
  • Long-term predictors of sudden and low output death in chronic congestive heart failure secondary to coronary artery disease. 
  • Long-term survival of patients with ischemic cardiomyopathy treated by coronary artery bypass grafting versus medical therapy. 
  • Long-term trends in the incidence of heart failure after myocardial infarction. 
  • Longitudinal Changes in Cardiac Troponin and Risk of Heart Failure Among Black Adults. 
  • Longitudinal tracking of left ventricular mass over the adult life course: clinical correlates of short- and long-term change in the framingham offspring study. 
  • Look After You Leap. 
  • Loop Diuretic Use and Outcomes in Chronic Stable Heart Failure With Preserved Ejection Fraction-Reply. 
  • Loop diuretic adjustments in patients with chronic heart failure: Insights from HF-ACTION. 
  • Loop diuretic dose adjustments after a hospitalization for heart failure: insights from ASCEND-HF. 
  • Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil? 
  • Loop diuretics in heart failure. 
  • Loss of Endothelial Hypoxia Inducible Factor-Prolyl Hydroxylase 2 Induces Cardiac Hypertrophy and Fibrosis. 
  • Low Accuracy of the HeartMate Risk Score for Predicting Mortality Using the INTERMACS Registry Data. 
  • Low Blood Pressure Threshold for Adverse Outcomes During Left Ventricular Assist Device Support. 
  • Low doses vs. high doses of the angiotensin converting-enzyme inhibitor lisinopril in chronic heart failure: a cost-effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival (ATLAS) study. The ATLAS Study Group. 
  • Low lead one ratio predicts clinical outcomes in left bundle branch block. 
  • Low lymphocyte ratio as a novel prognostic factor in acute heart failure: results from the Pre-RELAX-AHF study. 
  • Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. 
  • Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. 
  • Lower urine sodium predicts longer length of stay in acute heart failure patients: Insights from the ROSE AHF trial. 
  • Lymphatic Dysregulation in Patients With Heart Failure: JACC Review Topic of the Week. 
  • M-mode echocardiographic observations during and after healing of active bacterial endocarditis limited to the mitral valve. 
  • M-mode echocardiographic observations in active bacterial endocarditis limited to the aortic valve. 
  • MAPK-activated protein kinase-2 in cardiac hypertrophy and cyclooxygenase-2 regulation in heart. 
  • MRI for the assessment of myocardial viability. 
  • Machine Learning Algorithm Predicts Cardiac Resynchronization Therapy Outcomes: Lessons From the COMPANION Trial. 
  • Machine Learning Methods Improve Prognostication, Identify Clinically Distinct Phenotypes, and Detect Heterogeneity in Response to Therapy in a Large Cohort of Heart Failure Patients. 
  • Machine learning to define phenotypes and outcomes of patients hospitalized for heart failure with preserved ejection fraction: Findings from ASCEND-HF. 
  • Macrovolt T-wave alternans and polymorphic ventricular tachycardia. 
  • Maintenance of sinus rhythm and survival in patients with heart failure and atrial fibrillation. 
  • Major depression and physical illness trajectories in heart failure and pulmonary disease. 
  • Making the case for sacubitril/valsartan in patients with heart failure with a preserved ejection fraction. 
  • Management of Heart Failure with Preserved Ejection Fraction: Current Challenges and Future Directions. 
  • Management of acute decompensated heart failure. 
  • Management of asymptomatic chronic aortic regurgitation with left ventricular dysfunction: a decision analysis. 
  • Management of heart failure in cardiac amyloidosis using an ambulatory diuresis clinic. 
  • Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). 
  • Management of hypertension in heart failure with preserved ejection fraction: is there a blood pressure goal? 
  • Management of newly treated diabetes in Medicare beneficiaries with and without heart failure. 
  • Management of primary graft failure after heart transplantation: Preoperative risks, perioperative events, and postoperative decisions. 
  • Managing Heart Failure in Patients on Dialysis: State-of-the-Art Review. 
  • Marginal Donor Use in Patients Undergoing Heart Transplantation With Left Ventricular Assist Device Explantation. 
  • Marginal cardiac allografts do not have increased primary graft dysfunction in alternate list transplantation. 
  • Marijuana use and inpatient outcomes among hospitalized patients: analysis of the nationwide inpatient sample database. 
  • Marital status improves survival after orthotopic heart transplantation. 
  • Marked enhancement in myocardial function resulting from overexpression of a human beta-adrenergic receptor gene. 
  • Markers of Atherosclerosis, Clinical Characteristics, and Treatment Patterns in Heart Failure: A Case-Control Study of Middle-Aged Adult Heart Failure Patients in Rural Kenya. 
  • Markers of decongestion, dyspnea relief, and clinical outcomes among patients hospitalized with acute heart failure. 
  • Matching mechanism of death with mechanism of action: considerations for drug development for hospitalized heart failure. 
  • Maternal Obesity Affects Cardiac Remodeling and Recovery in Women with Peripartum Cardiomyopathy. 
  • Maximizing benefits and mitigating risks with mineralocorticoid receptor antagonist therapy. 
  • Maximizing survival benefit with primary prevention implantable cardioverter-defibrillator therapy in a heart failure population. 
  • Measured Versus Estimated Resting Metabolic Rate in Heart Failure With Preserved Ejection Fraction. 
  • Measurement of troponin and natriuretic peptides shortly after admission in patients with heart failure-does it add useful prognostic information? An analysis of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Studies (VERITAS). 
  • Measures of Ventricular-Arterial Coupling and Incident Heart Failure With Preserved Ejection Fraction: A Matched Case-Control Analysis. 
  • Measuring heart failure quality: does perfection matter? 
  • Measuring hospital mortality rates: are 30-day data enough? Ischemic Heart Disease Patient Outcomes Research Team. 
  • Measuring left ventricular mechanical dyssynchrony from ECG-gated SPECT myocardial perfusion imaging. 
  • Measuring shortness of breath in heart failure (SOB-HF): development and validation of a new dyspnoea assessment tool. 
  • Mechanical Circulatory Support Device Utilization and Heart Transplant Waitlist Outcomes in Patients With Restrictive and Hypertrophic Cardiomyopathy. 
  • Mechanical dyssynchrony in acute heart failure: A marker and a target? 
  • Mechanical unloading promotes myocardial energy recovery in human heart failure. 
  • Mechanical ventricular support lowers pulmonary vascular resistance in a patient with congential heart disease. 
  • Mechanism of action of angiotensin-converting enzyme (ACE) inhibitors in hypertension and heart failure. Role of plasma versus tissue ACE. 
  • Mechanisms and Models in Heart Failure: A Translational Approach. 
  • Mechanisms of bleeding and approach to patients with axial-flow left ventricular assist devices. 
  • Mechanisms of membrane-receptor regulation. Biochemical, physiological, and clinical insights derived from studies of the adrenergic receptors. 
  • Mechanosensitive channels in striated muscle and the cardiovascular system: not quite a stretch anymore. 
  • Mediastinitis after coronary artery bypass graft surgery. Risk factors and long-term survival. 
  • Medical Management of Heart Failure With Reduced Ejection Fraction in Patients With Advanced Renal Disease. 
  • Medical Management of Patients With a Left Ventricular Assist Device for the Non-Left Ventricular Assist Device Specialist. 
  • Medical Therapy During Hospitalization for Heart Failure With Reduced Ejection Fraction: The VICTORIA Registry. 
  • Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry. 
  • Medical advances in the treatment of congestive heart failure. 
  • Medical editors' grand rounds: a discussion of timely topics and editorial emergencies. 
  • Medical resource use, costs, and quality of life in patients with acute decompensated heart failure: findings from ASCEND-HF. 
  • Medicare Expenditures by Race/Ethnicity After Hospitalization for Heart Failure With Preserved Ejection Fraction. 
  • Medication Initiation Burden Required to Comply With Heart Failure Guideline Recommendations and Hospital Quality Measures. 
  • Medication Trajectory and Treatment Patterns in Medicare Patients With Heart Failure and Reduced Ejection Fraction. 
  • Medication dosing for heart failure with reduced ejection fraction - opportunities and challenges. 
  • Medication dosing in outpatients with heart failure after implementation of a practice-based performance improvement intervention: findings from IMPROVE HF. 
  • Medications Are Important for Sudden Cardiac Death Prevention But So Is the Implantable Cardioverter-Defibrillator. 
  • Meet Me in the Middle: Lessons From the Cardiorenal Advisory Committee for Sacubitril/Valsartan in HFpEF. 
  • Mesenchymal precursor cells as adjunctive therapy in recipients of contemporary left ventricular assist devices. 
  • Meta-Analysis of Effects of Digoxin on Survival in Patients with Atrial Fibrillation or Heart Failure: An Update. 
  • Meta-Analysis of Efficacy of Sacubitril/Valsartan in Heart Failure With Preserved Ejection Fraction. 
  • Meta-Analysis of Nonalcoholic Fatty Liver Disease and Incident Heart Failure. 
  • Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone. 
  • Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. 
  • Metaanalysis and review of heart failure disease management randomized controlled clinical trials. 
  • Metaanalysis on effects of cardiac resynchronization therapy in heart failure patients with narrow QRS complex. 
  • Metabolic Dysfunction in Heart Failure: Diagnostic, Prognostic, and Pathophysiologic Insights From Metabolomic Profiling. 
  • Metabolomic Profiling Identifies Novel Circulating Biomarkers of Mitochondrial Dysfunction Differentially Elevated in Heart Failure With Preserved Versus Reduced Ejection Fraction: Evidence for Shared Metabolic Impairments in Clinical Heart Failure. 
  • Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF. 
  • Metabolomic differences in heart failure patients with and without major depression. 
  • Metabolomic profiling for the identification of novel biomarkers and mechanisms related to common cardiovascular diseases: form and function. 
  • Methods of creatine kinase-MB analysis to predict mortality in patients with myocardial infarction treated with reperfusion therapy. 
  • MicroRNAs relate to early worsening of renal function in patients with acute heart failure. 
  • Midregional proadrenomedullin predicts mortality and major adverse cardiac events in patients presenting with chest pain: results from the CHOPIN trial. 
  • Migration of Intraaortic Balloon Pump Placed Via the Axillary Artery. 
  • Mineralocorticoid Receptor Antagonism for the Treatment of AF and HFpEF: Preserving Hope. 
  • Mineralocorticoid receptor antagonist use in hospitalized patients with heart failure, reduced ejection fraction, and diabetes mellitus (from the EVEREST Trial). 
  • Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. 
  • Minor depression and physical outcome trajectories in heart failure and pulmonary disease. 
  • Missing the True Target in Advanced Heart Failure: It Is Time to Look in the Mirror. 
  • Mitochondrial CaMKII causes adverse metabolic reprogramming and dilated cardiomyopathy. 
  • Mitochondrial Creatine Kinase Attenuates Pathologic Remodeling in Heart Failure. 
  • Mode of Death After Acute Heart Failure Hospitalization　- A Clue to Possible Mechanisms. 
  • Mode of death and hospitalization from the Second Follow-up Serial Infusions of Nesiritide (FUSION II) trial and comparison of clinical events committee adjudicated versus investigator reported outcomes. 
  • Modeling defibrillation benefit for survival among cardiac resynchronization therapy defibrillator recipients. 
  • Modification effect of ideal cardiovascular health metrics on genetic association with incident heart failure in the China Kadoorie Biobank and the UK Biobank. 
  • Modifier genes and heart failure. 
  • Molecular biology and pathophysiology of the intrarenal renin-angiotensin system. 
  • Monitoring Pulmonary Arterial Hypertension Using an Implantable Hemodynamic Sensor. 
  • More Evidence That Caffeine Consumption Appears to Be Safe in Patients With Heart Failure. 
  • More bad news for cardiac resynchronization therapy in atrial fibrillation patients: what to do? 
  • Mortality and Macrovascular Risk in Elderly With Hypertension and Diabetes: Effect of Intensive Drug Therapy. 
  • Mortality and rate of stroke or embolism in atrial fibrillation during long-term follow-up in the embolism in left atrial thrombi (ELAT) study. 
  • Mortality benefits from implantable cardioverter-defibrillator therapy are not restricted to patients with remote myocardial infarction: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). 
  • Moving Beyond the Walls of the Clinic: Opportunities and Challenges to the Future of Telehealth in Heart Failure. 
  • Multi-ethnic comparisons of diabetes in heart failure with reduced ejection fraction: insights from the HF-ACTION trial and the ASIAN-HF registry. 
  • Multi-marker strategies in heart failure: clinical and statistical approaches. 
  • Multifaceted intervention to promote beta-blocker use in heart failure. 
  • Multimarker Risk Stratification in Patients With Acute Myocardial Infarction. 
  • Multimodal analgesia using opioid-sparing regimen in patients undergoing left ventricular assist device implantation. 
  • Multinational and multiethnic variations in health-related quality of life in patients with chronic heart failure. 
  • Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). 
  • Multiparameter diagnostic sensor measurements in heart failure patients presenting with SARS-CoV-2 infection. 
  • Multiple Comorbidities and Response to Cardiac Resynchronization Therapy: MADIT-CRT Long-Term Follow-Up. 
  • Multiple cArdiac seNsors for mAnaGEment of Heart Failure (MANAGE-HF) - Phase I Evaluation of the Integration and Safety of the HeartLogic Multisensor Algorithm in Patients With Heart Failure. 
  • Multiple quantitative trait loci modify the heart failure phenotype in murine cardiomyopathy. 
  • Multivessel coronary artery disease and poor left ventricle function: It is consistent and clear, coronary artery bypass grafting wins again. 
  • Must I keep taking all these medicines? Optimizing diuretics in chronic heart failure. 
  • Mustard Baffle Revision With Systemic Ventricular Assist Device Placement. 
  • Myocardial Energetics in Heart Failure With Preserved Ejection Fraction. 
  • Myocardial G protein-coupled receptor kinases: implications for heart failure therapy. 
  • Myocardial beta-adrenergic receptor signaling in vivo: insights from transgenic mice. 
  • Myocardial myoglobin deficiency in various animal models of congestive heart failure. 
  • Myocardial perfusion, function, and dyssynchrony in patients with heart failure: baseline results from the single-photon emission computed tomography imaging ancillary study of the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing (HF-ACTION) Trial. 
  • Myocardial remodelling and matrix metalloproteinases in heart failure: turmoil within the interstitium. 
  • Myocardial scar in sarcoidosis by 12-lead ECG and pathology. 
  • Myocardial viability and impact of surgical ventricular reconstruction on outcomes of patients with severe left ventricular dysfunction undergoing coronary artery bypass surgery: results of the Surgical Treatment for Ischemic Heart Failure trial. 
  • Myocardial viability and survival in ischemic left ventricular dysfunction. 
  • N-1 and Sequencing Clinical Heart Failure Trials: Charting the Path for Future Clinical Care. 
  • N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study. 
  • N-of-1 Clinical Trials. 
  • N-terminal pro-B-type natriuretic peptide and the risk of stroke among patients hospitalized with acute heart failure: an APEX trial substudy. 
  • N-terminal pro-brain natriuretic peptide and exercise capacity in chronic heart failure: data from the Heart Failure and a Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) study. 
  • NADPH Oxidase 4 Regulates Inflammation in Ischemic Heart Failure: Role of Soluble Epoxide Hydrolase. 
  • NICE guideline for management of chronic heart failure in adults. 
  • NSAID use and association with cardiovascular outcomes in outpatients with stable atherothrombotic disease. 
  • NT-proBNP Goal Achievement Is Associated With Significant Reverse Remodeling and Improved Clinical Outcomes in HFrEF. 
  • Nasally Inhaled Nitric Oxide for Sudden Right-Sided Heart Failure in the Intensive Care Unit: NO Time Like the Present. 
  • National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical utilization of cardiac biomarker testing in heart failure. 
  • National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure. 
  • National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: analytical issues for biomarkers of heart failure. 
  • National Heart, Lung, and Blood Institute working group on emergency department management of acute heart failure: research challenges and opportunities. 
  • National Trends in the Burden of Atrial Fibrillation During Hospital Admissions for Heart Failure. 
  • National survey of hospital strategies to reduce heart failure readmissions: findings from the Get With the Guidelines-Heart Failure registry. 
  • Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction. 
  • Natriuretic Peptide-guided therapy for heart failure. 
  • Natriuretic Peptides and Stratification for ICD Therapy in Nonischemic Heart Failure: A Definite Maybe? 
  • Natriuretic Peptides as Inclusion Criteria in Clinical Trials: A JACC: Heart Failure Position Paper. 
  • Natriuretic Peptides in Older Patients With Heart Failure: A Look Into the Seeds of Time. 
  • Natriuretic peptide-guided heart failure management. 
  • Natriuretic peptide-guided management in heart failure. 
  • Natriuretic peptides in the diagnosis and management of heart failure. 
  • Natural History of Patients Postacute Coronary Syndrome Based on Heart Failure Status. 
  • Natural history and clinical effect of aortic valve regurgitation after left ventricular assist device implantation. 
  • Nebivolol in older adults with heart failure: reduced rates for seniors? 
  • Neighborhood Household Income and Trends in 30-Day Readmission for Patients With Heart Failure. 
  • Neighborhood Socioeconomic Disadvantage and Hospitalized Heart Failure Outcomes in the American Heart Association Get With The Guidelines-Heart Failure Registry. 
  • Nesiritide in acute decompensated heart failure. 
  • Nesiritide in patients hospitalized for acute heart failure: does timing matter? Implication for future acute heart failure trials. 
  • Nesiritide, renal function, and associated outcomes during hospitalization for acute decompensated heart failure: results from the Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure (ASCEND-HF). 
  • Neural modulation for hypertension and heart failure. 
  • Neurocognitive assessments in advanced heart failure patients receiving continuous-flow left ventricular assist devices. 
  • Neurocognitive function in destination therapy patients receiving continuous-flow vs pulsatile-flow left ventricular assist device support. 
  • Neurohumoral mechanisms in heart failure: role in pathogenesis, therapy, and drug tolerance. 
  • Neutrophil CD11b upregulation during cardiopulmonary bypass is associated with postoperative renal injury. 
  • New Decongestion Strategies in an Evolving Heart Failure Landscape. 
  • New Equations for Predicting Maximum Oxygen Uptake in Patients With Heart Failure. 
  • New York Heart Association class and the survival benefit from primary prevention implantable cardioverter defibrillators: A pooled analysis of 4 randomized controlled trials. 
  • New York Heart Association functional class predicts exercise parameters in the current era. 
  • New atrial fibrillation after acute myocardial infarction independently predicts death: the GUSTO-III experience. 
  • New developments in cardiovascular adrenergic receptor pharmacology: molecular mechanisms and clinical relevance. 
  • New diagnostic devices in heart failure. 
  • New frontiers in cardiovascular behavioral medicine: comparative effectiveness of exercise and medication in treating depression. 
  • New insights into diastolic heart failure: role of diabetes mellitus. 
  • Newer Drugs to Reduce High Blood Pressure and Mitigate Hypertensive Target Organ Damage. 
  • Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. 
  • Nifedipine in severely hypertensive patients with congestive heart failure and preserved ventricular systolic function. 
  • Nitrate's effect on activity tolerance in heart failure with preserved ejection fraction trial: rationale and design. 
  • No benefit from defibrillation threshold testing in the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial). 
  • No benefit of a dual coil over a single coil ICD lead: evidence from the Sudden Cardiac Death in Heart Failure Trial. 
  • Nomenclature in heart failure: a call for objective, reproducible, and biologically-driven terminology. 
  • Non-Alcoholic Fatty Liver Disease, Heart Failure, and Long-Term Mortality: Insights From the National Health and Nutrition Examination Survey. 
  • Non-culprit coronary artery percutaneous coronary intervention during acute ST-segment elevation myocardial infarction: insights from the APEX-AMI trial. 
  • Non-evidence-based ICD implantations in the United States. 
  • Non-invasively quantified changes in left ventricular activation predict outcomes in patients undergoing cardiac resynchronization therapy. 
  • Nonalcoholic Fatty Liver Disease and Risk of Heart Failure Among Medicare Beneficiaries. 
  • Noncardiac comorbidities and acute heart failure patients. 
  • Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. 
  • Noninvasive assessment of hemodynamics: an emphasis on bioimpedance cardiography. 
  • Nonpharmacologic therapy in heart failure: an overview. 
  • Nonplatelet thromboxane generation is associated with impaired cardiovascular performance and mortality in heart failure. 
  • Normal skeletal muscle Na(+)-K(+) pump concentration in patients with chronic heart failure. 
  • Normalization of hematocrit in hemodialysis patients does not affect silent ischemia. 
  • Not Your Mother's FDA. 
  • Novel Acoustic Biomarker of Quality of Life in Left Ventricular Assist Device Recipients. 
  • Novel Approaches to Imaging the Pulmonary Vasculature and Right Heart. 
  • Novel Biomarkers for the Risk Stratification of Heart Failure with Preserved Ejection Fraction. 
  • Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide. 
  • Novel Utilization of the Bridge During Weaning Off Venoarterial ECMO: The Hoffman Clamp Method. 
  • Novel approaches to the management of chronic systolic heart failure: future directions and unanswered questions. 
  • Novel biomarkers in chronic heart failure. 
  • Novel mechanism of premature battery failure due to lithium cluster formation in implantable cardioverter-defibrillators. 
  • Novel multi-marker proteomics in phenotypically matched patients with ST-segment myocardial infarction: association with clinical outcomes. 
  • Novel vascular effects of isoprenaline following pacing-induced heart failure in the dog. 
  • Nutrition, Obesity, and Cachexia in Patients With Heart Failure: A Consensus Statement from the Heart Failure Society of America Scientific Statements Committee. 
  • Nutritional modulation of heart failure in mitochondrial pyruvate carrier-deficient mice. 
  • OUTpatient intravenous LASix Trial in reducing hospitalization for acute decompensated heart failure (OUTLAST). 
  • Obese-Inflammatory Phenotypes in Heart Failure With Preserved Ejection Fraction. 
  • Obesity Status and Physical Rehabilitation in Older Patients Hospitalized With Acute HF: Insights From REHAB-HF. 
  • Obesity and Outcomes Following Cardiogenic Shock Requiring Acute Mechanical Circulatory Support. 
  • Obesity and the response to intensified diuretic treatment in decompensated heart failure: a DOSE trial substudy. 
  • Old Device, New Tricks: Exploring Axillary Intra-Aortic Balloon Pump Use in Advanced Heart Failure. 
  • Older Patients With Acute Decompensated Heart Failure Who Live Alone: An Analysis From the REHAB-HF Trial. 
  • Older patients' experiences of heart failure-an integrative literature review. 
  • Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: Rationale and Design of GALACTIC-HF. 
  • Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials. 
  • One-year mortality after implantable cardioverter-defibrillator placement within the Veterans Affairs Health System. 
  • Open Access in Heart Failure: Ready or Not, Here We Come. 
  • Operating in the Dark: When Is Surgery Necessary for Left Ventricular Assist Device Hemolysis? 
  • OptiVol for Volume Assessment in Patients With Continuous Flow Left Ventricular Assist Device. 
  • Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials: JACC Review Topic of the Week. 
  • Optimal medical therapy with or without surgical revascularization and long-term outcomes in ischemic cardiomyopathy. 
  • Optimal timing of hydration to erase contrast-associated nephropathy: the OTHER CAN study. 
  • Optimal utilization and management of implanted cardiac rhythm devices in patients hospitalized for heart failure. 
  • Optimism, Pessimism, and Pragmatism: Musings on the Cost of Medical Innovation. 
  • Optimizing The Management of Obese HFpEF Phenotype: Can We Mind Both The Heart and The Kidney? 
  • Optimizing clinical use of biomarkers in high-risk acute heart failure patients. 
  • Oral Anticoagulation and Adverse Outcomes after Ischemic Stroke in Heart Failure Patients without Atrial Fibrillation. 
  • Oral Iron Therapy for Heart Failure With Reduced Ejection Fraction: Design and Rationale for Oral Iron Repletion Effects on Oxygen Uptake in Heart Failure. 
  • Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design. 
  • Orthodromic reciprocating tachycardia and heart failure in a dog with a concealed posteroseptal accessory pathway. 
  • Orthostatic Hypotension in Patients With Left Ventricular Assist Devices: Acquired Autonomic Dysfunction. 
  • Out-of-pocket payments for part d covered medications by medicare fee-for-service beneficiaries with heart failure with reduced ejection fraction. 
  • Outcome in African Americans and other minorities in the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). 
  • Outcome in medically treated coronary artery disease. Ischemic events: nonfatal infarction and death. 
  • Outcome of Flow-Gradient Patterns of Aortic Stenosis After Aortic Valve Replacement: An Analysis of the PARTNER 2 Trial and Registry. 
  • Outcomes After Extracorporeal Right Ventricular Assist Device Combined With Durable Left Ventricular Assist Device Support. 
  • Outcomes after implantable left ventricular assist device replacement procedures. 
  • Outcomes and cost among Medicare beneficiaries hospitalized for heart failure assigned to accountable care organizations. 
  • Outcomes and costs within a disease management program for advanced congestive heart failure. 
  • Outcomes and predictors of recovery in acute-onset cardiomyopathy: A single-center experience of patients undergoing endomyocardial biopsy for new heart failure. 
  • Outcomes and worsening renal function in patients hospitalized with heart failure with preserved ejection fraction. 
  • Outcomes associated with warfarin use in older patients with heart failure and atrial fibrillation and a cardiovascular implantable electronic device: findings from the ADHERE registry linked to Medicare claims. 
  • Outcomes by race and etiology of patients with left ventricular systolic dysfunction. 
  • Outcomes in Patients Bridged With Univentricular and Biventricular Devices in the Modern Era of Heart Transplantation. 
  • Outcomes in advanced heart failure patients with left ventricular assist devices for destination therapy. 
  • Outcomes in heart failure patients after major noncardiac surgery. 
  • Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population. 
  • Outcomes of Adult Patients with Small Body Size Supported with a Continuous-Flow Left Ventricular Assist Device. 
  • Outcomes of Laparoscopic Cholecystectomy in Patients Supported with a Left Ventricular Assist Device. 
  • Outcomes of Medicare beneficiaries undergoing catheter ablation for atrial fibrillation. 
  • Outcomes of implantable cardioverter-defibrillator use in patients with comorbidities: results from a combined analysis of 4 randomized clinical trials. 
  • Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection. 
  • Outcomes of medicare beneficiaries with heart failure and atrial fibrillation. 
  • Outcomes of transcatheter aortic valve replacement for patients with severe aortic stenosis and concomitant aortic insufficiency: Insights from the TVT Registry. 
  • Outcomes research in cardiovascular imaging: report of a workshop sponsored by the National Heart, Lung, and Blood Institute. 
  • Outcomes research in cardiovascular imaging: report of a workshop sponsored by the National Heart, Lung, and Blood Institute. 
  • Outcomes with ambulatory advanced heart failure from the Medical Arm of Mechanically Assisted Circulatory Support (MedaMACS) Registry. 
  • Outcomes, health policy, and managed care: relationships between patient-reported outcome measures and clinical measures in outpatients with heart failure. 
  • Outpatient Intravenous Diuretic Therapy for Heart Failure in the United States. 
  • Outpatient Worsening Heart Failure as a Target for Therapy: A Review. 
  • Outpatient cardiology practices with advanced practice nurses and physician assistants provide similar delivery of recommended therapies (findings from IMPROVE HF). 
  • Outpatient management of heart failure in the United States, 2006-2008. 
  • Outpatient versus inpatient intravenous diuretic therapy for heart failure in the United States. 
  • Outpatient versus inpatient worsening heart failure: distinguishing biology and risk from location of care. 
  • Overall health at diagnosis predicts the risk of complications within the first year after breast cancer diagnosis. 
  • Overexpression of the cardiac beta(2)-adrenergic receptor and expression of a beta-adrenergic receptor kinase-1 (betaARK1) inhibitor both increase myocardial contractility but have differential effects on susceptibility to ischemic injury. 
  • Overview of current noninodilator therapies for acute heart failure syndromes. 
  • Oxidative phenotype protects myofibers from pathological insults induced by chronic heart failure in mice. 
  • PARAGON-HF Clinical Trial Eligibility in a Population of Patients Hospitalized With Heart Failure. 
  • PKM1 Exerts Critical Roles in Cardiac Remodeling Under Pressure Overload in the Heart. 
  • PR interval identifies clinical response in patients with non-left bundle branch block: a Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy substudy. 
  • PREVENTion of non-surgical bleeding by management of HeartMate II patients without anti-platelet therapy (PREVENT II) trial. 
  • PREVENtion of HeartMate II Pump Thrombosis Through Clinical Management: The PREVENT multi-center study. 
  • PROVIDE-HF primary results: Patient-Reported Outcomes inVestigation following Initiation of Drug therapy with Entresto (sacubitril/valsartan) in heart failure. 
  • Paced QRS duration as a predictor for clinical heart failure events during right ventricular apical pacing in patients with idiopathic complete atrioventricular block: results from an observational cohort study (PREDICT-HF). 
  • Pacemaker-induced transient asynchrony suppresses heart failure progression. 
  • Pacing in Patients with Congenital Heart Disease: When Is It Helpful and When Is It Harmful? 
  • Pacing-induced heart failure in the dog: evaluation of peripheral vascular alpha-adrenoceptor subtypes. 
  • Pacing-induced heart failure: a model to study the mechanism of disease progression and novel therapy in heart failure. 
  • Palliative Care in Heart Failure: The PAL-HF Randomized, Controlled Clinical Trial. 
  • Palliative care and hospital readmissions in patients with advanced heart failure: Insights from the PAL-HF trial. 
  • Pancreatic beta-cell function as a predictor of cardiovascular outcomes and costs: findings from the Cardiovascular Health Study. 
  • Partial adenosine A1 receptor agonism: a potential new therapeutic strategy for heart failure. 
  • Participation in a Heart Failure Clinical Trial: Perspectives and Opportunities From the VICTORIA Trial and VICTORIA Simultaneous Registry. 
  • Pathophysiological role of changing atrial size and pressure in modulation of atrial natriuretic factor during evolving experimental heart failure. 
  • Pathophysiology and clinical evaluation of acute heart failure. 
  • Pathophysiology and treatment options for cardiac anorexia. 
  • Patient Perceptions and Familiarity With Medical Therapy for Heart Failure. 
  • Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes: Insights From the EMPA-REG OUTCOME Trial. 
  • Patient Portals: Who uses them? What features do they use? And do they reduce hospital readmissions? 
  • Patient and hospital characteristics associated with traditional measures of inpatient quality of care for patients with heart failure. 
  • Patient and implanting physician factors associated with mortality and complications after implantable cardioverter-defibrillator implantation, 2002-2005. 
  • Patient and informal caregivers' knowledge of heart failure: necessary but insufficient for effective self-care. 
  • Patient characteristics from a regional multicenter database of acute decompensated heart failure in Asia Pacific (ADHERE International-Asia Pacific). 
  • Patient journey after admission for acute heart failure: length of stay, 30-day readmission and 90-day mortality. 
  • Patient perception of the effect of treatment with candesartan in heart failure. Results of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. 
  • Patient perspectives on having multiple versus single prescribers of chronic disease medications: results of a qualitative study in a veteran population. 
  • Patient satisfaction and use of Veterans Affairs versus non-Veterans Affairs healthcare services by veterans. 
  • Patient selection for advanced heart failure therapy referral. 
  • Patient selection for left ventricular assist devices. 
  • Patient selection for mechanical circulatory support. 
  • Patient selection in heart failure with preserved ejection fraction clinical trials. 
  • Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United States. 
  • Patient, physician, and procedural factors influencing the use of defibrillation testing during initial implantable cardioverter defibrillator insertion: findings from the NCDR®. 
  • Patient-Centered Measures of Treatment Benefit. 
  • Patient-Reported Health-Related Quality of Life Is a Predictor of Outcomes in Ambulatory Heart Failure Patients Treated With Left Ventricular Assist Device Compared With Medical Management: Results From the ROADMAP Study (Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management). 
  • Patient-reported and Clinical Outcomes Among Patients Hospitalized for Heart Failure With Reduced Versus Preserved Ejection Fraction. 
  • Patient-reported outcomes for heart failure with preserved ejection fraction: conducting quality studies on quality of life. 
  • Patients Commonly Believe Their Heart Failure Hospitalizations Are Preventable and Identify Worsening Heart Failure, Nonadherence, and a Knowledge Gap as Reasons for Admission. 
  • Patients Hospitalized for De Novo Versus Worsening Chronic Heart Failure in the United States. 
  • Patients with CHF and depression have greater risk of mortality and morbidity than patients without depression. 
  • Patients' Willingness to Accept Mitral Valve Procedure-Associated Risks Varies Across Severity of Heart Failure Symptoms. 
  • Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry. 
  • Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial. 
  • Patterns and predictors of evidence-based medication continuation among hospitalized heart failure patients (from Get With the Guidelines-Heart Failure). 
  • Patterns of Change in Individual Domains of the Kansas City Cardiomyopathy Questionnaire With a Palliative Care Intervention for Patients With Advanced Heart Failure: Insights from PAL-HF. 
  • Patterns of care for first-detected atrial fibrillation: Insights from the Get With The Guidelines® - Atrial Fibrillation registry. 
  • Patterns of leukocyte counts on admissions for acute heart failure--presentation and outcome--results from a community based registry. 
  • Paying Homage to the Power of Proteomics: Insights Into Obesity and Heart Failure From the HOMAGE Trial. 
  • Payment source, quality of care, and outcomes in patients hospitalized with heart failure. 
  • Peer Review of Peer Review: Somewhere Over the Rainbow. 
  • Perceived Discrimination and Cardiovascular Outcomes in Older African Americans: Insights From the Jackson Heart Study. 
  • Percutaneous coronary intervention outcomes in patients with stable coronary disease and left ventricular systolic dysfunction. 
  • Percutaneous edge-to-edge leaflet repair: a solution to the risk-treatment paradox of mitral regurgitation complicated by pulmonary hypertension? 
  • Percutaneous repair or surgery for mitral regurgitation. 
  • Percutaneous transcatheter aortic valve closure successfully treats left ventricular assist device-associated aortic insufficiency and improves cardiac hemodynamics. 
  • Performance of a novel active fixation quadripolar left ventricular lead for cardiac resynchronization therapy: Attain Stability Quad Clinical Study results. 
  • Performance of current risk stratification models for predicting mortality in patients with heart failure: a systematic review and meta-analysis. 
  • Pericardial Adipose Tissue Volume and Left Ventricular Assist Device-Associated Outcomes. 
  • Perioperative Right Ventricular Dysfunction: Analysis of Outcomes. 
  • Perioperative experience with amrinone. 
  • Perioperative morbidity and mortality in combined vs. staged approaches to carotid and coronary revascularization. 
  • Periprocedural Risk and Survival Associated With Implantable Cardioverter-Defibrillator Placement in Older Patients With Advanced Heart Failure. 
  • Permanent pacemaker use among patients with heart failure and preserved ejection fraction: Findings from the Acute Decompensated Heart Failure National Registry (ADHERE) National Registry. 
  • Permutation criteria to evaluate multiple clinical endpoints in a proof-of-concept study: lessons from Pre-RELAX-AHF. 
  • Persistent high serum bicarbonate and the risk of heart failure in patients with chronic kidney disease (CKD): A report from the Chronic Renal Insufficiency Cohort (CRIC) study. 
  • Personalized Therapeutic Approach: Gun Control for Shotgun Therapy. 
  • Perspectives on Implementing a Multidomain Approach to Caring for Older Adults With Heart Failure. 
  • Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. 
  • Pharmacogenetics in heart failure trials. 
  • Pharmacogenomic study of heart failure and candesartan response from the CHARM programme. 
  • Pharmacogenomics of Bucindolol in Atrial Fibrillation and Heart Failure. 
  • Pharmacokinetic-hemodynamic studies of intravenous nitroglycerin in congestive cardiac failure. 
  • Pharmacokinetic-hemodynamic studies of nitroglycerin in congestive cardiac failure. 
  • Pharmacokinetic-hemodynamic studies of nitroglycerin ointment in congestive heart failure. 
  • Pharmacokinetic-hemodynamic studies of transdermal nitroglycerin in congestive heart failure. 
  • Pharmacokinetics, hemodynamic, renal, and neurohormonal effects of atrial natriuretic factor in experimental heart failure. 
  • Pharmacologic Therapy for Heart Failure with Preserved Ejection Fraction. 
  • Pharmacologic and mechanical methods of discontinuing extracorporeal circulation in patients with heart failure. 
  • Pharmacologic prophylaxis for venous thromboembolism and 30-day outcomes among older patients hospitalized with heart failure: an analysis from the ADHERE national registry linked to Medicare claims. 
  • Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: review of trials and practical considerations. 
  • Pharmacological management of atrial fibrillation in patients with heart failure with reduced ejection fraction: review of current knowledge and future directions. 
  • Phase III clinical trial end points in acute heart failure syndromes: a virtual roundtable with the Acute Heart Failure Syndromes International Working Group. 
  • Phenomapping for novel classification of heart failure with preserved ejection fraction. 
  • Phenomapping for the Identification of Hypertensive Patients with the Myocardial Substrate for Heart Failure with Preserved Ejection Fraction. 
  • Phenotyping heart failure patients for iron deficiency and use of intravenous iron therapy: data from the Swedish Heart Failure Registry. 
  • Phosphodiesterase-5 Inhibitors and Outcomes During Left Ventricular Assist Device Support: A Systematic Review and Meta-Analysis. 
  • Phosphoproteomic profiling of human myocardial tissues distinguishes ischemic from non-ischemic end stage heart failure. 
  • Physical Activity and Incident Heart Failure in High-Risk Subgroups: The ARIC Study. 
  • Physical Activity, All-Cause and Cardiovascular Mortality, and Cardiovascular Disease. 
  • Physical Activity, Quality of Life, and Biomarkers in Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction (from the NEAT-HFpEF Trial). 
  • Physical Activity, Subclinical Myocardial Injury, and Risk of Heart Failure Subtypes in Black Adults. 
  • Physical Function, Frailty, Cognition, Depression, and Quality of Life in Hospitalized Adults ≥60 Years With Acute Decompensated Heart Failure With Preserved Versus Reduced Ejection Fraction. 
  • Physical Functioning in Heart Failure With Preserved Ejection Fraction. 
  • Physical Rehabilitation for Older Patients Hospitalized for Heart Failure. 
  • Physical Rehabilitation in Older Patients Hospitalized with Acute Heart Failure and Diabetes: Insights from REHAB-HF. 
  • Physical Rehabilitation in Patients with Heart Failure. Reply. 
  • Physical activity and relationship to physical function, quality of life, and cognitive function in older patients with acute decompensated heart failure. 
  • Physical activity to combat depression in chronic heart failure. 
  • Physician Perspective. 
  • Physician attitudes toward treatment of depression in older medical inpatients. 
  • Physician-determined worsening heart failure: a novel definition for early worsening heart failure in patients hospitalized for acute heart failure--association with signs and symptoms, hospitalization duration, and 60-day outcomes. 
  • Physiological basis of fatigue. 
  • Pilot investigation of a novel testing strategy for bleeding in ventricular assist device recipients. 
  • Planned right ventricular support for combined heart-liver transplantation. 
  • Plasma Levels of MicroRNA-155 Are Upregulated with Long-Term Left Ventricular Assist Device Support. 
  • Plasma Volume Status and Its Association With In-Hospital and Postdischarge Outcomes in Decompensated Heart Failure. 
  • Plasma and cardiac tissue atrial and brain natriuretic peptides in experimental heart failure. 
  • Plasma biomarkers to predict or rule out early post-discharge events after hospitalization for acute heart failure. 
  • Plasma kidney injury molecule-1 in heart failure: renal mechanisms and clinical outcome. 
  • Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure. 
  • Plasma metabolites associated with functional and clinical outcomes in heart failure with reduced ejection fraction with and without type 2 diabetes. 
  • Plasma omega-3 polyunsaturated fatty acids and survival in patients with chronic heart failure and major depressive disorder. 
  • Plasma renin activity, response to aliskiren, and clinical outcomes in patients hospitalized for heart failure: the ASTRONAUT trial. 
  • Platelet activation in patients with congestive heart failure: do we have enough evidence to consider clopidogrel? 
  • Pleiotropic Associations of Allelic Variants in a 2q22 Region with Risks of Major Human Diseases and Mortality. 
  • Politically Correct Heart Failure Research in America to Avoid Geographic Variation. 
  • Polygenic Score for β-Blocker Survival Benefit in European Ancestry Patients With Reduced Ejection Fraction Heart Failure. 
  • Polypharmacy in Heart Failure with Reduced Ejection Fraction: Progress, Not Problem. 
  • Polypharmacy in Palliative Care for Advanced Heart Failure: The PAL-HF Experience. 
  • Polyvascular disease and increased risk of cardiovascular events in patients with type 2 diabetes: Insights from the EXSCEL trial. 
  • Population Pharmacokinetics of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: An Integrated Analysis. 
  • Population-Level Implications of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Preserved Ejection Fraction in the US. 
  • Positive Pressure Ventilation in the Cardiac Intensive Care Unit. 
  • Possible protein binding displacement interaction between glibenclamide and metolazone. 
  • Post-Myocardial Infarction Heart Failure. 
  • Post-Traumatic Stress Disorder and Heart Failure in Men Within the Veteran Affairs Health System. 
  • Post-cardiac transplant survival after support with a continuous-flow left ventricular assist device: impact of duration of left ventricular assist device support and other variables. 
  • Post-discharge Follow-up Characteristics Associated With 30-Day Readmission After Heart Failure Hospitalization. 
  • Post-discharge haemodilution, congestion, and clinical outcomes among patients hospitalized for heart failure with reduced ejection fraction: results from the EVEREST trial. 
  • Post-operative heparin may not be required for transitioning patients with a HeartMate II left ventricular assist system to long-term warfarin therapy. 
  • Post-recovery COVID-19 and incident heart failure in the National COVID Cohort Collaborative (N3C) study. 
  • Postdischarge international normalized ratio testing and long-term clinical outcomes of patients with heart failure receiving warfarin: findings from the ADHERE registry linked to Medicare claims. 
  • Postimplantation ventricular ectopic burden and clinical outcomes in cardiac resynchronization therapy-defibrillator patients: a MADIT-CRT substudy. 
  • Postoperative management of heart transplantation patients. 
  • Posttraumatic stress disorder and incident heart failure among a community-based sample of US veterans. 
  • Potassium Abnormalities Across the Spectrum of Heart Failure. 
  • Potential Implications of Expanded US Food and Drug Administration Labeling for Sacubitril/Valsartan in the US. 
  • Potential Mortality Reduction With Optimal Implementation of Angiotensin Receptor Neprilysin Inhibitor Therapy in Heart Failure. 
  • Potential advantages of torsemide in patients with heart failure: more than just a 'water pill'? 
  • Potential applications of pharmacogenomics to heart failure therapies. 
  • Potential impact of optimal implementation of evidence-based heart failure therapies on mortality. 
  • Potential role of the tissue renin-angiotensin system in the pathophysiology of congestive heart failure. 
  • Practical and Evidence-Based Approaches to In-Hospital Decongestion for Heart Failure: Are We There Yet? 
  • Pragmatic Design of Randomized Clinical Trials for Heart Failure: Rationale and Design of the TRANSFORM-HF Trial. 
  • Pre-discharge and early post-discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial. 
  • Pre-operative atrial fibrillation and early right ventricular failure after left ventricular assist device implantation: a systematic review and meta-analysis. 
  • Pre-operative proteinuria in left ventricular assist devices and clinical outcome. 
  • Pre-operative risk factors of bleeding and stroke during left ventricular assist device support: an analysis of more than 900 HeartMate II outpatients. 
  • Pre-transplant panel reactive antibody in lung transplant recipients is associated with significantly worse post-transplant survival in a multicenter study. 
  • Precipitating Clinical Factors, Heart Failure Characterization, and Outcomes in Patients Hospitalized With Heart Failure With Reduced, Borderline, and Preserved Ejection Fraction. 
  • Precision Medicine for Heart Failure: Lessons From Oncology. 
  • Precision and predictive medicine: lessons learned from our oncology colleagues. 
  • Predicting Outcomes Over Time in Patients With Heart Failure, Left Ventricular Systolic Dysfunction, or Both Following Acute Myocardial Infarction. 
  • Predicting Prognosis in Heart Failure: Important, But Easier Said Than Done. 
  • Predicting appropriate shocks in patients with heart failure: Patient level meta-analysis from SCD-HeFT and MADIT II. 
  • Predicting atrial fibrillation recurrence after ablation in patients with heart failure: Validity of the APPLE and CAAP-AF risk scoring systems. 
  • Predicting costs among medicare beneficiaries with heart failure. 
  • Predicting freedom from clinical events in non-ST-elevation acute coronary syndromes: the Global Registry of Acute Coronary Events. 
  • Predicting maximal HR in heart failure patients on β-blockade therapy. 
  • Predicting non-elective hospital readmissions: a multi-site study. Department of Veterans Affairs Cooperative Study Group on Primary Care and Readmissions. 
  • Predicting survival in patients receiving continuous flow left ventricular assist devices: the HeartMate II risk score. 
  • Prediction of 30-Day All-Cause Readmissions in Patients Hospitalized for Heart Failure: Comparison of Machine Learning and Other Statistical Approaches. 
  • Prediction of Left Ventricular Ejection Fraction Change Following Treatment With Sacubitril/Valsartan. 
  • Prediction of incident heart failure in general practice: the Atherosclerosis Risk in Communities (ARIC) Study. 
  • Prediction of readmissions and mortality in patients with heart failure: lessons from the IMPEDANCE-HF extended trial. 
  • Prediction of rehospitalization and death in severe heart failure by physicians and nurses of the ESCAPE trial. 
  • Predictive capabilities of the European registry for patients with mechanical circulatory support right-sided heart failure risk score after left ventricular assist device implantation. 
  • Predictive models in heart failure: who cares? 
  • Predictive value of low relative lymphocyte count in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. 
  • Predictors and Associations With Outcomes of Length of Hospital Stay in Patients With Acute Heart Failure: Results From VERITAS. 
  • Predictors and Prognostic Implications of Incident Heart Failure in Patients With Prevalent Atrial Fibrillation. 
  • Predictors of Atrial Fibrillation in Patients With Stroke Attributed to Large- or Small-Vessel Disease: A Prespecified Secondary Analysis of the STROKE AF Randomized Clinical Trial. 
  • Predictors of Mortality by Sex and Race in Heart Failure With Preserved Ejection Fraction: ARIC Community Surveillance Study. 
  • Predictors of clinical outcomes in acute decompensated heart failure: Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure outcome models. 
  • Predictors of contemporary coronary artery bypass grafting outcomes. 
  • Predictors of costs of caring for elderly patients discharged with heart failure. 
  • Predictors of delivery of hospital-based heart failure patient education: a report from OPTIMIZE-HF. 
  • Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program. 
  • Predictors of early dyspnoea relief in acute heart failure and the association with 30-day outcomes: findings from ASCEND-HF. 
  • Predictors of hospital length of stay in heart failure: findings from Get With the Guidelines. 
  • Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). 
  • Predictors of incident heart failure hospitalizations among patients with impaired glucose tolerance: insight from the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research study. 
  • Predictors of intra-aortic balloon pump hemodynamic failure in non-acute myocardial infarction cardiogenic shock. 
  • Predictors of long-term clinical endpoints in patients with refractory angina. 
  • Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). 
  • Predictors of mortality and morbidity in patients with chronic heart failure. 
  • Predictors of outcome and the lack of effect of percutaneous coronary intervention across the risk strata in patients with persistent total occlusion after myocardial infarction: Results from the OAT (Occluded Artery Trial) study. 
  • Predictors of outcome of myocarditis. 
  • Predictors of postdischarge outcomes from information acquired shortly after admission for acute heart failure: a report from the Placebo-Controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function (PROTECT) Study. 
  • Predictors of proarrhythmic effect in heart failure patients after 9-week hybrid comprehensive telerehabilitation and their influence on cardiovascular mortality in long-term follow-up: Subanalysis of the TELEREH-HF randomized clinical trial. 
  • Predictors of sustained ventricular arrhythmias in cardiac resynchronization therapy. 
  • Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT study. 
  • Predictors, Trends, and Outcomes (Among Older Patients ≥65 Years of Age) Associated With Beta-Blocker Use in Patients With Stable Angina Undergoing Elective Percutaneous Coronary Intervention: Insights From the NCDR Registry. 
  • PredischaRge initiation of Ivabradine in the ManagEment of Heart Failure: Results of the PRIME-HF Trial. 
  • Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure. 
  • Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. 
  • Preexisting Cardiovascular Risk and Subsequent Heart Failure Among Non-Hodgkin Lymphoma Survivors. 
  • Preferences of people with advanced heart failure-a structured narrative literature review to inform decision making in the palliative care setting. 
  • Pregnancy course and outcomes in women with arrhythmogenic right ventricular cardiomyopathy. 
  • Preoperative Determinants of Quality of Life and Functional Capacity Response to Left Ventricular Assist Device Therapy. 
  • Preoperative evaluation for major noncardiac surgery: focusing on heart failure. 
  • Preparedness planning before mechanical circulatory support: a "how-to" guide for palliative medicine clinicians. 
  • Prescriber continuity and medication adherence for complex patients. 
  • Prescribing BiDil: is it black and white? 
  • Prescribing warfarin at discharge for heart failure patients: findings from the Get With The Guidelines-Heart Failure Registry. 
  • Prescription of Guideline-Recommended Implantable Cardioverter Defibrillator and Cardiac Resynchronization Therapy Among Patients Hospitalized With Heart Failure and Varying Degrees of Renal Function. 
  • Presence of atrial fibrillation is independently associated with adverse outcomes in patients hospitalized with heart failure: an analysis of get with the guidelines-heart failure. 
  • Preservation of myocardial beta-adrenergic receptor signaling delays the development of heart failure after myocardial infarction. 
  • Pressures do not equal volumes: implications for heart failure management in patients with CardioMEMS. 
  • Prevalence and Prognostic Significance of Left Ventricular Noncompaction in Patients Referred for Cardiac Magnetic Resonance Imaging. 
  • Prevalence and Prognostic Significance of Polyvascular Disease in Patients Hospitalized With Acute Decompensated Heart Failure: The ARIC Study. 
  • Prevalence and clinical associations of mitral and aortic regurgitation in patients with aortic stenosis. 
  • Prevalence and mortality rate of congestive heart failure in the United States. 
  • Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme. 
  • Prevalence and prognostic impact of non-cardiac co-morbidities in heart failure outpatients with preserved and reduced ejection fraction: a community-based study. 
  • Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme. 
  • Prevalence and prognostic importance of precipitating factors leading to heart failure hospitalization: recurrent hospitalizations and mortality. 
  • Prevalence of AAV1 neutralizing antibodies and consequences for a clinical trial of gene transfer for advanced heart failure. 
  • Prevalence of Prediabetes and Undiagnosed Diabetes in Patients with HFpEF and HFrEF and Associated Clinical Outcomes. 
  • Prevalence of symptomatic diastolic heart failure in patients hospitalized with cerebral or peripheral vascular disease. 
  • Prevalence, Profile, and Prognosis of Severe Obesity in Contemporary Hospitalized Heart Failure Trial Populations. 
  • Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure. 
  • Prevalence, risk factors, and cardiovascular disease outcomes associated with persistent blood pressure control: The Jackson Heart Study. 
  • Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes. 
  • Prevalent digoxin use and subsequent risk of death or hospitalization in ambulatory heart failure patients with a reduced ejection fraction-Findings from the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) randomized controlled trial. 
  • Preventing Heart Failure by Treating Systolic Hypertension: What Does the SPRINT Add? 
  • Preventing Heart Failure in Diabetes: Glycemic Targets or Class Effect? 
  • Preventing heart failure in atrial fibrillation: In the middle of difficulty lies opportunity. 
  • Preventing heart failure. 
  • Preventing tomorrow's sudden cardiac death today: dissemination of effective therapies for sudden cardiac death prevention. 
  • Prevention of atrial fibrillation by bucindolol is dependent on the beta₁389 Arg/Gly adrenergic receptor polymorphism. 
  • Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. 
  • Prevention of heart failure: a scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. 
  • Primary Prevention Implantable Cardioverter Defibrillators in Patients With Nonischemic Cardiomyopathy: A Meta-analysis. 
  • Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Nonischemic Cardiomyopathy. 
  • Primary Prevention of Heart Failure in Patients With Type 2 Diabetes Mellitus. 
  • Primary Prevention of Heart Failure in Women. 
  • Primary left ventricular unloading with delayed reperfusion in patients with anterior ST-elevation myocardial infarction: Rationale and design of the STEMI-DTU randomized pivotal trial. 
  • Primary prevention implantable cardioverter defibrillators are effective in preventing overall mortality in older patients. 
  • Primary prevention implantable cardioverter defibrillators in end-stage kidney disease patients on dialysis: a matched cohort study. 
  • Primary prevention implantable cardioverter defibrillators in women: More questions than answers. 
  • Primary prevention implantable cardioverter-defibrillators and survival in older women. 
  • Primary prevention with defibrillator therapy in women: results from the Sudden Cardiac Death in Heart Failure Trial. 
  • Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. 
  • Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes. 
  • Priorities for comparative effectiveness reviews in cardiovascular disease. 
  • Prioritizing Quad Therapy and the Path Forward in Guideline-Directed Medical Therapy for Patients With Heart Failure With Reduced Ejection Fraction. 
  • Prioritizing prevention of de novo and worsening chronic heart failure. 
  • Pro-Inflammatory Biomarkers in Stable Versus Acutely Decompensated Heart Failure With Preserved Ejection Fraction. 
  • Probabilistic Readjudication of Heart Failure Hospitalization Events in the PARAGON-HF Study. 
  • Procainamide-induced sinus node dysfunction in patients with chronic renal failure. 
  • Procalcitonin-based indication of bacterial infection identifies high risk acute heart failure patients. 
  • Process of care performance measures and long-term outcomes in patients hospitalized with heart failure. 
  • Profile of Patients Hospitalized for Heart Failure Who Leave Against Medical Advice. 
  • Prognosis and mechanism of death in treated heart failure: data from the placebo arm of Val-HeFT. 
  • Prognosis for patients with heart failure and reduced ejection fraction with and without diabetes: A 7 year nationwide veteran administration analysis. 
  • Prognosis of heart failure in the elderly: not an affair of the heart? 
  • Prognosis on chronic dobutamine or milrinone infusions for stage D heart failure. 
  • Prognostic Impact of Pulmonary Artery Pulsatility Index (PAPi) in Patients With Advanced Heart Failure: Insights From the ESCAPE Trial. 
  • Prognostic Implications of Changes in Amino-Terminal Pro-B-Type Natriuretic Peptide in Acute Decompensated Heart Failure: Insights From ASCEND-HF. 
  • Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction: PARADIGM-HF. 
  • Prognostic Interplay Between COVID-19 and Heart Failure With Reduced Ejection Fraction. 
  • Prognostic Role of Prior Heart Failure Hospitalization Among Patients Hospitalized for Worsening Chronic Heart Failure. 
  • Prognostic Significance of Creatinine Increases During an Acute Heart Failure Admission in Patients With and Without Residual Congestion: A Post Hoc Analysis of the PROTECT Data. 
  • Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction. 
  • Prognostic Value of Baseline and Changes in Circulating Soluble ST2 Levels and the Effects of Nesiritide in Acute Decompensated Heart Failure. 
  • Prognostic Value of Peak Oxygen Uptake in Patients Supported With Left Ventricular Assist Devices (PRO-VAD). 
  • Prognostic implications of quantitative evaluation of baseline Q-wave width in ST-segment elevation myocardial infarction. 
  • Prognostic importance of defibrillator shocks in patients with heart failure. 
  • Prognostic importance of new small Q waves following non-ST-elevation acute coronary syndromes. 
  • Prognostic importance of pathophysiologic markers in patients with heart failure and preserved ejection fraction. 
  • Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program. 
  • Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: an APEX AMI substudy. 
  • Prognostic significance of anaemia in patients with heart failure with preserved and reduced ejection fraction: results from the MAGGIC individual patient data meta-analysis. 
  • Prognostic significance of depression in blacks with heart failure: insights from Heart Failure: a Controlled Trial Investigating Outcomes of Exercise Training. 
  • Prognostic significance of obstructive coronary artery disease in patients admitted with acute decompensated heart failure: the ARIC study community surveillance. 
  • Prognostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial). 
  • Prognostic usefulness of the six-minute walk in patients with advanced congestive heart failure secondary to ischemic or nonischemic cardiomyopathy. 
  • Prognostic value of anxiety and depression in patients with chronic heart failure. 
  • Prognostic value of blood urea nitrogen in patients hospitalized with worsening heart failure: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) study. 
  • Prognostic value of congestive heart failure history in patients undergoing percutaneous coronary interventions. 
  • Prognostic value of estimated plasma volume in acute heart failure in three cohort studies. 
  • Prognostic value of left ventricular apical tissue removed for HeartMate II left ventricular assist device placement. 
  • Prognostic value of monocyte count in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial). 
  • Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. 
  • Progress in angiotensin-converting enzyme inhibition in heart failure: rationale, mechanisms, and clinical responses. 
  • Progression of Myocardial Fibrosis in Nonischemic DCM and Association With Mortality and Heart Failure Outcomes. 
  • Progression of Tricuspid Regurgitation After Surgery for Ischemic Mitral Regurgitation. 
  • Progression of aortic valve insufficiency during centrifugal versus axial flow left ventricular assist device support. 
  • Progressive mitochondrial protein lysine acetylation and heart failure in a model of Friedreich's ataxia cardiomyopathy. 
  • Projected Clinical Benefits of Implementation of SGLT-2 Inhibitors Among Medicare Beneficiaries Hospitalized for Heart Failure. 
  • Prolonged QRS in Heart Failure With Preserved Ejection Fraction: Risk Marker and Therapeutic Target? 
  • Promoting Diversity in Clinical Trial Leadership: A Call to Action. 
  • Proportion of patients followed in a specialized heart failure clinic needing an implantable cardioverter defibrillator as determined by applying different trial eligibility criteria. 
  • Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics. 
  • Prospective Association of Daily Steps With Cardiovascular Disease: A Harmonized Meta-Analysis. 
  • Prospective assessment of the occurrence of anemia in patients with heart failure: results from the Study of Anemia in a Heart Failure Population (STAMINA-HFP) Registry. 
  • Prospective evaluation of beta-blocker use at the time of hospital discharge as a heart failure performance measure: results from OPTIMIZE-HF. 
  • Prospective evaluation of the association between cardiac troponin T and markers of disturbed erythropoiesis in patients with heart failure. 
  • Prospective evaluation of the association between hemoglobin concentration and quality of life in patients with heart failure. 
  • Prospective study of perceived stress in cardiac patients. 
  • Prospects for cardiovascular research. 
  • Prostaglandins in severe congestive heart failure. Relation to activation of the renin--angiotensin system and hyponatremia. 
  • Prosthetic mitral valve replacement: late complications after native valve preservation. 
  • Protein biomarkers of cardiac remodeling and inflammation associated with HFpEF and incident events. 
  • Protein kinetic signatures of the remodeling heart following isoproterenol stimulation. 
  • Protein turnover in the failing heart: an ever-changing landscape. 
  • Proteomic differences among patients with heart failure taking furosemide or torsemide. 
  • Provider Perspectives on the Feasibility and Utility of Routine Patient-Reported Outcomes Assessment in Heart Failure: A Qualitative Analysis. 
  • Providing Rapid Out of Hospital Acute Cardiovascular Treatment 3 (PROACT-3). 
  • Psychometric Evaluation of the Kansas City Cardiomyopathy Questionnaire in Men and Women With Heart Failure. 
  • Psychosocial Factors, Exercise Adherence, and Outcomes in Heart Failure Patients: Insights From Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION). 
  • Publication Rates of Heart Failure Clinical Trials Remain Low. 
  • Pulmonary Catherization Data Correlate Poorly with Renal Function in Heart Failure. 
  • Pulmonary Hypertension Is Associated With a Higher Risk of Heart Failure Hospitalization and Mortality in Patients With Chronic Kidney Disease: The Jackson Heart Study. 
  • Pulsatile hemodynamic effects of candesartan in patients with chronic heart failure: the CHARM Program. 
  • Pulsus alternans: a visual clue to a grave disorder! 
  • Pump speed modulations and sub-maximal exercise tolerance in left ventricular assist device recipients: A double-blind, randomized trial. 
  • Pump thrombosis in the Thoratec HeartMate II device: An update analysis of the INTERMACS Registry. 
  • Putting the "Optimal" in Optimal Medical Therapy. 
  • QRS duration in patients hospitalized for worsening heart failure. 
  • QRS duration, bundle-branch block morphology, and outcomes among older patients with heart failure receiving cardiac resynchronization therapy. 
  • Quadruple Medical Therapy for Heart Failure: Medications Working Together to Provide the Best Care. 
  • Quality of Care and Outcomes Among Medicare Advantage vs Fee-for-Service Medicare Patients Hospitalized With Heart Failure. 
  • Quality of Life Trajectory and Its Mediators in Older Patients With Acute Decompensated Heart Failure Receiving a Multi-Domain Rehabilitation Intervention: Results From the Rehabilitation Therapy in Older Acute Heart Failure Patients Trial. 
  • Quality of care and outcomes among patients with heart failure and chronic kidney disease: A Get With the Guidelines -- Heart Failure Program study. 
  • Quality of care and outcomes in women hospitalized for heart failure. 
  • Quality of care for atrial fibrillation among patients hospitalized for heart failure. 
  • Quality of care of and outcomes for African Americans hospitalized with heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure) registry. 
  • Quality of life and economic outcomes with surgical ventricular reconstruction in ischemic heart failure: results from the Surgical Treatment for Ischemic Heart Failure trial. 
  • Quality of life and treatment preference for ventricular assist device therapy in ambulatory advanced heart failure: A report from the REVIVAL study. 
  • Quality of life in heart failure with preserved ejection fraction: importance of obesity, functional capacity, and physical inactivity. 
  • Quality of life with defibrillator therapy or amiodarone in heart failure. 
  • Quality outcomes, healthcare resource utilization and costs in Medicare patients with chronic heart failure with reduced ejection fraction with and without a worsening event. 
  • Quality still doesn't pay in heart failure management. 
  • Quality-of-life outcomes with coronary artery bypass graft surgery in ischemic left ventricular dysfunction: a randomized trial. 
  • Quantification of Vasoactive Medications and the "Pharmaco-Mechanical Continuum" in Cardiogenic Shock. 
  • Quantifying Benefit-Risk Preferences for Heart Failure Devices: A Stated-Preference Study. 
  • Quantifying the Impact of Atrial Fibrillation on Heart Failure-Related Patient-Reported Outcomes in the Utah mEVAL Program. 
  • Quantitative Blood Volume Analysis and Hemodynamic Measures of Vascular Compliance in Patients With Worsening Heart Failure. 
  • RBFox1-mediated RNA splicing regulates cardiac hypertrophy and heart failure. 
  • RBFox2-miR-34a-Jph2 axis contributes to cardiac decompensation during heart failure. 
  • RELAX-AHF: consistency across subgroups and new hypotheses generated. 
  • REPORT-HF: the unique blend of global heart failure registry and longitudinal cohort study. 
  • RV instantaneous intraventricular diastolic pressure and velocity distributions in normal and volume overload awake dog disease models. 
  • Race Differences in Quality of Life following a Palliative Care Intervention in Patients with Advanced Heart Failure: Insights from the Palliative Care in Heart Failure Trial. 
  • Race and Sex Differences in QRS Interval and Associated Outcome Among Patients with Left Ventricular Systolic Dysfunction. 
  • Race and improvements in the use of guideline-recommended therapies for patients with heart failure: findings from IMPROVE HF. 
  • Race, common genetic variation, and therapeutic response disparities in heart failure. 
  • Race, exercise training, and outcomes in chronic heart failure: findings from Heart Failure - a Controlled Trial Investigating Outcomes in Exercise TraiNing (HF-ACTION). 
  • Race- and Gender-Based Differences in Cardiac Structure and Function and Risk of Heart Failure. 
  • Race/Ethnic Differences in Outcomes Among Hospitalized Medicare Patients With Heart Failure and Preserved Ejection Fraction. 
  • Race/Ethnicity and Cardiovascular Outcomes in Adults With CKD: Findings From the CRIC (Chronic Renal Insufficiency Cohort) and Hispanic CRIC Studies. 
  • Racial Differences and Temporal Obesity Trends in Heart Failure with Preserved Ejection Fraction. 
  • Racial Differences in Diuretic Efficiency, Plasma Renin, and Rehospitalization in Subjects With Acute Heart Failure. 
  • Racial Differences in Serial NT-proBNP Levels in Heart Failure Management: Insights From the GUIDE-IT Trial. 
  • Racial analysis of patients with myocardial infarction complicated by heart failure and/or left ventricular dysfunction treated with valsartan, captopril, or both. 
  • Racial and Ethnic Differences in Biomarkers, Health Status, and Cardiac Remodeling in Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan. 
  • Racial and Ethnic Differences in Trajectories of Hospitalization in US Men and Women With Heart Failure. 
  • Racial differences in hospice use and patterns of care after enrollment in hospice among Medicare beneficiaries with heart failure. 
  • Racial differences in the characteristics of patients admitted for acute decompensated heart failure and their relation to outcomes: results from the OPTIME-CHF trial. 
  • Racial differences in the outcomes of patients with diastolic heart failure. 
  • Racial differences in the prevalence and outcomes of atrial fibrillation among patients hospitalized with heart failure. 
  • Racial disparities and the use of technology for self-management in blacks with heart failure: a literature review. 
  • Racial/Ethnic differences in B-type natriuretic peptide levels and their association with care and outcomes among patients hospitalized with heart failure: findings from Get With The Guidelines-Heart Failure. 
  • Radiofrequency catheter ablation for dyssynchrony-induced dilated cardiomyopathy in an infant. 
  • Radiographic and Clinical Predictors of Cardiac Dysfunction Following Isolated Traumatic Brain Injury. 
  • Radionuclide viability testing: should it affect treatment strategy in patients with cardiomyopathy and significant coronary artery disease? 
  • Ramp Study Hemodynamics, Functional Capacity, and Outcome in Heart Failure Patients with Continuous-Flow Left Ventricular Assist Devices. 
  • Randomized Clinical Trials of Catheter Ablation of Atrial Fibrillation in Congestive Heart Failure: Knowns and Unmet Needs. 
  • Randomized Evaluation of Heart Failure With Preserved Ejection Fraction Patients With Acute Heart Failure and Dopamine: The ROPA-DOP Trial. 
  • Randomized Placebo-Controlled Trial of Ferric Carboxymaltose in Heart Failure With Iron Deficiency: Rationale and Design. 
  • Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. 
  • Randomized trial of a nurse-administered, telephone-based disease management program for patients with heart failure. 
  • Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. 
  • Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. 
  • Rapid assay brain natriuretic peptide and troponin I in patients hospitalized with decompensated heart failure (from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness Trial). 
  • Rapid clinical assessment of patients with acute heart failure: first blood pressure and oxygen saturation--is that all we need? 
  • Rapid ventricular pacing in the dog: pathophysiologic studies of heart failure. 
  • Rapid ventricular pacing of dogs to heart failure: biochemical and physiological studies. 
  • Rapid-rate nonsustained ventricular tachycardia found on implantable cardioverter-defibrillator interrogation: relationship to outcomes in the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial). 
  • Rate pressure product and the components of heart rate and systolic blood pressure in hospitalized heart failure patients with preserved ejection fraction: Insights from ASCEND-HF. 
  • Rational use of inotropic therapy in heart failure. 
  • Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure. 
  • Rationale and Design of the VITALITY-HFpEF Trial. 
  • Rationale and design for the development of a novel nitroxyl donor in patients with acute heart failure. 
  • Rationale and design of a randomized clinical trial to assess the safety and efficacy of cardiac resynchronization therapy in patients with advanced heart failure: the Multicenter InSync Randomized Clinical Evaluation (MIRACLE). 
  • Rationale and design of a randomized controlled trial of allogeneic mesenchymal stem cells in patients with nonischemic cardiomyopathy. 
  • Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). 
  • Rationale and design of the Children's Oncology Group (COG) study ALTE1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at high risk for developing heart failure. 
  • Rationale and design of the OPTIME CHF trial: outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure. 
  • Rationale and design of the Transendocardial Injection of Autologous Human Cells (bone marrow or mesenchymal) in Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction (TAC-HFT) trial: A randomized, double-blind, placebo-controlled study of safety and efficacy. 
  • Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial. 
  • Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). 
  • Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1-receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction. 
  • Rationale and design of the pilot randomized study of nesiritide versus dobutamine in heart failure (PRESERVD-HF). 
  • Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure. 
  • Rationale for and design of the TRUE-AHF trial: the effects of ularitide on the short-term clinical course and long-term mortality of patients with acute heart failure. 
  • Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin ANtagonist in CHF patients undergoing Exercise) trial. 
  • Rationale, design, and baseline characteristics of a Program to Assess and Review Trending INformation and Evaluate CorRelation to Symptoms in Patients with Heart Failure (PARTNERS HF). 
  • Re-adjudication of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) with study-level meta-analysis of hospitalization for heart failure from cardiovascular outcomes trials with dipeptidyl peptidase-4 (DPP-4) inhibitors. 
  • Re: Desmopressin Use in Refractory Gastrointestinal Bleeding in LVAD Patient. 
  • Reactive hyperemia is associated with adverse clinical outcomes in heart failure. 
  • Reading RVUs: How can we meet the informational needs of cardiologists? 
  • Readmissions in Patients With Heart Failure and Mental Health Disorders (from a National Database). 
  • Real-World Evidence for Medication Safety: Causal, Confounded, or Capable? 
  • Realizing the Potential of Metabolomics in Heart Failure: Signposts on the Path to Clinical Utility. 
  • Reaping from Reciprocity: the Mentor-Mentee Relationship. 
  • Reasons for underuse of angiotensin-converting enzyme inhibitors in patients with heart failure and left ventricular dysfunction. 
  • Reassessing Phase II Heart Failure Clinical Trials: Consensus Recommendations. 
  • Reassessing Recipient Mortality Under the New Heart Allocation System: An Updated UNOS Registry Analysis. 
  • Reassessing the Role of Surrogate End Points in Drug Development for Heart Failure. 
  • Recent advances in porcine cardiac xenotransplantation: from aortic valve replacement to heart transplantation. 
  • Reciprocal in vivo regulation of myocardial G protein-coupled receptor kinase expression by beta-adrenergic receptor stimulation and blockade. 
  • Reclassifying heart failure: time for disruptive innovation? 
  • Recognition of depression in medical patients with heart failure. 
  • Recognizing Efforts that Support Clinical Trial Success: Site-Based Research Awards from the Heart Failure Collaboratory and Heart Failure Society of America. 
  • Recognizing Heart Failure Awareness Week. 
  • Recognizing the Significance of Outpatient Worsening Heart Failure. 
  • Recommendations for the Use of Mechanical Circulatory Support: Ambulatory and Community Patient Care: A Scientific Statement From the American Heart Association. 
  • Recommendations for the use of mechanical circulatory support: device strategies and patient selection: a scientific statement from the American Heart Association. 
  • Recovery from heart failure: structural and functional analysis in a canine model. 
  • Recovery of attenuated baroreflex sensitivity in conscious dogs after reversal of pacing induced heart failure. 
  • Recurrence of heart failure symptoms after LVAD placement due to bradycardia-induced inflow obstruction. 
  • Red Cell Distribution Width Predicts 90 Day Mortality in Continuous-Flow Left Ventricular Assist Device Patients. 
  • Red blood cell distribution width and 1-year mortality in acute heart failure. 
  • Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. 
  • Red cell distribution width is a predictor of mortality in patients undergoing percutaneous coronary intervention. 
  • Redefining the role of biomarkers in heart failure trials: expert consensus document. 
  • Redirecting cardiac growth mechanisms for therapeutic regeneration. 
  • Reduced ejection fraction, sudden cardiac death, and heart failure death in the mode selection trial (MOST): implications for device selection in elderly patients with sinus node disease. 
  • Reduced junctional Na+/Ca2+-exchanger activity contributes to sarcoplasmic reticulum Ca2+ leak in junctophilin-2-deficient mice. 
  • Reduced kidney function as a risk factor for incident heart failure: the atherosclerosis risk in communities (ARIC) study. 
  • Reduced valve replacement surgery and complication rate in Staphylococcus aureus endocarditis patients receiving acetyl-salicylic acid. 
  • Reducing the costs of phase III cardiovascular clinical trials. 
  • Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) Study. 
  • Reframing Global Variation in Heart Failure Trials: Thinking Beyond Location on the Map. 
  • Regional Adipose Distribution and its Relationship to Exercise Intolerance in Older Obese Patients Who Have Heart Failure With Preserved Ejection Fraction. 
  • Regional Adiposity and Risk of Heart Failure and Mortality: The Jackson Heart Study. 
  • Regional Variations in Heart Failure Quality and Outcomes: Get With The Guidelines-Heart Failure Registry. 
  • Regional absence of mitochondria causing energy depletion in the myocardium of muscle LIM protein knockout mice. 
  • Regional adiposity and heart failure with preserved ejection fraction. 
  • Regional differences in the characteristics and treatment of patients participating in an international heart failure trial. The Assessment of Treatment with Lisinopril and Survival (ATLAS) Trial Investigators. 
  • Registry Evidence for Modulation of the Acute Ischemic Heart Disease Pathway: Statins Prevent Heart Failure? 
  • Regulation of intrarenal and circulating renin-angiotensin systems in severe heart failure in the rat. 
  • Rehabilitation Intervention in Older Patients With Acute Heart Failure With Preserved Versus Reduced Ejection Fraction. 
  • Rehabilitation Therapy in Older Acute Heart Failure Patients (REHAB-HF) trial: Design and rationale. 
  • Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. 
  • Relation between pressure and volume unloading during ramp testing in patients supported with a continuous-flow left ventricular assist device. 
  • Relation between volume of exercise and clinical outcomes in patients with heart failure. 
  • Relation of Angina Pectoris to Outcomes, Quality of Life, and Response to Exercise Training in Patients With Chronic Heart Failure (from HF-ACTION). 
  • Relation of Early Repolarization (J Point Elevation) to Mortality in Blacks (from the Jackson Heart Study). 
  • Relation of Elevated Heart Rate in Patients With Heart Failure With Reduced Ejection Fraction to One-Year Outcomes and Costs. 
  • Relation of Low Normal Left Ventricular Ejection Fraction to Heart Failure Hospitalization in Blacks (From the Jackson Heart Study). 
  • Relation of Serum Uric Acid and Cardiovascular Events in Young Adults Aged 20-49 Years. 
  • Relation of Volume Overload to Clinical Outcomes in Acute Heart Failure (From ASCEND-HF). 
  • Relation of anemia to diastolic heart failure and the effect on outcome. 
  • Relation of atrial natriuretic factor to vasoconstrictor hormones and regional blood flow in congestive heart failure. 
  • Relation of circulating liver transaminase concentrations to risk of new-onset atrial fibrillation. 
  • Relation of clinical and angiographic factors to functional capacity as measured by the Duke Activity Status Index. 
  • Relation of depression to severity of illness in heart failure (from Heart Failure And a Controlled Trial Investigating Outcomes of Exercise Training [HF-ACTION]). 
  • Relation of dyspnea severity on admission for acute heart failure with outcomes and costs. 
  • Relation of frequency and severity of mitral regurgitation to survival among patients with left ventricular systolic dysfunction and heart failure. 
  • Relation of left atrial function with exercise capacity and muscle endurance in patients with heart failure. 
  • Relation of low hemoglobin and anemia to morbidity and mortality in patients hospitalized with heart failure (insight from the OPTIMIZE-HF registry). 
  • Relation of serum levels of mast cell tryptase of left ventricular systolic function, left ventricular volume or congestive heart failure. 
  • Relation of serum magnesium levels and postdischarge outcomes in patients hospitalized for heart failure (from the EVEREST Trial). 
  • Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial). 
  • Relation of temporal creatine kinase-MB release and outcome after thrombolytic therapy for acute myocardial infarction. TAMI Study Group. 
  • Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. 
  • Relational processes in heart failure care transitions: A data-driven case report. 
  • Relationship Between Arterial Access and Outcomes in ST-Elevation Myocardial Infarction With a Pharmacoinvasive Versus Primary Percutaneous Coronary Intervention Strategy: Insights From the STrategic Reperfusion Early After Myocardial Infarction (STREAM) Study. 
  • Relationship Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End Points. 
  • Relationship Between Hospital Characteristics and Early Adoption of Angiotensin-Receptor/Neprilysin Inhibitor Among Eligible Patients Hospitalized for Heart Failure. 
  • Relationship Between Infarct Size and Outcomes Following Primary PCI: Patient-Level Analysis From 10 Randomized Trials. 
  • Relationship between Hospital 30-Day Mortality Rates for Heart Failure and Patterns of Early Inpatient Comfort Care. 
  • Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. 
  • Relationship between anemia and health care costs in heart failure. 
  • Relationship between baseline systolic blood pressure and long-term outcomes in acute heart failure patients treated with TRV027: an exploratory subgroup analysis of BLAST-AHF. 
  • Relationship between cardiac rehabilitation and long-term risks of death and myocardial infarction among elderly Medicare beneficiaries. 
  • Relationship between changing patient-reported outcomes and subsequent clinical events in patients with chronic heart failure: insights from HF-ACTION. 
  • Relationship between clinical trial site enrollment with participant characteristics, protocol completion, and outcomes: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) trial. 
  • Relationship between depressive symptoms and long-term mortality in patients with heart failure. 
  • Relationship between early physician follow-up and 30-day readmission among Medicare beneficiaries hospitalized for heart failure. 
  • Relationship between galectin-3 levels and mineralocorticoid receptor antagonist use in heart failure: analysis from HF-ACTION. 
  • Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. 
  • Relationship between left ventricular ejection fraction and cardiovascular outcomes following hospitalization for heart failure: insights from the RELAX-AHF-2 trial. 
  • Relationship between microvascular obstruction and adverse events following primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: an individual patient data pooled analysis from seven randomized trials. 
  • Relationship between patient satisfaction with inpatient care and hospital readmission within 30 days. 
  • Relationship between physician financial incentives and clinical pathway compliance: a cross-sectional study of 18 public hospitals in China. 
  • Relationship between renal function and left ventricular assist device use. 
  • Relationship between repolarization heterogeneity and abnormal myocardial mechanics. 
  • Relationship between sex, ejection fraction, and B-type natriuretic peptide levels in patients hospitalized with heart failure and associations with inhospital outcomes: findings from the Get With The Guideline-Heart Failure Registry. 
  • Relationship between stage of kidney disease and incident heart failure in older adults. 
  • Relationship between timing of trial randomization, protocol completion, and clinical outcomes among patients hospitalized for heart failure: from the ASTRONAUT trial. 
  • Relationship of Liver Stiffness With Congestion in Patients Presenting With Acute Decompensated Heart Failure. 
  • Relationship of age and exercise performance in patients with heart failure: the HF-ACTION study. 
  • Relationship of depression to death or hospitalization in patients with heart failure. 
  • Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. 
  • Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial. 
  • Relationship of female sex to outcomes after myocardial infarction with persistent total occlusion of the infarct artery: analysis of the Occluded Artery Trial (OAT). 
  • Relationship of physical function with quality of life in older patients with acute heart failure. 
  • Relationship of right- to left-sided ventricular filling pressures in advanced heart failure: insights from the ESCAPE trial. 
  • Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. 
  • Relationship of technetium-99m tetrofosmin-gated rest single-photon emission computed tomography myocardial perfusion imaging to death and hospitalization in heart failure patients: results from the nuclear ancillary study of the HF-ACTION trial. 
  • Relationships between changes in patient-reported health status and functional capacity in outpatients with heart failure. 
  • Relationships between emerging measures of heart failure processes of care and clinical outcomes. 
  • Relative wall thickness analysis by two-dimensional echocardiography. 
  • Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. 
  • Relaxin, a pleiotropic vasodilator for the treatment of heart failure. 
  • Reliability and construct validity of PROMIS® measures for patients with heart failure who undergo heart transplant. 
  • Reliability of echocardiographic measurements of left ventricular systolic function in potential pediatric heart transplant donors. 
  • Relief and Recurrence of Congestion During and After Hospitalization for Acute Heart Failure: Insights From Diuretic Optimization Strategy Evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARESS-HF). 
  • Religion and depression in older medical inpatients. 
  • Religion and remission of depression in medical inpatients with heart failure/pulmonary disease. 
  • Remembering the Calling - Where Patients and Caregivers Are Front and Center. 
  • Remodeled cardiac calcium channels. 
  • Remodeling and reparation of the cardiovascular system. 
  • Renal Denervation for Patients With Heart Failure: Making a Full Circle. 
  • Renal Dysfunction in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial. 
  • Renal Effects of Intensive Volume Removal in Heart Failure Patients With Preexisting Worsening Renal Function. 
  • Renal Function and Exercise Training in AmbulatoryHeart Failure Patients With a Reduced Ejection Fraction. 
  • Renal Outcomes in Patients Bridged to Heart Transplant With a Left Ventricular Assist Device. 
  • Renal Response in Patients with Chronic Kidney Disease Predicts Outcome Following Cardiac Resynchronization Therapy. 
  • Renal and circulatory mechanisms in congestive heart failure. 
  • Renal and hepatic function improve in advanced heart failure patients during continuous-flow support with the HeartMate II left ventricular assist device. 
  • Renal effects of angiotensin-converting enzyme inhibition in cardiac failure. 
  • Renal effects of guideline-directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology. 
  • Renal function and coronary bypass surgery in patients with ischemic heart failure. 
  • Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial. 
  • Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. 
  • Renal function trajectories and clinical outcomes in acute heart failure. 
  • Renal function, atherothrombosis extent, and outcomes in high-risk patients. 
  • Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. 
  • Renal response to captopril in severe heart failure: role of furosemide in natriuresis and reversal of hyponatremia. 
  • Renin-angiotensin blockade in heart failure with preserved ejection fraction: a systematic review and meta-analysis. 
  • Renin-angiotensin system and renal circulation in clinical congestive heart failure. 
  • Reoperative sternotomy is associated with increased mortality after heart transplantation. 
  • Replacement of continuous-flow left ventricular assist device via left subcostal incision. 
  • Reply: Adoption of Sacubitril/Valsartan Must Take Into Account Different Heart Failure Patient Types. 
  • Reply: Complications and Mortality Following CRT-D vs ICD. 
  • Reply: Diuretic Strategies and Renal Dysfunction in Heart Failure With Preserved Ejection Fraction. 
  • Reply: Echocardiographic Substrate for Biventricular Pacing. 
  • Reply: Efficacy of Subcutaneous vs. Intravenous Administration of Furosemide in Patients With Worsening Heart Failure: The Devil Is in the Details. 
  • Reply: Factors That May Affect Body Change During and After Hospitalization for Acute Heart Failure. 
  • Reply: Heart Failure With Preserved Ejection Fraction: Types 1 and 2? 
  • Reply: Heart Transplant Allocation Under New Policy: Perceived Risk and Gaming the System. 
  • Reply: Improving Heart Failure Therapeutics: Thinking Outside the Pillbox? 
  • Reply: Is Pump the Answer to Heart Failure With Preserved Ejection Fraction? 
  • Reply: Mode of Death Prevention by Serelaxin. 
  • Reply: Optimal Positioning of Novel Heart Failure Pharmacotherapies: The Case of Vericiguat. 
  • Reply: Potential Mechanisms to Improve Heart Failure Clinical Trial Publication Rates. 
  • Reply: Pragmatic Clinical Trials: The Big Picture. 
  • Reply: Revisited Metformin Therapy in Heart Failure With Preserved Ejection Fraction. 
  • Reply: Temporary Mechanical Circulatory Support as a Bridge to Transplantation: Return of the Intra-Aortic Balloon Pump. 
  • Reply: Titration of Guideline-Directed Medical Therapy Improves Patient-Centered Outcomes in Heart Failure With Reduced Ejection Fraction. 
  • Reply: Vaccination in Patients With Heart Failure: An Established Recommendation in Patients With Chronic Heart Disease. 
  • Reply: circadian variations of ventricular arrhythmias and sleep-disordered breathing in HF patients. 
  • Reply: considerations for drug development for heart failure. 
  • Reply: rapid rate nonsustained ventricular tachycardia found on ICD interrogation: relationship of RR-NSVT to outcomes in the SCD-HeFT trial. 
  • Report from a forum on US heart allocation policy. 
  • Report from the 94th Cardiovascular and Renal Drugs Advisory Committee Meeting, October 11, 2001. 
  • Reporting and interpretation of subgroup analyses in heart failure randomized controlled trials. 
  • Representation of black patients in randomized clinical trials of heart failure with reduced ejection fraction. 
  • Representativeness of RELAX-AHF clinical trial population in acute heart failure. 
  • Representativeness of a Heart Failure Trial by Race and Sex: Results From ASCEND-HF and GWTG-HF. 
  • Representativeness of a national heart failure quality-of-care registry: comparison of OPTIMIZE-HF and non-OPTIMIZE-HF Medicare patients. 
  • Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized With Heart Failure and Reduced Ejection Fraction. 
  • Representativeness of the VICTORIA Trial Population in Clinical Practice: Analysis of the PINNACLE Registry. 
  • Reproducibility of peak oxygen uptake and other cardiopulmonary exercise testing parameters in patients with heart failure (from the Heart Failure and A Controlled Trial Investigating Outcomes of exercise traiNing). 
  • Rescue of Pressure Overload-Induced Heart Failure by Estrogen Therapy. 
  • Residual Heart Failure on Mechanically Assisted Circulation: A Call to Action. 
  • Residual mitral regurgitation in patients with left ventricular assist device support - An INTERMACS analysis. 
  • Resource use and costs of treatment with anticoagulation and antiplatelet agents: results of the WATCH trial economic evaluation. 
  • Resource use in the last 6 months of life among medicare beneficiaries with heart failure, 2000-2007. 
  • Resource use in the last 6 months of life among patients with heart failure in Canada. 
  • Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT). 
  • Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. 
  • Response by Hess et al to Letter Regarding Article, "Sex and Race/Ethnicity Differences in Implantable Cardioverter-Defibrillator Counseling and Use Among Patients Hospitalized With Heart Failure: Findings From the Get With The Guidelines-Heart Failure Program". 
  • Response by Kumbhani et al to Letters Regarding Article, "Association Between Hospital Volume, Processes of Care, and Outcomes in Patients Admitted With Heart Failure: Insights From Get With The Guidelines-Heart Failure". 
  • Response by Lopes et al to Letter Regarding Article, "Initial Invasive Versus Conservative Management of Stable Ischemic Heart Disease Patients With a History of Heart Failure or Left Ventricular Dysfunction: Insights From the ISCHEMIA Trial". 
  • Response by Truby and Topkara to Letter Regarding Article, "Impact of Bridge to Transplantation With Continuous-Flow Left Ventricular Assist Devices on Posttransplantation Mortality: A Propensity-Matched Analysis of the United Network of Organ Sharing Database". 
  • Response of atrial natriuretic factor to postural change in patients with heart failure versus subjects with normal hemodynamics. 
  • Response to Exercise Training and Outcomes in Patients With Heart Failure and Diabetes Mellitus: Insights From the HF-ACTION Trial. 
  • Response to Letter Regarding Article, "Temporal Trends and Variation in Early Scheduled Follow-up After a Hospitalization for Heart Failure: Findings from Get With The Guidelines-Heart Failure. 
  • Response to Letter to the Editor by Dr Kobayashi and Colleagues. 
  • Response to preventive cardiac resynchronization therapy in patients with ischaemic and nonischaemic cardiomyopathy in MADIT-CRT. 
  • Response to role of the carotid body in obesity-related sympathoactivation. 
  • Responsiveness of atrial natriuretic factor to reduction in right atrial pressure in patients with chronic congestive heart failure. 
  • Restenosis, reocclusion and adverse cardiovascular events after successful balloon angioplasty of occluded versus nonoccluded coronary arteries. Results from the Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR). 
  • Resting Heart Rate and Long-term Outcomes Among the African American Population: Insights From the Jackson Heart Study. 
  • Resting ventricular-vascular function and exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study. 
  • Restoration of beta-adrenergic receptor signaling and contractile function in heart failure by disruption of the betaARK1/phosphoinositide 3-kinase complex. 
  • Restoration of beta-adrenergic signaling in failing cardiac ventricular myocytes via adenoviral-mediated gene transfer. 
  • Restrictive left ventricular filling patterns in very old patients with congestive heart failure: clinical correlates and prognostic significance. 
  • Results of the Chronic Heart Failure Intervention to Improve MEdication Adherence study: A randomized intervention in high-risk patients. 
  • Resuscitation preferences among patients with severe congestive heart failure: results from the SUPPORT project. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. 
  • Rethinking Revascularization in Left Ventricular Systolic Dysfunction. 
  • Retinal arteriolar narrowing and left ventricular remodeling: the multi-ethnic study of atherosclerosis. 
  • Return on Investment in Implantable Devices: Cardiac Resynchronization Therapy in Mildly Symptomatic Heart Failure. 
  • Revascularization for Heart Failure: Can We Do Better? 
  • Revascularization for heart failure. 
  • Reversal of cardiac remodeling by modulation of adrenergic receptors: a new frontier in heart failure. 
  • Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes. 
  • Reverse Cardiac Remodeling and Outcome After Initiation of Sacubitril/Valsartan. 
  • Review of advanced heart failure device diagnostics examined in clinical trials and the potential benefit from monitoring capabilities. 
  • Review: In CAD without HF, RAS inhibitors reduce deaths more than placebo but not active control. 
  • Review: In HF with iron deficiency, iron supplementation reduces HF admissions and improves cardiac function. 
  • Reviewers Hall of Fame: 2020 Top Reviewers. 
  • Rhythm Control Versus Rate Control in Patients With Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction: Insights From Get With The Guidelines-Heart Failure. 
  • Rhythm control in atrial fibrillation. 
  • Rhythm control in heart failure patients with atrial fibrillation: contemporary challenges including the role of ablation. 
  • Rhythm control versus rate control for atrial fibrillation and heart failure. 
  • Right Ventricular Failure and Congenital Heart Disease. 
  • Right atrial volume by cardiovascular magnetic resonance predicts mortality in patients with heart failure with reduced ejection fraction. 
  • Right ventricular afterload sensitivity dramatically increases after left ventricular assist device implantation: A multi-center hemodynamic analysis. 
  • Right ventricular diastolic function in canine models of pressure overload, volume overload, and ischemia. 
  • Right ventricular failure in patients with the HeartMate II continuous-flow left ventricular assist device: incidence, risk factors, and effect on outcomes. 
  • Right ventricular lead location and outcomes among patients with cardiac resynchronization therapy: A meta-analysis. 
  • Right-Sided Cardiac Dysfunction in Heart Failure With Preserved Ejection Fraction and Worsening Renal Function. 
  • Rinse, Wash, Repeat: The Evolution of the UNOS Heart Transplant Allocation System. 
  • Risk Adjustment Model for Preserved Health Status in Patients With Heart Failure and Reduced Ejection Fraction: The CHAMP-HF Registry. 
  • Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients: Results From the ROADMAP Study. 
  • Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients: The ROADMAP Study 2-Year Results. 
  • Risk Assessment in Patients with a Left Ventricular Assist Device Across INTERMACS Profiles Using Bayesian Analysis. 
  • Risk Factors for Heart Failure in Patients With Chronic Kidney Disease: The CRIC (Chronic Renal Insufficiency Cohort) Study. 
  • Risk Profiles in Heart Failure: Baseline, Residual, Worsening, and Advanced Heart Failure Risk. 
  • Risk assessment and comparative effectiveness of left ventricular assist device and medical management in ambulatory heart failure patients: design and rationale of the ROADMAP clinical trial. 
  • Risk assessment for continuous flow left ventricular assist devices: does the destination therapy risk score work? An analysis of over 1,000 patients. 
  • Risk assessment for incident heart failure in individuals with atrial fibrillation. 
  • Risk factors for hospital admission among older persons with newly diagnosed heart failure: findings from the Cardiovascular Health Study. 
  • Risk factors for mortality in patients admitted to intensive care units with pneumonia. 
  • Risk factors for stroke on left ventricular assist devices. 
  • Risk factors for surgical site infections in older people. 
  • Risk for cardiovascular outcomes among subjects with atherosclerotic cardiovascular disease and greater-than-normal estimated glomerular filtration rate. 
  • Risk of heart failure complication during hospitalization for acute myocardial infarction in a contemporary population: insights from the National Cardiovascular Data ACTION Registry. 
  • Risk of severe primary graft dysfunction in patients bridged to heart transplantation with continuous-flow left ventricular assist devices. 
  • Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). 
  • Risk score derived from pre-operative data analysis predicts the need for biventricular mechanical circulatory support. 
  • Risk stratification after hospitalization for decompensated heart failure. 
  • Risk-based evaluation of efficacy of rolofylline in patients hospitalized with acute heart failure - Post-hoc analysis of the PROTECT trial. 
  • Robotic-assisted or minithoracotomy incision for left ventricular lead placement: a single-surgeon, single-center experience. 
  • Robustness of outcomes in trials evaluating sodium-glucose co-transporter 2 inhibitors for heart failure. 
  • Role in decision making among congestive heart failure patients and its association with patient outcomes: a baseline analysis of the SCOPAH study. 
  • Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association. 
  • Role of Volume Redistribution in the Congestion of Heart Failure. 
  • Role of amiodarone or implantable cardioverter/defibrillator in patients with atrial fibrillation and heart failure. 
  • Role of beta-adrenergic receptor signaling and desensitization in heart failure: new concepts and prospects for treatment. 
  • Role of cytokines in the mechanism of action of amlodipine: the PRAISE Heart Failure Trial. Prospective Randomized Amlodipine Survival Evaluation. 
  • Role of guanylate cyclase modulators in decompensated heart failure. 
  • Role of microvolt T-wave alternans in assessment of arrhythmia vulnerability among patients with heart failure and systolic dysfunction: primary results from the T-wave alternans sudden cardiac death in heart failure trial substudy. 
  • Role of phosphoinositide 3-kinase in cardiac function and heart failure. 
  • Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. 
  • Role of sodium channel deglycosylation in the genesis of cardiac arrhythmias in heart failure. 
  • Role of soluble and platelet-bound P-selectin in discriminating cardiac from noncardiac chest pain at presentation in the emergency department. 
  • Roles for SGLT2 Inhibitors in Cardiorenal Disease. 
  • Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. 
  • Routine laboratory results and thirty day and one-year mortality risk following hospitalization with acute decompensated heart failure. 
  • SCD-HeFT: Use of R-R interval statistics for long-term risk stratification for arrhythmic sudden cardiac death. 
  • SGLT-2 Inhibitors for Patients with Heart Failure: What Have We Learned Recently? 
  • SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. 
  • SSRI/SNRI Therapy is Associated With a Higher Risk of Gastrointestinal Bleeding in LVAD Patients. 
  • ST-segment recovery and outcome after primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. 
  • ST-segment-elevation myocardial infarction patients randomized to a pharmaco-invasive strategy or primary percutaneous coronary intervention: Strategic Reperfusion Early After Myocardial Infarction (STREAM) 1-year mortality follow-up. 
  • STICH (Surgical Treatment for Ischemic Heart Failure) trial enrollment. 
  • Sacubitril/Valsartan Adherence and Postdischarge Outcomes Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. 
  • Sacubitril/Valsartan Initiation and Postdischarge Adherence Among Patients Hospitalized for Heart Failure. 
  • Sacubitril/Valsartan Therapy for AF and HFpEF: Is the Glass Half Empty or Half Full? 
  • Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial. 
  • Sacubitril/valsartan versus ramipril for patients with acute myocardial infarction: win-ratio analysis of the PARADISE-MI trial. 
  • Safety and Clinical Outcomes of Catheter Ablation of Atrial Fibrillation in Patients With Chronic Kidney Disease. 
  • Safety and Efficacy of Exercise Training in Patients With an Implantable Cardioverter-Defibrillator: A Meta-Analysis. 
  • Safety and Tolerability of Neladenoson Bialanate, a Novel Oral Partial Adenosine A1 Receptor Agonist, in Patients With Chronic Heart Failure. 
  • Safety and Utility of Cardiopulmonary Exercise Testing in Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia. 
  • Safety and efficacy of aerobic training in patients with cancer who have heart failure: an analysis of the HF-ACTION randomized trial. 
  • Safety and efficacy of sertraline for depression in patients with CHF (SADHART-CHF): a randomized, double-blind, placebo-controlled trial of sertraline for major depression with congestive heart failure. 
  • Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. 
  • Safety and efficacy of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced ejection fraction: a phase IIb, randomized, double-blind, placebo-controlled trial. 
  • Safety of symptom-limited cardiopulmonary exercise testing in patients with chronic heart failure due to severe left ventricular systolic dysfunction. 
  • Same bridge, new destinations rethinking paradigms for mechanical cardiac support in heart failure. 
  • Same protocol, different continents, different patients: should we continue to conduct global heart failure trials? 
  • Sarcopenic obesity and the pathogenesis of exercise intolerance in heart failure with preserved ejection fraction. 
  • Sarcoplasmic reticulum Ca-release channel and ATP-synthesis activities are early myocardial markers of heart failure produced by rapid ventricular pacing in dogs. 
  • Scar burden assessed by Selvester QRS score predicts prognosis, not CRT clinical benefit in preventing heart failure event and death: A MADIT-CRT sub-study. 
  • Scintigraphic perfusion patterns in patients with diffuse lung disease. 
  • Scope of Sacubitril/Valsartan Eligibility After Heart Failure Hospitalization: Findings From the GWTG-HF Registry (Get With The Guidelines-Heart Failure). 
  • Screening for Hypertension and Lowering Blood Pressure for Prevention of Cardiovascular Disease Events. 
  • Secondhand Smoke Exposure is Associated with Prevalent Heart Failure: Longitudinal Examination of the National Health and Nutrition Examination Survey. 
  • Selective serotonin reuptake inhibitors yield additional antiplatelet protection in patients with congestive heart failure treated with antecedent aspirin. 
  • Self-Reported Health and Outcomes in Patients With Stable Coronary Heart Disease. 
  • Self-reported medication adherence for heart failure is associated with lower risk of all-cause hospitalisation and death. 
  • Semiquantitative assessed proteinuria and risk of heart failure: analysis of a nationwide epidemiological database. 
  • Sequential Evaluation of NT-proBNP in Heart Failure: Insights Into Clinical Outcomes and Efficacy of Vericiguat. 
  • Sequential echocardiographic-Doppler assessment of left ventricular remodelling and mitral regurgitation during evolving experimental heart failure. 
  • Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial. 
  • Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial. 
  • Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study. 
  • Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. 
  • Serial echocardiographic assessment of left ventricular geometry and function after large myocardial infarction in the rat. 
  • Serial echocardiographic-Doppler assessment of left ventricular geometry and function in rats with pressure-overload hypertrophy. Chronic angiotensin-converting enzyme inhibition attenuates the transition to heart failure. 
  • Serial high sensitivity cardiac troponin T measurement in acute heart failure: insights from the RELAX-AHF study. 
  • Serum Bicarbonate in Acute Heart Failure: Relationship to Treatment Strategies and Clinical Outcomes. 
  • Serum Osmolality and Postdischarge Outcomes After Hospitalization for Heart Failure. 
  • Serum Potassium Levels and Outcome in Acute Heart Failure (Data from the PROTECT and COACH Trials). 
  • Serum insulin-like growth factor-1 and its binding protein-7: potential novel biomarkers for heart failure with preserved ejection fraction. 
  • Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF. 
  • Session highlights from the American College of Cardiology Scientific Sessions: March 29 to April 1, 1998. 
  • Setting the Stage for a Multimarker-Based Heart Failure Prevention Trial? 
  • Severe heart failure and mechanical circulatory support. 
  • Severity of functional impairments by race and sex in older patients hospitalized with acute decompensated heart failure. 
  • Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment. 
  • Sex Differences at the Time of Myectomy in Hypertrophic Cardiomyopathy. 
  • Sex Differences in Clinical Course and Patient-Reported Outcomes Among Patients Hospitalized for Heart Failure. 
  • Sex Differences in Heart Failure. 
  • Sex Differences in Mortality Based on United Network for Organ Sharing Status While Awaiting Heart Transplantation. 
  • Sex Differences in Quality of Life and Clinical Outcomes in Patients With Advanced Heart Failure: Insights From the PAL-HF Trial. 
  • Sex Differences in the Management and Outcomes of Heart Failure With Preserved Ejection Fraction in Patients Presenting to the Emergency Department With Acute Heart Failure. 
  • Sex and Race/Ethnicity Differences in Implantable Cardioverter-Defibrillator Counseling and Use Among Patients Hospitalized With Heart Failure: Findings from the Get With The Guidelines-Heart Failure Program. 
  • Sex and racial differences in the use of implantable cardioverter-defibrillators among patients hospitalized with heart failure. 
  • Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. 
  • Sex differences in early dyspnea relief between men and women hospitalized for acute heart failure: insights from the RELAX-AHF study. 
  • Sex differences in heart mitochondria regulate diastolic dysfunction. 
  • Sex differences in in-hospital mortality in acute decompensated heart failure with reduced and preserved ejection fraction. 
  • Sex-Based Differences in Left Ventricular Assist Device Utilization: Insights From the Nationwide Inpatient Sample 2004 to 2016. 
  • Sex-Based Differences in Outcomes After Mitral Valve Surgery for Severe Ischemic Mitral Regurgitation: From the Cardiothoracic Surgical Trials Network. 
  • Sex-Differences in Cause of Death for Patients Hospitalized for Heart Failure With Reduced Versus Preserved Ejection Fraction (from the ASCEND-HF Trial). 
  • Sex-Related Differences in Heart Failure With Preserved Ejection Fraction. 
  • Sex-Related Differences in Use and Outcomes of Left Ventricular Assist Devices as Bridge to Transplantation. 
  • Sex-Specific Differences in Heart Failure: Pathophysiology, Risk Factors, Management, and Outcomes. 
  • Sex-based differences in biomarkers, health status, and reverse cardiac remodelling in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan. 
  • Sex-related differences in the use and adverse effects of angiotensin-converting enzyme inhibitors in heart failure: the study of patients intolerant of converting enzyme inhibitors registry. 
  • Sex-specific acute heart failure phenotypes and outcomes from PROTECT. 
  • Sharing the care of mechanical circulatory support: collaborative efforts of patients/caregivers, shared-care sites, and left ventricular assist device implanting centers. 
  • Shining a light on the vulnerable intersection of pregnancy and heart failure. 
  • Short- and long-term rehospitalization and mortality for heart failure in 4 racial/ethnic populations. 
  • Short-Term Adverse Outcomes Associated With Hypoglycemia in Critically Ill Children. 
  • Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. 
  • Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. 
  • Should His Bundle Pacing Be Preferred over Cardiac Resynchronization Therapy Following Atrioventricular Junction Ablation? 
  • Should providers prescribe sacubitril/valsartan based on trial eligibility, approval indication, or guideline recommendations? 
  • Shunt vascularity in a young patient with right-sided aortic arch. 
  • Signal transduction in cardiac hypertrophy--dissecting compensatory versus pathological pathways utilizing a transgenic approach. 
  • Signature of circulating microRNAs in patients with acute heart failure. 
  • Significance of a coronary artery with thrombolysis in myocardial infarction grade 2 flow "patency" (outcome in the thrombolysis and angioplasty in myocardial infarction trials). Thrombolysis and Angioplasty in Myocardial Infarction Study Group. 
  • Significance of hyponatremia in heart failure. 
  • Significant variation in P2Y12 inhibitor use after peripheral vascular intervention in Medicare beneficiaries. 
  • Sildenafil Treatment in Heart Failure With Preserved Ejection Fraction: Targeted Metabolomic Profiling in the RELAX Trial. 
  • Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium. 
  • Simplified peak power reserve in patients with an implantable cardioverter-defibrillator and advanced heart failure. 
  • Simulation of Daily Snapshot Rhythm Monitoring to Identify Atrial Fibrillation in Continuously Monitored Patients with Stroke Risk Factors. 
  • Simultaneous or Rapid Sequence Initiation of Quadruple Medical Therapy for Heart Failure-Optimizing Therapy With the Need for Speed. 
  • Simultaneous or rapid sequence initiation of medical therapies for heart failure: seeking to avoid the case of 'too little, too late'. 
  • Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS. 
  • Site enrollment rate, outcomes, and study drug effects in a multicenter trial. Results from RELAX-AHF. 
  • Site selection for heart failure clinical trials in the USA. 
  • Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions. 
  • Size Matters: Normalization of QRS Duration to Left Ventricular Dimension Improves Prediction of Long-Term Cardiac Resynchronization Therapy Outcome. 
  • Skeletal muscle abnormalities and exercise intolerance in older patients with heart failure and preserved ejection fraction. 
  • Sleep Breathing Disorders in Heart Failure. 
  • Sleep Breathing Disorders in Heart Failure. 
  • Sleep-disordered breathing in patients with heart failure. 
  • Smartphone, Mom, and HFpEF. 
  • Social Media: Can It Reduce Heart Failure Events? 
  • Society of Thoracic Surgeons Risk Score and EuroSCORE-2 Appropriately Assess 30-Day Postoperative Mortality in the STICH Trial and a Contemporary Cohort of Patients With Left Ventricular Dysfunction Undergoing Surgical Revascularization. 
  • Socioeconomic and partner status in chronic heart failure: Relationship to exercise capacity, quality of life, and clinical outcomes. 
  • Sodium Glucose Cotransporter-2 Inhibition for Acute Myocardial Infarction: JACC Review Topic of the Week. 
  • Sodium-Glucose Co-Transporter-2 Inhibitor Therapy During Anthracycline Treatment: Is There a Role for Cardioprotection? 
  • Sodium-Glucose Cotransporter 2 Inhibitors and Cardiac Remodeling. 
  • Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction: The Heart and Kidney Working Better Together. 
  • Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction. 
  • Sodium-glucose co-transporter 2 inhibitors for heart failure: clinical trial efficacy and clinical practice effectiveness. 
  • Sodium-glucose cotransporter 2 inhibitors for heart failure with mildly reduced or preserved ejection fraction: time to deliver implementation. 
  • Solid organ transplantation after treatment for childhood cancer: a retrospective cohort analysis from the Childhood Cancer Survivor Study. 
  • Soluble ST2 in ambulatory patients with heart failure: Association with functional capacity and long-term outcomes. 
  • Soluble guanylate cyclase stimulators in patients with heart failure with reduced ejection fraction across the risk spectrum. 
  • Soluble guanylate cyclase: a potential therapeutic target for heart failure. 
  • Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. 
  • Sparing a little may save a lot: lessons from the Studies of Left Ventricular Dysfunction (SOLVD). 
  • Specificity of administrative coding for older adults with acute heart failure hospitalizations. 
  • Spirituality in Patients With Heart Failure. 
  • Spironolactone did not reduce cardiac outcomes in symptomatic heart failure with preserved ejection fraction. 
  • Spironolactone in Acute Heart Failure Patients With Renal Dysfunction and Risk Factors for Diuretic Resistance: From the ATHENA-HF Trial. 
  • Spironolactone metabolite concentrations in decompensated heart failure: insights from the ATHENA-HF trial. 
  • Splanchnic Nerve Block Mediated Changes in Stressed Blood Volume in Heart Failure. 
  • Splanchnic Nerve Block for Acute Heart Failure. 
  • Splanchnic Nerve Block for Chronic Heart Failure. 
  • Splanchnic nerve block for decompensated chronic heart failure: splanchnic-HF. 
  • Splanchnic nerve modulation in heart failure: mechanistic overview, initial clinical experience, and safety considerations. 
  • Spot urine sodium in acute heart failure: differences in prognostic value on admission and discharge. 
  • Stage A Heart Failure Is Not Adequately Recognized in US Adults: Analysis of the National Health and Nutrition Examination Surveys, 2007-2010. 
  • Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel From the Heart Failure Collaboratory and Academic Research Consortium. 
  • Standardized definitions for evaluation of heart failure therapies: scientific expert panel from the Heart Failure Collaboratory and Academic Research Consortium. 
  • Standardizing care for acute decompensated heart failure in a large megatrial: the approach for the Acute Studies of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF). 
  • State of the art: strategies for extracorporeal membrane oxygenation in respiratory failure. 
  • State of the science: promoting self-care in persons with heart failure: a scientific statement from the American Heart Association. 
  • Statement regarding the pre and post market assessment of durable, implantable ventricular assist devices in the United States. 
  • Statement regarding the pre and post market assessment of durable, implantable ventricular assist devices in the United States. 
  • Statement regarding the pre and post market assessment of durable, implantable ventricular assist devices in the United States. 
  • Statement regarding the pre and post market assessment of durable, implantable ventricular assist devices in the United States: executive summary. 
  • Statin therapy--Part II: Clinical considerations for cardiovascular disease. 
  • Statins and Exercise Training Response in Heart Failure Patients: Insights From HF-ACTION. 
  • Stem cells for the ischaemic heart. 
  • Strategic lessons from the clinical event classification process for the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. 
  • Strategies for Mechanical Right Ventricular Support During Left Ventricular Assist Device Implant. 
  • Strategies for supporting intervention fidelity in the rehabilitation therapy in older acute heart failure patients (REHAB-HF) trial. 
  • Strategies to attenuate pathological remodeling in heart failure. 
  • Strategy to identify subjects with diabetes mellitus more suitable for selective echocardiographic screening: The DAVID-Berg study. 
  • Stress-activated MAP kinases in cardiac remodeling and heart failure; new insights from transgenic studies. 
  • Strict Versus Lenient Versus Poor Rate Control Among Patients With Atrial Fibrillation and Heart Failure (from the Get With The Guidelines - Heart Failure Program). 
  • Structural remodelling in heart failure: gelatinase induction. 
  • Study protocol for a cohort study of patients with advanced heart failure in Singapore. 
  • Subcutaneous implantable cardioverter-defibrillator troubleshooting in patients with a left ventricular assist device: A case series and systematic review. 
  • Sudden Cardiac Death in Patients With Ischemic Heart Failure Undergoing Coronary Artery Bypass Grafting: Results From the STICH Randomized Clinical Trial (Surgical Treatment for Ischemic Heart Failure). 
  • Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial). 
  • Sudden cardiac death after acute heart failure hospital admission: insights from ASCEND-HF. 
  • Sudden cardiac death following admission for acute heart failure: adding insult to injury. 
  • Suicide in HF Patients: A Call for Recognition. 
  • Summary of the 2015 International Paediatric Heart Failure Summit of Johns Hopkins All Children's Heart Institute. 
  • Supervised exercise training improves aerobic capacity and muscle strength in older women with heart failure. 
  • Suppression of Tumorigenicity 2 in Heart Failure With Preserved Ejection Fraction. 
  • Surfing the biomarker tsunami at JACC: heart failure. 
  • Surgical ablation of the right greater splanchnic nerve for the treatment of heart failure with preserved ejection fraction: first-in-human clinical trial. 
  • Surgical correction of aortic valve insufficiency after left ventricular assist device implantation. 
  • Surgical treatments for advanced heart failure. 
  • Surgically placed left ventricular leads provide similar outcomes to percutaneous leads in patients with failed coronary sinus lead placement. 
  • Surrogate end points in heart failure trials. 
  • Survival after primary prevention implantable cardioverter-defibrillator placement among patients with chronic kidney disease. 
  • Survival in renal vascular disease. 
  • Survival of patients receiving a primary prevention implantable cardioverter-defibrillator in clinical practice vs clinical trials. 
  • Survival of patients removed from the heart transplant waiting list. 
  • Survival with cardiac-resynchronization therapy in mild heart failure. 
  • Sustained blood pressure control and coronary heart disease, stroke, heart failure, and mortality: An observational analysis of ALLHAT. 
  • Sustained effectiveness of converting-enzyme inhibition in patients with severe congestive heart failure. 
  • Sympathectomy for Stabilization of Heart Failure Due to Drug-Refractory Ventricular Tachycardia. 
  • Synchronized diaphragmatic stimulation for heart failure using the VisONE system: a first-in-patient study. 
  • Synchronized diaphragmatic stimulation: a case report of a novel extra-cardiac intervention for chronic heart failure. 
  • Syncope predicts the outcome of cardiomyopathy patients: analysis of the SCD-HeFT study. 
  • Systems Genetics Approach Identifies Gene Pathways and Adamts2 as Drivers of Isoproterenol-Induced Cardiac Hypertrophy and Cardiomyopathy in Mice. 
  • Systems Genetics Approach to Biomarker Discovery: GPNMB and Heart Failure in Mice and Humans. 
  • Systems proteomics of cardiac chromatin identifies nucleolin as a regulator of growth and cellular plasticity in cardiomyocytes. 
  • Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan. 
  • Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trial. 
  • Systolic blood pressure reduction during the first 24 h in acute heart failure admission: friend or foe? 
  • TRIM35-mediated degradation of nuclear PKM2 destabilizes GATA4/6 and induces P53 in cardiomyocytes to promote heart failure. 
  • TRPC1 channels are critical for hypertrophic signaling in the heart. 
  • Tackling Inflammation in Heart Failure With Preserved Ejection Fraction: Resurrection of Vagus Nerve Stimulation? 
  • Tackling Patient-Reported Outcomes in Atrial Fibrillation and Heart Failure: Identifying Disease-Specific Symptoms? 
  • Tailoring mineralocorticoid receptor antagonist therapy in heart failure patients: are we moving towards a personalized approach? 
  • Tailoring your heart failure project for success in rural areas. 
  • Taking heart failure to new heights: its pathophysiology at simulated altitude. 
  • Target Doses of Heart Failure Medical Therapy and Blood Pressure: Insights From the CHAMP-HF Registry. 
  • Targeted beta-adrenergic receptor kinase (betaARK1) inhibition by gene transfer in failing human hearts. 
  • Targeted inhibition of phosphoinositide 3-kinase activity as a novel strategy to normalize beta-adrenergic receptor function in heart failure. 
  • Targeting Comorbidities in Elderly Patients With Heart Failure: The OPTIMIZE-HFPEF Trial. 
  • Targeting Natriuretic Peptide Levels in Heart Failure with Therapy: Does "X" Really Mark the Spot? 
  • Targeting Preload in Heart Failure: Splanchnic Nerve Blockade and Beyond. 
  • Targeting heart failure therapeutics: a historical perspective. 
  • Targeting the kidney in acute heart failure: can old drugs provide new benefit? Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF) trial. 
  • Targeting the vulnerable phase of heart failure: initiate novel therapies in stable patients prior to hospitalization. 
  • Team-Based Care for Managing Cardiac Comorbidities in Heart Failure. 
  • Technologist Corner: Value of radionuclide ventriculography to assess mechanical dyssynchrony and predict the cardiac resynchronization therapy response. 
  • Telehealth for the Longitudinal Management of Chronic Conditions: Systematic Review. 
  • Temperature-activated ion channels in neural crest cells confer maternal fever-associated birth defects. 
  • Temporal Changes in Postdischarge Mortality Risk After Hospitalization for Heart Failure (from the EVEREST Trial). 
  • Temporal Trends and Clinical Trial Characteristics Associated With the Inclusion of Women in Heart Failure Trial Steering Committees: A Systematic Review. 
  • Temporal Trends and Factors Associated With Cardiac Rehabilitation Participation Among Medicare Beneficiaries With Heart Failure. 
  • Temporal Trends and Factors Associated With Cardiac Rehabilitation Referral Among Patients Hospitalized With Heart Failure: Findings From Get With The Guidelines-Heart Failure Registry. 
  • Temporal Trends and Prognosis of Physical Examination Findings in Patients With Acute Decompensated Heart Failure: The ARIC Study Community Surveillance. 
  • Temporal Trends and Variation in Early Scheduled Follow-Up After a Hospitalization for Heart Failure: Findings from Get With The Guidelines-Heart Failure. 
  • Temporal Trends in Prevalence and Prognostic Implications of Comorbidities Among Patients With Acute Decompensated Heart Failure: The ARIC Study Community Surveillance. 
  • Temporal Trends of Digoxin Use in Patients Hospitalized With Heart Failure: Analysis From the American Heart Association Get With The Guidelines-Heart Failure Registry. 
  • Temporal alterations in peripheral vascular responsiveness during both the development and recovery from pacing-induced heart failure. 
  • Temporal changes in biomarkers and their relationships to reperfusion and to clinical outcomes among patients with ST segment elevation myocardial infarction. 
  • Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: Findings from Get With The Guidelines-Heart Failure registry. 
  • Temporal trends and predictors in the use of aldosterone antagonists post-acute myocardial infarction. 
  • Temporal trends in risk profiles among patients hospitalized for heart failure. 
  • Ten-Year Outcomes After Coronary Artery Bypass Grafting According to Age in Patients With Heart Failure and Left Ventricular Systolic Dysfunction: An Analysis of the Extended Follow-Up of the STICH Trial (Surgical Treatment for Ischemic Heart Failure). 
  • Ten-year experience with extended criteria cardiac transplantation. 
  • Testing for Coronary Artery Disease in Older Patients With New-Onset Heart Failure: Findings From Get With The Guidelines-Heart Failure. 
  • Testing new targets of therapy in advanced heart failure: the design and rationale of the Strategies for Tailoring Advanced Heart Failure Regimens in the Outpatient Setting: BRain NatrIuretic Peptide Versus the Clinical CongesTion ScorE (STARBRITE) trial. 
  • Testosterone supplementation in heart failure: a meta-analysis. 
  • Testosterone therapy in women with heart failure "why can't a woman be more like a man?". 
  • Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the Randomized Intravenous Tezosentan study (RITZ-4). 
  • Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the fourth Randomized Intravenous Tezosentan Study (RITZ-4). 
  • Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4). 
  • Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS). 
  • Thank You for the Privilege. 
  • The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: executive summary. 
  • The ABCs of managing systolic heart failure: Past, present, and future. 
  • The Additive Prognostic Value of Serial Plasma Interleukin-6 Levels over Changes in Brain Natriuretic Peptide in Patients with Acute Heart Failure. 
  • The Association of Digital Health Application Use With Heart Failure Care and Outcomes: Insights From CONNECT-HF. 
  • The Athena trials: Autologous adipose-derived regenerative cells for refractory chronic myocardial ischemia with left ventricular dysfunction. 
  • The Axillary Intra-Aortic Balloon Pump as a Bridge to Recovery Allows Early Ambulation in Long-Term Use: Case Series and Literature Review. 
  • The Burden of Congestion in Patients Hospitalized With Acute Decompensated Heart Failure. 
  • The Burden of Hypertension and Diabetes in an Emergency Department in Northern Tanzania. 
  • The CHARM programme. 
  • The Comparison of the Outcomes between Primary PCI, Fibrinolysis, and No Reperfusion in Patients ≥ 75 Years Old with ST-Segment Elevation Myocardial Infarction: Results from the Chinese Acute Myocardial Infarction (CAMI) Registry. 
  • The Connected Learning Model for disseminating evidence-based care practices in clinical settings. 
  • The Cost-Effectiveness of Palliative Care: Insights from the PAL-HF Trial. 
  • The Degree of the Predischarge Pulmonary Congestion in Patients Hospitalized for Worsening Heart Failure Predicts Readmission and Mortality. 
  • The Dietary Approaches to Stop Hypertension (DASH) eating pattern in special populations. 
  • The Digital Drag and Drop Pillbox: Design and Feasibility of a Skill-based Education Model to Improve Medication Management. 
  • The ECG Belt for CRT response trial: Design and clinical protocol. 
  • The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial. 
  • The FDA in the 21st Century: How Is the FDA Responding to the New World? A Focus on Cardiovascular Drug Development. 
  • The FDA in the 21st Century: How Is the FDA Responding to the New World? A Focus on Heart Failure Devices. 
  • The Failing Heart Relies on Ketone Bodies as a Fuel. 
  • The Future of Wearables in Heart Failure Patients. 
  • The Future of the Journal of Cardiac Failure: A Reinvigorated Focus on People, Partnerships and Presentation. 
  • The Globalization of Heart Failure Research. 
  • The HVAD Left Ventricular Assist Device: Risk Factors for Neurological Events and Risk Mitigation Strategies. 
  • The HeartMate 6. 
  • The Heart Failure High Five: Medical Therapy and Policy: 2019. 
  • The Hospital Readmissions Reduction Program: Nationwide Perspectives and Recommendations: A JACC: Heart Failure Position Paper. 
  • The Hybrid Mouse Diversity Panel: a resource for systems genetics analyses of metabolic and cardiovascular traits. 
  • The Impact of Adverse Events on Functional Capacity and Quality of Life After HeartWare Ventricular Assist Device Implantation. 
  • The Impact of Depression on Outcomes in Patients With Heart Failure and Reduced Ejection Fraction Treated in the GUIDE-IT Trial. 
  • The Impact of Worsening Heart Failure in the United States. 
  • The Incidence and Consequence of Prosthesis-Patient Mismatch After Surgical Aortic Valve Replacement. 
  • The Initiation Management Predischarge Process for Assessment of Carvedilol Therapy for Heart Failure (IMPACT-HF) Study: design and implications. 
  • The International Olympic Games: Heart Teams and Heart Failure. 
  • The Intersection Between Heart Failure and Critical Care Cardiology: An International Perspective on Structure, Staffing, and Design Considerations. 
  • The Journey of an American Black Cardiologist. 
  • The Maximally Tolerated Dose: The Key Context for Interpreting Subtarget Medication Dosing for Heart Failure. 
  • The Nexus of Heart Failure and Critical Care Cardiology. 
  • The Obesity and Heart Failure Epidemics Among African Americans: Insights From the Jackson Heart Study. 
  • The PARACHUTE IV trial design and rationale: percutaneous ventricular restoration using the parachute device in patients with ischemic heart failure and dilated left ventricles. 
  • The PROTECT in-hospital risk model: 7-day outcome in patients hospitalized with acute heart failure and renal dysfunction. 
  • The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. 
  • The Pathobiology of Pulmonary Arterial Hypertension. 
  • The Perfect Storm: Carcinoid Heart Disease and Acute Right Ventricular Failure. 
  • The Pilot Randomized Study of Nesiritide Versus Dobutamine in Heart Failure (PRESERVD-HF). 
  • The Potential Impact of Expanding Cardiac Rehabilitation in Heart Failure. 
  • The Risk of Stroke on Left Ventricular Assist Device Support: Steady Gains or Stalled Progress? 
  • The Road Not Yet Traveled: Distinction in Critical Care Cardiology through the Advanced Heart Failure and Transplant Cardiology Training Pathway. 
  • The Role of Sodium and Chloride in Heart Failure: Does It Take Two to Tango? 
  • The S1103Y cardiac sodium channel variant is associated with implantable cardioverter-defibrillator events in blacks with heart failure and reduced ejection fraction. 
  • The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. 
  • The STARBRITE trial: a randomized, pilot study of B-type natriuretic peptide-guided therapy in patients with advanced heart failure. 
  • The STICH trial (Surgical Treatment for Ischemic Heart Failure): mode-of-death results. 
  • The Support, Education, and Research in Chronic Heart Failure Study (SEARCH): a mindfulness-based psychoeducational intervention improves depression and clinical symptoms in patients with chronic heart failure. 
  • The Time Is Now for Sodium Glucose Co-Transporter 2 Inhibitors for Heart Failure: A Call to Overcome Clinical Inertia. 
  • The Universal Definition of Heart Failure: Perspectives from Diverse Stakeholders. 
  • The Urgency of Doing: Addressing Gaps in Use of Evidence-Based Medical Therapy for Heart Failure. 
  • The Use of Sacubitril/Valsartan for Hospitalized Heart Failure-Why Do We Care About Cost and Value? 
  • The Valsalva maneuver: a bedside "biomarker" for heart failure. 
  • The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristics. 
  • The Year in Heart Failure Review 2015 to 2016. 
  • The association between biventricular pacing and cardiac resynchronization therapy-defibrillator efficacy when compared with implantable cardioverter defibrillator on outcomes and reverse remodelling. 
  • The association between blood pressure and long-term outcomes of patients with ischaemic cardiomyopathy with and without surgical revascularization: an analysis of the STICH trial. 
  • The association between depression and chronic kidney disease and mortality among patients hospitalized with congestive heart failure. 
  • The association between meteorological events and acute heart failure: new insights from ASCEND-HF. 
  • The association of improvement in left ventricular ejection fraction with outcomes in patients with heart failure with reduced ejection fraction: data from CHAMP-HF. 
  • The association of the heart failure score with mortality and heart failure hospitalizations in elderly patients: insights from the Mode Selection Trial (MOST). 
  • The benefit of implementing a heart failure disease management program. 
  • The beta-adrenergic receptor in heart failure. 
  • The burden of non-cardiac comorbidities and association with clinical outcomes in an acute heart failure trial - insights from ASCEND-HF. 
  • The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction. 
  • The cVAD registry for percutaneous temporary hemodynamic support: A prospective registry of Impella mechanical circulatory support use in high-risk PCI, cardiogenic shock, and decompensated heart failure. 
  • The carotid body as a therapeutic target for the treatment of sympathetically mediated diseases. 
  • The chromatin-binding protein Smyd1 restricts adult mammalian heart growth. 
  • The clinical course of health status and association with outcomes in patients hospitalized for heart failure: insights from ASCEND-HF. 
  • The clinical course of pulmonary embolism. 
  • The complexity and cost of drug regimens of older patients hospitalized with heart failure in the United States, 1998-2001. 
  • The congestion score: a simple tool for a complicated disease? 
  • The continuous heart failure spectrum: moving beyond an ejection fraction classification. 
  • The disconnect between phase II and phase III trials of drugs for heart failure. 
  • The economic burden of chronic cardiovascular disease for major insurers. 
  • The economics of heart failure. 
  • The effect of Aliskiren on exercise capacity in older patients with heart failure and preserved ejection fraction: A randomized, placebo-controlled, double-blind trial. 
  • The effect of beta-adrenergic blockers on the prognostic value of peak exercise oxygen uptake in patients with heart failure. 
  • The effect of intermittent atrial tachyarrhythmia on heart failure or death in cardiac resynchronization therapy with defibrillator versus implantable cardioverter-defibrillator patients: a MADIT-CRT substudy (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy). 
  • The effect of the cardiac myosin activator, omecamtiv mecarbil, on right ventricular structure and function in chronic systolic heart failure (COSMIC-HF). 
  • The effects of acute afterload change on systolic ventricular function in conscious dogs with normal vs. failing hearts. 
  • The effects of exercise on cardiovascular biomarkers in patients with chronic heart failure. 
  • The efficacy and safety of cardiac resynchronization therapy combined with implantable cardioverter defibrillator for heart failure: a meta-analysis of 5674 patients. 
  • The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction: results from the Azimilide Postinfarct Survival Evaluation (ALIVE) trial. 
  • The emerging role of novel antihyperglycemic agents in the treatment of heart failure and diabetes: A focus on cardiorenal outcomes. 
  • The failing heart utilizes 3-hydroxybutyrate as a metabolic stress defense. 
  • The gene expression profile of patients with new-onset heart failure reveals important gender-specific differences. 
  • The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. 
  • The heart failure clinic: a consensus statement of the Heart Failure Society of America. 
  • The hospital frailty risk score in patients with heart failure is strongly associated with outcomes but less so with pharmacotherapy. 
  • The immunological axis in heart failure: importance of the leukocyte differential. 
  • The impact of a failing right heart in patients supported by intra-aortic balloon counterpulsation. 
  • The impact of arrhythmias in acute heart failure. 
  • The impact of race on utilization of durable left ventricular assist device therapy in patients with advanced heart failure. 
  • The importance of consistent, high-quality acute myocardial infarction and heart failure care results from the American Heart Association's Get with the Guidelines Program. 
  • The incidence, risk factors, and outcomes associated with late right-sided heart failure in patients supported with an axial-flow left ventricular assist device. 
  • The influence of comorbidities on achieving an N-terminal pro-b-type natriuretic peptide target: a secondary analysis of the GUIDE-IT trial. 
  • The influence of heart failure on clinical and economic outcomes among older adults ≥75 years of age with acute myocardial infarction. 
  • The interaction among sex, hemoglobin and outcomes in a specialty heart failure clinic. 
  • The long-term effects of dietary sodium restriction on clinical outcomes in patients with heart failure. The SODIUM-HF (Study of Dietary Intervention Under 100 mmol in Heart Failure): a pilot study. 
  • The lower is not always the better: a more comprehensive understanding of loop diuretics in heart failure. 
  • The meanings associated with medicines in heart failure patients. 
  • The mechanical and hemodynamic effects of left ventricular pacing in heart failure with preserved ejection fraction and left bundle branch block. 
  • The modifying effects of social support on psychological outcomes in patients with heart failure. 
  • The natural history and recommended management of patients with traumatic coronary artery fistulas. 
  • The need for multiple measures of hospital quality: results from the Get with the Guidelines-Heart Failure Registry of the American Heart Association. 
  • The new heart failure guidelines: strategies for implementation. 
  • The nuclear receptor RORα protects against angiotensin II-induced cardiac hypertrophy and heart failure. 
  • The p38 mitogen-activated protein kinase pathway--a potential target for intervention in infarction, hypertrophy, and heart failure. 
  • The palliative care in heart failure trial: rationale and design. 
  • The past, present and future of renin-angiotensin aldosterone system inhibition. 
  • The pathophysiology of acute heart failure--is it all about fluid accumulation? 
  • The physiological role of cardiac cytoskeleton and its alterations in heart failure. 
  • The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors. 
  • The potential role of natriuretic peptide-guided management for patients hospitalized for heart failure. 
  • The potential role of nonpharmacologic electrophysiology-based interventions in improving outcomes in patients hospitalized for heart failure. 
  • The predictive value of short-term changes in hemoglobin concentration in patients presenting with acute decompensated heart failure. 
  • The problem of decompensated heart failure: nomenclature, classification, and risk stratification. 
  • The prognostic importance of different definitions of worsening renal function in congestive heart failure. 
  • The prognostic significance of heart rate in patients hospitalized for heart failure with reduced ejection fraction in sinus rhythm: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study With Tolvaptan) trial. 
  • The prognostic value of diastolic and systolic mechanical left ventricular dyssynchrony among patients with coronary artery disease and heart failure. 
  • The rationale and design of the Surgical Treatment for Ischemic Heart Failure (STICH) trial. 
  • The real world of de novo heart failure: the next frontier for heart failure clinical trials? 
  • The regenerative capacity of zebrafish reverses cardiac failure caused by genetic cardiomyocyte depletion. 
  • The relationship between baseline and follow-up left ventricular ejection fraction with adverse events among primary prevention ICD patients. 
  • The relationship between left ventricular ejection fraction and mortality in patients with acute heart failure: insights from the ASCEND-HF Trial. 
  • The right ventricular transcriptome signature in Ossabaw swine with cardiometabolic heart failure: implications for the coronary vasculature. 
  • The role of atrial fibrillation catheter ablation in patients with heart failure. 
  • The role of cardiac MR in new-onset heart failure. 
  • The role of cardiovascular MRI in heart failure and the cardiomyopathies. 
  • The role of heart failure pharmacotherapy after left ventricular assist device support. 
  • The role of modulatory calcineurin-interacting proteins in calcineurin signaling. 
  • The role of type 1 angiotensin receptors on T lymphocytes in cardiovascular and renal diseases. 
  • The safety of an adenosine A(1)-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: findings from PROTECT. 
  • The serine/threonine-protein kinase/endoribonuclease IRE1α protects the heart against pressure overload-induced heart failure. 
  • The spectrum of complications following left ventricular assist device placement. 
  • The state of exercise training: a need for action. 
  • The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. 
  • The systemic inflammatory response syndrome in patients with ST-segment elevation myocardial infarction. 
  • The third beta is not the charm. 
  • The ubiquitin ligase MuRF1 regulates PPARα activity in the heart by enhancing nuclear export via monoubiquitination. 
  • The use of beta-blockers in a tertiary care heart failure clinic: dosing, tolerance, and outcomes. 
  • The vulnerable phase after hospitalization for heart failure. 
  • The worst symptom as defined by patients during heart failure hospitalization: implications for response to therapy. 
  • Therapeutic Effect of Targeting Branched-Chain Amino Acid Catabolic Flux in Pressure-Overload Induced Heart Failure. 
  • Therapeutic Targets for Heart Failure Identified Using Proteomics and Mendelian Randomization. 
  • Therapeutic exercise for individuals with heart failure: special attention to older women with heart failure. 
  • Therapeutic implications of biomarkers in chronic heart failure. 
  • Therapies to prevent heart failure post-myocardial infarction. 
  • Therapy and clinical trials. 
  • Therapy for heart failure with preserved ejection fraction: current status, unique challenges, and future directions. 
  • Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence? 
  • Thinking Outside the Box: Treating Acute Heart Failure Outside the Hospital to Improve Care and Reduce Admissions. 
  • Third universal definition of myocardial infarction. 
  • Thromboembolism and antithrombotic therapy in patients with heart failure in sinus rhythm: current status and future directions. 
  • Thrombolysis and counterpulsation to improve survival in myocardial infarction complicated by hypotension and suspected cardiogenic shock or heart failure: results of the TACTICS Trial. 
  • Thrombus on the inflow cannula of the HeartWare HVAD: an update. 
  • Thyroid function in heart failure and impact on mortality. 
  • Ticagrelor in patients with heart failure after acute coronary syndromes-Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. 
  • Time for Recognition. 
  • Time to Clinical Benefit of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial. 
  • Time to diuretics in acute heart failure: the tortoise or the hare? 
  • Time-dependent analysis in CHF follow-up. 
  • Timing and Causes of Readmission After Acute Heart Failure Hospitalization-Insights From the Heart Failure Network Trials. 
  • Timing of Postdischarge Follow-Up and Medication Adherence Among Patients With Heart Failure. 
  • Timing of cardiac resynchronization therapy device implantation in heart failure patients and its association with outcomes. 
  • Timing of cardiac transplantation in patients with heart failure receiving beta-adrenergic blockers. 
  • Timing of in-hospital coronary artery bypass graft surgery for non-ST-segment elevation myocardial infarction patients results from the National Cardiovascular Data Registry ACTION Registry-GWTG (Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines). 
  • Tiny solutions for giant cardiac problems. 
  • Tissue renin-angiotensin system in myocardial hypertrophy and failure. 
  • Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction. 
  • Titration of medical therapy and clinical outcomes among patients with heart failure with reduced ejection fraction: Findings from the HF-ACTION trial. 
  • Tobacco smoking in patients with heart failure and coronary artery disease: A 20-year experience at Duke University Medical Center. 
  • Tocainide kinetics in congestive heart failure. 
  • Tolerability and safety barriers to sodium-glucose cotransporter 2 inhibitor initiation in heart failure with reduced ejection fraction. 
  • Tolerability of Sacubitril/Valsartan in Patients With Advanced Heart Failure: Analysis of the LIFE Trial Run-In. 
  • Tolerance to organic nitrates: clinical and experimental perspectives. 
  • Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. The Assessment of Treatment with Lisinopril and Survival. 
  • Tolvaptan in Patients Hospitalized With Acute Heart Failure: Rationale and Design of the TACTICS and the SECRET of CHF Trials. 
  • Tolvaptan, an oral vasopressin V2 receptor antagonist for heart failure? 
  • Tonapofylline: a selective adenosine-1 receptor antagonist for the treatment of heart failure. 
  • Too much, too little, or just right?: untangling endogenous erythropoietin in heart failure. 
  • Tools for Economic Analysis of Patient Management Interventions in Heart Failure Cost-Effectiveness Model: A Web-based program designed to evaluate the cost-effectiveness of disease management programs in heart failure. 
  • Top Ten Tips Palliative Care Clinicians Should Know About Caring for Patients with Left Ventricular Assist Devices. 
  • Top Ten Tips for Palliative Care Clinicians Caring for Heart Failure Patients. 
  • Top-down quantitative proteomics identified phosphorylation of cardiac troponin I as a candidate biomarker for chronic heart failure. 
  • Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial). 
  • Torsemide versus furosemide in heart failure patients: insights from Duke University Hospital. 
  • Total shoulder arthroplasty in patients with HIV infection: complications, comorbidities, and trends. 
  • Toward a Self-Actuating Continuous Flow Ventricular Assist Device: The Pudding Is in the Proof. 
  • Toward more optimal use of primary prevention implantable cardioverter-defibrillators: how do we get there? 
  • Trained and supervised physician assistants can safely perform diagnostic cardiac catheterization with coronary angiography. 
  • Training trials in heart failure: time to exercise restraint? 
  • Trajectories of Changes in Renal Function in Patients with Acute Heart Failure. 
  • Trajectory classes of depression in a randomized depression trial of heart failure patients: a reanalysis of the SADHART-CHF trial. 
  • Trajectory of Congestion Metrics by Ejection Fraction in Patients With Acute Heart Failure (from the Heart Failure Network). 
  • Transcriptomic biomarkers for individual risk assessment in new-onset heart failure. 
  • Transfer times and outcomes in patients with ST-segment-elevation myocardial infarction undergoing interhospital transfer for primary percutaneous coronary intervention: APEX-AMI insights. 
  • Transient and persistent worsening renal function during hospitalization for acute heart failure. 
  • Transitional adherence and persistence in the use of aldosterone antagonist therapy in patients with heart failure. 
  • Transitions of care in heart failure: a scientific statement from the American Heart Association. 
  • Translating Nursing Partnerships in Clinical Care to Scientific Publishing. 
  • Translating clinical trials into clinical practice: a survey assessing the potential impact of the Pediatric Heart Network Infant Single Ventricle Trial. 
  • Translating evidence into practice: use of statins in real-world patients with heart failure. 
  • Transthoracic impedance compared to magnetic resonance imaging in the assessment of cardiac output. 
  • Transthyretin V142I Genetic Variant and Cardiac Remodeling, Injury, and Heart Failure Risk in Black Adults. 
  • Transvenous Right Greater Splanchnic Nerve Ablation in Heart Failure and Preserved Ejection Fraction: First-in-Human Study. 
  • Traveling the Interstices of Data Sharing. 
  • Treatment Persistence of Renin-Angiotensin-Aldosterone-System Inhibitors Over Time in Heart Failure with Reduced Ejection Fraction. 
  • Treatment and risk in heart failure: gaps in evidence or quality? 
  • Treatment gaps in the pharmacologic management of heart failure. 
  • Treatment of HF in an Era of Multiple Therapies: Statement From the HF Collaboratory. 
  • Treatment of functional mitral valve regurgitation with the permanent percutaneous transvenous mitral annuloplasty system: results of the multicenter international Percutaneous Transvenous Mitral Annuloplasty System to Reduce Mitral Valve Regurgitation in Patients with Heart Failure trial. 
  • Treatment of sleep-disordered breathing in heart failure impacts cardiac remodeling: Insights from the CAT-HF Trial. 
  • Treatment with 24 hour istaroxime infusion in patients hospitalised for acute heart failure: a randomised, placebo-controlled trial. 
  • Trends and Characteristics of Hospitalizations in Patients With Heart Transplant. 
  • Trends and characteristics of hospitalizations for heart failure in the United States from 2004 to 2018. 
  • Trends and outcomes of patients with adult congenital heart disease and pulmonary hypertension listed for orthotopic heart transplantation in the United States. 
  • Trends in 30- and 90-Day Readmission Rates for Heart Failure. 
  • Trends in 30-Day Readmission Rates for Patients Hospitalized With Heart Failure: Findings From the Get With The Guidelines-Heart Failure Registry. 
  • Trends in Characteristics and Outcomes in Primary Heart Failure Hospitalizations Among Older Population in the United States, 2004 to 2018. 
  • Trends in HF Hospitalizations Among Young Adults in the United States From 2004 to 2018. 
  • Trends in Heart Failure Clinical Trials From 2001-2012. 
  • Trends in Heart Failure-Related Mortality Among Older Adults in the United States From 1999-2019. 
  • Trends in Hospice Discharge and Relative Outcomes Among Medicare Patients in the Get With The Guidelines-Heart Failure Registry. 
  • Trends in Hospitalizations and Survival of Acute Decompensated Heart Failure in Four US Communities (2005-2014): ARIC Study Community Surveillance. 
  • Trends in Noncardiovascular Comorbidities Among Patients Hospitalized for Heart Failure: Insights From the Get With The Guidelines-Heart Failure Registry. 
  • Trends in Readmissions and Length of Stay for Patients Hospitalized With Heart Failure in Canada and the United States. 
  • Trends in Substance Abuse Disorders Among Patients Hospitalized for Heart Failure in the United States. 
  • Trends in Treatment for Patients Hospitalized with Heart Failure with Preserved Ejection Fraction Before and After Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT). 
  • Trends in cardiovascular medicine: Update on cardiac transplantation. 
  • Trends in heart failure-related cardiovascular mortality in rural versus urban United States counties, 2011-2018: A cross-sectional study. 
  • Trends in hospitalizations for heart failure, acute myocardial infarction, and stroke in the United States from 2004 to 2018. 
  • Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. 
  • Trends in prevalence of comorbidities in heart failure clinical trials. 
  • Trends in the use and outcomes of ventricular assist devices among medicare beneficiaries, 2006 through 2011. 
  • Trends in use of implantable cardioverter-defibrillator therapy among patients hospitalized for heart failure: have the previously observed sex and racial disparities changed over time? 
  • Triage after hospitalization with advanced heart failure: the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) risk model and discharge score. 
  • Tricuspid Valve Regurgitation Immediately After Heart Transplant and Long-Term Outcomes. 
  • Troponin T levels in patients with acute heart failure: clinical and prognostic significance of their detection and release during hospitalisation. 
  • Troponin elevation in heart failure prevalence, mechanisms, and clinical implications. 
  • Tumor necrosis factor, natural killer activity and other measures of immune function and inflammation in elderly men with heart failure. 
  • Two-Year Outcomes of Surgical Treatment of Severe Ischemic Mitral Regurgitation. 
  • Two-Year Outcomes with a Magnetically Levitated Cardiac Pump in Heart Failure. 
  • Two-stage total cardioaortic replacement for end-stage heart and aortic disease in Marfan syndrome: case report and review of the literature. 
  • Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of America. 
  • Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. 
  • UNUSUAL NEUROLOGICAL AND CARDIOVASCULAR COMPLICATIONS OF RESPIRATORY FAILURE. 
  • Ultrafiltration in Acute Heart Failure: Implications of Ejection Fraction and Early Response to Treatment From CARRESS-HF. 
  • Ultrafiltration in decompensated heart failure with cardiorenal syndrome. 
  • Ultrafiltration in heart failure with cardiorenal syndrome. 
  • Undercover and overlooked. 
  • Underdiagnosis of Ischemic Heart Disease in New-Onset Heart Failure: A Call to Action. 
  • Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. 
  • Understanding and recognizing cardiac amyloidosis. 
  • Understanding heart failure through the HF-ACTION baseline characteristics. 
  • Understanding risk factors and predictors for stroke subtypes in the ENDURANCE trials. 
  • Unexpected deviation in circadian variation of ventricular arrhythmias: the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial). 
  • Unexplained Dyspnea on Exertion: The Difference the Right Test Can Make. 
  • Unique microRNA profile in end-stage heart failure indicates alterations in specific cardiovascular signaling networks. 
  • Universal Definition and Classification of Heart Failure: Pharmacists' Perspective: Optimizing Guideline-Directed Medical Therapy and Educating Stakeholders. 
  • Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. 
  • Unmet expectations of medications and care providers among patients with heart failure assessed to be poorly adherent: results from the Chronic Heart Failure Intervention to Improve MEdication Adherence (CHIME) study. 
  • Unraveling the Mystery of Troponin Elevation in Heart Failure. 
  • Unraveling the pathophysiology of acute heart failure: an inflammatory proposal. 
  • Up-regulation of connexin45 in heart failure. 
  • Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee. 
  • Update on the Impact of Comorbidities on the Efficacy and Safety of Heart Failure Medications. 
  • Upright Cheyne-Stokes Respiration in Heart Failure: An Ominous Sign of Cardiovascular Dysregulation. 
  • Urologic sepsis/shock. 
  • Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure. 
  • Use and predictors of heart failure disease management referral in patients hospitalized with heart failure: insights from the Get With the Guidelines Program. 
  • Use of Actigraphy (Wearable Digital Sensors to Monitor Activity) in Heart Failure Randomized Clinical Trials: A Scoping Review. 
  • Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial Fibrillation. 
  • Use of Heart Failure Medical Therapies Among Patients With Left Ventricular Assist Devices: Insights From INTERMACS. 
  • Use of HeartWare Ventricular Assist System for systemic ventricular support of a pediatric patient after Mustard procedure. 
  • Use of High-Sensitivity Troponin T to Identify Patients With Acute Heart Failure at Lower Risk for Adverse Outcomes: An Exploratory Analysis From the RELAX-AHF Trial. 
  • Use of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Comorbid Diabetes Mellitus or Chronic Kidney Disease. 
  • Use of Oral Anticoagulation in Eligible Patients Discharged With Heart Failure and Atrial Fibrillation. 
  • Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart. 
  • Use of a continuous-flow device in patients awaiting heart transplantation. 
  • Use of aldosterone antagonists in heart failure. 
  • Use of biomarkers to establish potential role and function of circulating microRNAs in acute heart failure. 
  • Use of cardiac resynchronization therapy in patients hospitalized with heart failure. 
  • Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial. 
  • Use of guideline-recommended therapies for heart failure in the Medicare population. 
  • Use of hand carried ultrasound, B-type natriuretic peptide, and clinical assessment in identifying abnormal left ventricular filling pressures in patients referred for right heart catheterization. 
  • Use of hydralazine-isosorbide dinitrate combination in African American and other race/ethnic group patients with heart failure and reduced left ventricular ejection fraction. 
  • Use of nitroglycerin by bolus prevents intensive care unit admission in patients with acute hypertensive heart failure. 
  • Use of remifentanil in infants. 
  • Use of the 6-min walk distance to identify variations in treatment benefits from implantable cardioverter-defibrillator and amiodarone: results from the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial). 
  • Usefulness and Cost-Effectiveness of Universal Echocardiographic Contrast to Detect Left Ventricular Thrombus in Patients with Heart Failure and Reduced Ejection Fraction. 
  • Usefulness and consequences of cardiac resynchronization therapy in dialysis-dependent patients with heart failure. 
  • Usefulness of 2 centrifugal ventricular assist devices in a total artificial heart configuration: A preliminary report. 
  • Usefulness of Coronary Artery Calcium to Predict Heart Failure With Preserved Ejection Fraction in Men Versus Women (from the Multi-Ethnic Study of Atherosclerosis). 
  • Usefulness of Noninvasively Measured Pulse Amplitude Changes During the Valsalva Maneuver to Identify Hospitalized Heart Failure Patients at Risk of 30-Day Heart Failure Events (from the PRESSURE-HF Study). 
  • Usefulness of Palliative Care to Complement the Management of Patients on Left Ventricular Assist Devices. 
  • Usefulness of Pulse Amplitude Changes During the Valsalva Maneuver Measured Using Finger Photoplethysmography to Identify Elevated Pulmonary Capillary Wedge Pressure in Patients With Heart Failure. 
  • Usefulness of a Noninvasive Device to Identify Elevated Left Ventricular Filling Pressure Using Finger Photoplethysmography During a Valsalva Maneuver. 
  • Usefulness of an elevated troponin-I in predicting clinical events in patients admitted with acute heart failure and acute coronary syndrome (from the RITZ-4 trial). 
  • Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure. 
  • Usefulness of combining necrosis and platelet markers in triaging patients presenting with chest pain to the emergency department. 
  • Usefulness of hand-carried ultrasound to predict elevated left ventricular filling pressure. 
  • Usefulness of soluble and surface-bound P-selectin in detecting heightened platelet activity in patients with congestive heart failure. 
  • Usefulness of spironolactone in a specialized heart failure clinic. 
  • Using Natriuretic Peptides for Selection of Patients in Acute Heart Failure Clinical Trials. 
  • Using a gene-switch transgenic approach to dissect distinct roles of MAP kinases in heart failure. 
  • Utility of Growth Differentiation Factor-15, A Marker of Oxidative Stress and Inflammation, in Chronic Heart Failure: Insights From the HF-ACTION Study. 
  • Utility of Patient-Reported Outcome Instruments in Heart Failure. 
  • Utility of Restricted Mean Survival Time Analysis for Heart Failure Clinical Trial Evaluation and Interpretation. 
  • Utility of concomitant tricuspid valve procedures for patients undergoing implantation of a continuous-flow left ventricular device. 
  • Utility of diastolic dyssynchrony in the setting of cardiac resynchronization therapy. 
  • Utility of impedance cardiography for the identification of short-term risk of clinical decompensation in stable patients with chronic heart failure. 
  • Utility of socioeconomic status in predicting 30-day outcomes after heart failure hospitalization. 
  • Utility of the Cardiovascular Physical Examination and Impact of Spironolactone in Heart Failure With Preserved Ejection Fraction. 
  • Utilization of Implantable Cardioverter Defibrillators Among Patients with a Left Ventricular Assist Device: Insights From a National Database. 
  • Utilization of cardiac resynchronization therapy in eligible patients hospitalized for heart failure and its association with patient outcomes. 
  • Utilization of hospice and predicted mortality risk among older patients hospitalized with heart failure: findings from GWTG-HF. 
  • Utilizing mobile technologies to improve physical activity and medication adherence in patients with heart failure and diabetes mellitus: Rationale and design of the TARGET-HF-DM Trial. 
  • VDAC2 as a novel target for heart failure: Ca2+ at the sarcomere, mitochondria and SR. 
  • Vaccination Trends in Patients With Heart Failure: Insights From Get With The Guidelines-Heart Failure. 
  • Validated, electronic health record deployable prediction models for assessing patient risk of 30-day rehospitalization and mortality in older heart failure patients. 
  • Validation and potential mechanisms of red cell distribution width as a prognostic marker in heart failure. 
  • Validation of an atrial fibrillation risk algorithm in whites and African Americans. 
  • Validation of the WATCH-DM and TRS-HFDM Risk Scores to Predict the Risk of Incident Hospitalization for Heart Failure Among Adults With Type 2 Diabetes: A Multicohort Analysis. 
  • Value of Cardiovascular Magnetic Resonance Imaging-Derived Baseline Left Ventricular Ejection Fraction and Volumes for Precise Risk Stratification of Patients With Ischemic Cardiomyopathy: Insights From the Surgical Treatment for Ischemic Heart Failure (STICH) Trial. 
  • Value of clinician assessment of hemodynamics in advanced heart failure: the ESCAPE trial. 
  • Variables of importance in the Scientific Registry of Transplant Recipients database predictive of heart transplant waitlist mortality. 
  • Variation in Warfarin Use at Hospital Discharge After Isolated Bioprosthetic Mitral Valve Replacement: An Analysis of the Society of Thoracic Surgeons Adult Cardiac Surgery Database. 
  • Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities. 
  • Variations in and correlates of length of stay in academic hospitals among patients with heart failure resulting from systolic dysfunction. 
  • Vascular and renal prostaglandins as counter-regulatory systems in heart failure. 
  • Vascular smooth muscle responsiveness to noradrenaline and phenylephrine following experimental heart failure in dogs. 
  • Vasodilators in the management of congestive heart failure. 
  • Vasodilators in the treatment of acute heart failure: what we know, what we don't. 
  • Vasopeptidase inhibitor reduces inhospital costs for patients with congestive heart failure: results from the IMPRESS trial. Inhibition of Metallo Protease by BMS-186716 in a Randomized Exercise and Symptoms Study in Subjects With Heart Failure. 
  • Vasopressin receptor antagonists. 
  • Vasopressin receptor antagonists. Therapeutic potential in the management of acute and chronic heart failure. 
  • Vasopressin: a new target for the treatment of heart failure. 
  • Venous Tone and Stressed Blood Volume in Heart Failure: JACC Review Topic of the Week. 
  • Ventricular Assist Device Utilization in Heart Transplant Candidates: Nationwide Variability and Impact on Waitlist Outcomes. 
  • Ventricular Pacing in Single Ventricle Circulation: Making the Best of a Difficult Situation. 
  • Ventricular arrhythmia storms in postinfarction patients with implantable defibrillators for primary prevention indications: a MADIT-II substudy. 
  • Ventricular conduction and long-term heart failure outcomes and mortality in African Americans: insights from the Jackson Heart Study. 
  • Ventricular pacing or dual-chamber pacing for sinus-node dysfunction. 
  • Vericiguat and Health-Related Quality of Life in Patients With Heart Failure With Reduced Ejection Fraction: Insights From the VICTORIA Trial. 
  • Vericiguat in Heart Failure with Reduced Ejection Fraction. Reply. 
  • Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. 
  • Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction: insights from the VICTORIA trial. 
  • Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fraction. 
  • Vessel dilator enhances sodium and water excretion and has beneficial hemodynamic effects in persons with congestive heart failure. 
  • Vessel dilator, long acting natriuretic peptide, and kaliuretic peptide increase circulating prostaglandin E2. 
  • Virtual Visits for Care of Patients with Heart Failure in the Era of COVID-19: A Statement from the Heart Failure Society of America. 
  • Visit-to-Visit Glycemic Variability and Risks of Cardiovascular Events and All-Cause Mortality: The ALLHAT Study. 
  • WIPI1 is a conserved mediator of right ventricular failure. 
  • Warfarin and Aspirin Versus Warfarin Alone for Prevention of Embolic Events in Patients with a HeartMate II Left Ventricular Assist Device. 
  • Water and sodium in heart failure: a spotlight on congestion. 
  • Weekend hospital admission and discharge for heart failure: association with quality of care and clinical outcomes. 
  • Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. 
  • What Defines a Valuable Investment in Global Health Research? 
  • What If the Destination Is Transplant? Outcomes of Destination Therapy Patients Who Were Transplanted. 
  • What Is a Life Worth?: A Tribute to Dr. William Little, a Pioneer in the Understanding of Heart Failure With Preserved Ejection Fraction. 
  • What can heart failure trialists learn from oncology trialists? 
  • What is the economic value of digoxin therapy in congestive heart failure patients? Results from the DIG trial. 
  • What the dead can teach the living: systemic nature of heart failure with preserved ejection fraction. 
  • What's Harder: Seeing a Doctor or Reducing Readmissions? 
  • What's Next for Acute Heart Failure Research? 
  • What's One More Day? 
  • When Business and Science Clash, How Can We Avoid Harming Patients?: The Case of AVOID-HF. 
  • When Complementary and Alternative Medicine Meets Heart Failure-a Modest Proposal. 
  • When Is It Safe Not to Reimplant an Implantable Cardioverter Defibrillator at the Time of Battery Depletion? 
  • When VAD Things Happen to Good People. 
  • When the heart runs out of heartbeats: treatment options for refractory end-stage heart failure. 
  • Where patients with mild to moderate heart failure die: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). 
  • Which beta-blocker for heart failure? 
  • Which heart failure patients profit from natriuretic peptide guided therapy? A meta-analysis from individual patient data of randomized trials. 
  • Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction? 
  • Who enrolls in the Medicare Part D prescription drug benefit program? Medication use among patients with heart failure. 
  • Who wants a left ventricular assist device for ambulatory heart failure? Early insights from the MEDAMACS screening pilot. 
  • Whole blood impedance aggregometry for the assessment of platelet function in patients with congestive heart failure (EPCOT Trial). 
  • Why JACC: heart failure? 
  • Why Negative Trials Are Positive for Heart Failure Patients. 
  • Why We Respect Randomized Controlled Clinical Trials in Heart Failure. 
  • Why is depression bad for the failing heart? A review of the mechanistic relationship between depression and heart failure. 
  • Why the Authors Use Cardiac Resynchronization Therapy with Defibrillators. 
  • Why the Authors Use Cardiac Resynchronization Therapy with Defibrillators. 
  • Willingness to pay for telemedicine assessed by the double-bounded dichotomous choice method. 
  • Wireless, battery-free, fully implantable multimodal and multisite pacemakers for applications in small animal models. 
  • Working Toward an Improved Understanding of Chronic Cardiorenal Syndrome Type 4. 
  • Worldwide Experience of a Durable Centrifugal Flow Pump in Pediatric Patients. 
  • Worsening Heart Failure Following Admission for Acute Heart Failure: A Pooled Analysis of the PROTECT and RELAX-AHF Studies. 
  • Worsening Heart Failure Events in HFpEF: Underlying Biology Not Treatment Location. 
  • Worsening Renal Function in Patients With Acute Heart Failure Undergoing Aggressive Diuresis Is Not Associated With Tubular Injury. 
  • Worsening depressive symptoms are associated with adverse clinical outcomes in patients with heart failure. 
  • Worsening heart failure during hospitalization for acute heart failure: Insights from the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF). 
  • Worsening heart failure, a critical event during hospital admission for acute heart failure: results from the VERITAS study. 
  • Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme. 
  • Worsening renal function during decongestion among patients hospitalized for heart failure: Findings from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) trial. 
  • Worsening renal function in acute heart failure in the context of diuretic response. 
  • X-linked inhibitor of apoptosis protein-mediated attenuation of apoptosis, using a novel cardiac-enhanced adeno-associated viral vector. 
  • Xanthine oxidase inhibition for hyperuricemic heart failure patients: design and rationale of the EXACT-HF study. 
  • YAP: The nexus between metabolism and cardiac remodeling. 
  • [Brazilian guidelines on platelet antiaggregants and anticoagulants in cardiology]. 
  • [Calcium antagonists in the treatment of heart failure. Re-evaluation of therapeutic strategies]. 
  • [Cardiac contractility modulation in heart failure with reduced ejection fraction treatment]. 
  • [III Brazilian Guidelines on Chronic Heart Failure]. 
  • [Prognostic value of liver stiffness in decompensated heart failure: results of prospective observational transient elastography-based study]. 
  • c-Jun N-terminal kinase activation mediates downregulation of connexin43 in cardiomyocytes. 
  • microRNA-21-5p dysregulation in exosomes derived from heart failure patients impairs regenerative potential. 
  • p38 MAP kinase mediates inflammatory cytokine induction in cardiomyocytes and extracellular matrix remodeling in heart. 
  • patient and practice factors associated with improvement in use of guideline-recommended therapies for outpatients with heart failure (from the IMPROVE HF trial). 
  • Β-arrestin: a signaling molecule and potential therapeutic target for heart failure. 
  • β blockers for heart failure: which works best? 
• 

  Keywords of People

  • Alexander, John Hunter Peel, Professor of Medicine, Medicine, Cardiology
  • Barker, Piers Christopher Andrew, Professor of Pediatrics, Pediatrics, Cardiology
  • Bowers, Margaret Therese, Clinical Professor in the School of Nursing, School of Nursing
  • Bradford, William Dalton, Professor of Pathology, Pathology
  • Brennan, J. Matthew, Associate Professor of Medicine, Medicine, Cardiology
  • Cade, William Todd, Professor of Orthopaedic Surgery, Orthopaedic Surgery, Physical Therapy
  • Carboni, Michael Paul, Associate Professor of Pediatrics, Pediatrics, Cardiology
  • Curtis, Lesley H., Professor in Population Health Sciences, Medicine, General Internal Medicine
  • Ghadimi, Kamrouz, Associate Professor of Anesthesiology, Anesthesiology, Cardiothoracic
  • Grambow, Steven C., Associate Professor of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics
  • Granger, Christopher Bull, Professor of Medicine, School of Nursing
  • Grimsrud, Paul, Assistant Professor in Medicine, Medicine, Endocrinology, Metabolism, and Nutrition
  • Hirschey, Matthew, Associate Professor of Medicine, Cell Biology
  • Holley, Christopher Lee, Associate Professor of Medicine, Molecular Genetics and Microbiology
  • Landstrom, Andrew Paul, Associate Professor of Pediatrics, Cell Biology
  • Lekavich, Carolyn Louise, Assistant Professor in Medicine, School of Nursing
  • Limkakeng Jr., Alexander Tan, Professor of Emergency Medicine, Emergency Medicine
  • Mentz, Robert John, Associate Professor of Medicine, Medicine, Cardiology
  • Milano, Carmelo Alessio, Joseph W. and Dorothy W. Beard Distinguished Professor of Experimental Surgery, Surgery, Cardiovascular and Thoracic Surgery
  • O'Connor, Christopher Michael, Richard Sean Stack, M.D. Distinguished Professor, Medicine, Clinical Pharmacology
  • Patel, Uptal Dinesh, Adjunct Professor in the Department of Medicine, Medicine, Nephrology
  • Pitt, Geoffrey Stuart, Adjunct Professor in the Department of Medicine, Medicine, Cardiology
  • Rao, Vishal, House Staff, Medicine, Cardiology
  • Reed, Shelby Derene, Professor in Population Health Sciences, Duke Science & Society
  • Russell, Stuart Dean, Professor of Medicine, Medicine, Cardiology
  • Schickling, Brandon, Affiliate, Medicine, Cardiology
  • Selvaraj, Senthil, Assistant Professor of Medicine, Medicine, Cardiology
  • Stinnett, Sandra Sue, Associate Professor of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics
  • Sullivan, Daniel Carl, Professor Emeritus of Radiology, Radiology
  • Swaminathan, Madhav, Professor of Anesthesiology, Anesthesiology, Cardiothoracic
  • Turner, David Ashley, Consulting Professor in the Department of Pediatrics, Pediatrics, Critical Care Medicine
  • White, Phillip James, Assistant Professor in Medicine, Pharmacology & Cancer Biology